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Introduction: Observational studies play a valuable role in nephrology and have informed 
clinical practice. A significant challenge to observational research is external validity. Threats 
to generalisability can occur at the design stage due to selective inclusion criteria, at the 
recruitment stage due to non-participation of specific groups, and finally at the reporting 
stage due to poor reporting. 
Methods: The PhD thesis was a mixed method study of convergent parallel/ triangulation 
design, embedded into European QUALity Study on treatment in advanced chronic kidney 
disease (EQUAL). The thesis involved three studies: quantitative, qualitative and systematic 
review to understand more fully the various factors that could affect a study’s generalisability 
at the design, recruitment and reporting stages respectively. The quantitative arm was a 
retrospective observational study comparing patients in primary and secondary care meeting 
the same inclusion criteria as EQUAL. The qualitative arm involved semi-structured 
interviews with patients who agreed and did not agree to participate in EQUAL. The 
systematic review assessed the quality of reporting of cohort studies before (1/1/2002-
31/12/2007) and after (1/10/2008-31/12/2013) the publication of the STROBE statement. 
Results: The quantitative arm of the thesis showed that patients in EQUAL were more likely 
to be younger, male and from an urban setting compared to the primary and secondary care 
cohort patients. Overall lesser co-morbidity of EQUAL patients meant that they were more 
likely to be alive at one year or to be admitted to hospital for illnesses. In the qualitative arm 
of the thesis, patients who agreed to participate in research reported being activated in their 
healthcare, and this seemed to relate to their decision to take part in research. Altruistic 
morals had a strong influence on participation in EQUAL study. The issue of caring 
responsibility and transportation were the main reasons causing inconvenience and negatively 
influenced participation. The systematic review showed that there had been an improvement 
in the overall reporting quality of CKD cohort studies particularly in the latter three years of 
the post-STROBE period. 
Conclusion: The mixed methods approach of this PhD thesis aided a breadth and depth of 
understanding of some of the issues affecting generalisability with corroboration of the 
results from the quantitative and qualitative arms of the study. Sustained efforts of 
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CHAPTER 1. INTRODUCTION 
This chapter describes the two essential contexts of the thesis: Chronic Kidney 
Disease (CKD); and issues around generalisability. The chapter begins by describing 
the importance of CKD, its epidemiology and the increase in research to prevent CKD 
progression. This chapter also outlines the challenges of conducting research in 
patients with CKD and the need for proper research which should produce knowledge 
or evidence that applies to patients beyond the setting in which it was carried out 
(generalisability). This chapter discusses the threats to generalisability at various 
stages of research. It concludes by providing the aims, objectives and a plan of the 
thesis.  
1.1. Chronic Kidney Disease 
1.1.1. Definition 
The term Chronic Kidney Disease (CKD) encompasses some previously used 
terms, such as “chronic renal failure”, “chronic renal insufficiency” and “chronic 
kidney impairment”. The definition of CKD is “ the presence of kidney damage 
(usually detected by urinary protein) or reduced kidney function (defined as 
estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m
2
) for greater than 
three months, irrespective of the aetiology.” (1) The persistence of reduced kidney 
function for at least three months is necessary to distinguish CKD from acute 
kidney injury (AKI). CKD is often associated with a progressive reduction in 
kidney function over a period of time, culminating for some in established renal 
failure (ERF) or end-stage kidney disease (ESKD) which requires treatment with 
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comprehensive conservative care or renal replacement therapy (RRT) in the form 
of dialysis or transplantation. 
1.1.2. Diagnosis 
CKD can be diagnosed by screening patients who have the possibility of 
developing kidney problems, such as patients with high blood pressure, diabetes, a 
family history of kidney disease, older age, particular ethnic group and smoking. 
(1) CKD can also be picked up when it leads to one of its recognised 
complications, such as cardiovascular disease, anaemia, or bone disease. 
Alternatively, it can be silent and be detected in a blood sample taken for another 
reason. 
Creatinine is a waste product of muscle that can be measured by a blood test and 
used with data on age, gender and race to assess kidney function – estimated 
glomerular filtration rate (eGFR). The eGFR is a good measure of the degree of 
kidney function and necessary to determine the stage of kidney disease. The 
Modification of Diet in Renal Disease (MDRD) equation is used to calculate 
eGFR and has been the most widely used method to determine the level of kidney 
function, as it has proved the most robust and precise. (2) Although the National 
Institute of Health and Care Excellence (NICE) now recommend the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to determine 
the level of kidney function. (3, 4) Normal GFR is approximately 100 
ml/min/1.73m
2
 and has an inverse relationship with creatinine (greater the 
creatinine, the lower the GFR). Creatinine levels may be in the normal range or 
appear normal in the early stages of CKD. 
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CKD may also be discovered by testing a urine sample (urinalysis) where this 
shows that the kidney is losing protein or red blood cells into the urine. Various 
forms of medical imaging, blood tests and sometimes a kidney biopsy (removing a 
small sample of kidney tissue) are used to establish the cause and whether a 
reversible cause for the kidney dysfunction is present. 
1.1.3. Classification 
In February 2002, the National Kidney Foundation (NKF) in the USA published 
its Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice 
Guidelines containing the current definition of CKD. (5) This document:  
1. Classified CKD into five stages according to renal function. 
2. Suggested a standardised method of measuring and estimating renal function. 
3. Described the rate of associated complications within each stage of CKD. 
4. Suggested guidelines for the subsequent management of this disease.  




to stage 5 with severely impaired function (eGFR ≤15 ml/min/1.73 m
2
). Subjects 
with eGFR ≤ 60 mL/min/1.73 m
2
 for ≥ three months are classified as having 
CKD. (1) These guidelines have now been adopted and adapted worldwide. In the 
UK, the Royal College of Physicians (RCP) published the “Chronic Kidney 
Disease in Adults- UK guidelines for identification, management and referral” in 
March 2006 (6), and following this the National Institute for Health and Clinical 
Excellence (NICE) published the CKD guidelines in May 2008 (7). 
The spectrum of this condition ranges from stage 1, the mildest and usually 
causing few to no symptoms, to stage 5 the most severe requiring RRT with poor 
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life expectancy if untreated. Guidelines published by Kidney Disease: Improving 
Global Outcomes (KDIGO) have reclassified CKD taking into account not only 
glomerular filtration rate as in the KDOQI guidelines (G1, G2, G3a, G3b, G4 and 
G5) but also the level of albuminuria (A1, A2, A3).(8) The KDIGO classification 
of CKD and Albuminuria are described in Table 1.1: 
Table 1.1: Kidney Disease Improving Global Outcomes (KDIGO) stages of Chronic 







Normal or high 
2 
60-89 Mildly decreased 
G3a 
45-59 Mildly to moderately decreased 
G3b 
30-44 Moderately to severely decreased 
G4 
15-29 Severely decreased. 
G5 
<15 Kidney failure 
Stage 
Albuminuria (mg/mmol) Description 
A1 
<3 Normal to mildly increased 
A2 
3-30 Moderately increased 
A3 
>30 Severely increased 
 
1.1.4. Causes 
Diabetes and hypertension are the most common causes of CKD that lead to 
kidney failure. (9) Diabetes and high blood pressure may also speed up the 
progression of CKD in someone who already has the disease. Some of the other 
causes of CKD include(8): 
a. Kidney diseases such as glomerulonephritis. 
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b. Kidney conditions that cause infections such as reflux nephropathy and 
pyelonephritis. 
c. Inherited kidney conditions such as polycystic kidney disease.  
d. A vascular disease which causes narrowing of the renal artery which 
carries blood to the kidneys,  
e. Drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) and certain 
antibiotics. 
1.1.5. Prognosis 
CKD is a significant global public health problem (10) affecting 10–16% of the 
adult population in Asia, Australia, Europe, and the United States of America 
(USA). (11) An estimated 0.2% of the population (125,000 individuals in the UK 
approximately) have stage 5 CKD. (12) At this level of function, the patients 
develop symptoms and complications and might need to start RRT (dialysis or 
kidney transplantation). Each year in the UK almost 8,000 patients commence 
RRT, half of whom are over 65 years of age (13). The presence of CKD also 
markedly increases the risk of heart disease which is significant despite taking into 
consideration the traditional risk factors such as hypertension and diabetes 
mellitus. (14) Cardiovascular disease is the most common cause of death in 
patients with CKD. (15) Research has shown that overall mortality increases as 
kidney function decreases. (16) A systematic review conducted by Tonelli et al. 
has shown that unadjusted relative risk for mortality in participants with reduced 
kidney function compared with those without ranged from 0.94 to 5.0 and was 
significantly more than 1.0 in 93% of cohorts. (17) The research implications of 
increased mortality in CKD patients are discussed in detail in section 1.1.11.1. 




1.1.6 Chronic kidney disease in the elderly 
Over the next two decades, it is anticipated that the number of people aged over 
65 will increase by 51% in the UK(18). CKD is an independent risk factor for 
cardiovascular mortality in patients with diabetes, hypertension, heart disease, and 
stroke, all of which are significant co-morbidities in the elderly. (19) Elderly 
patients are more likely to have CKD. Also, with growing life expectancy, 
patients are living longer with chronic conditions such as CKD (20, 21). The last 
decade has seen an increasing number of elderly patients referred to nephrology 
with CKD. (22) Although over the last decade, as a result of the steady growth in 
renal services in the United Kingdom, the incidence rates of RRT had plateaued, 
the recent UK Renal Registry Report shows that there has been an increase in the 
recent years. (23) The improvements in patient survival have lead to an increase in 
the prevalence rates of RRT.(24) 
1.1.7. Epidemiology 
1.1.7.1 Prevalence of chronic kidney disease 
The introduction of eGFR reporting and consequent adoption of a five-stage CKD 
definition based on GFR has resulted in the detection of a significant number of 
people with previously undiagnosed CKD. (25) The estimated prevalence of CKD 
ranges from 2.5% to 7.2% (26-31) with the prevalence in the elderly significantly 
higher at 35% (32). Table 1.1 gives a summary of population-based studies that 
reported the prevalence of CKD defined by eGFR ≤ 60 mL/min/1.73 m
2
 using the 
MDRD equation. 
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1.1.7.2 The incidence of chronic kidney disease 
There are only a few studies reporting the incidence of new-onset CKD. In a 
population-based retrospective cohort study from the UK with 5.5 years of follow-
up, the estimated annual incidence of CKD (defined as serum creatinine ≥150 
micromol/L for six months or longer) was 1700 per million population. (33) In the 
Framingham Offspring study which consisted of 1223 men and 1362 women who 
had no pre-existing kidney disease, after a mean follow-up of 18.5 years, 244 
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Coresh et al. (30) 2005 US 
3
rd
 National Health and Nutrition Examination 
Survey (NHANES III, 1999–2000) 
3-5 No Yes 3.8% 
Hemmelgarn et al. (32) 2006 Canada 
A community-based cohort of elderly subjects (≥ 
66 years) in Calgary Health Region 
3-5 Yes No 35.5% 
de Lusignan et al. (35) 2005 UK Twelve General practices in UK 3-5 No No 4.9% 
Hallan et al. (29) 2006 Norway 
Health Survey of Nord-Trondelag County 
(HUNT II) study 
3-4 No Yes 4.7% 
Viktorsdottir et al. (28) 2005 Iceland Reykjavik Heart Study 3-5 No No 7.2% 
Chen et al. (27) 2005 China 
The International Collaborative Study of 
Cardiovascular Disease in ASIA (InterASIA) 
3-5 No No 2.5% 
Shankar et al. 2006 Singapore Private census study 3-5 No No 6.6% 
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1.1.8. Referral to Nephrologist 
Guidelines for referral to a nephrologist can be different between countries. In the 
UK, NICE CKD guidelines suggest referral of patients with: (4) 
a. eGFR ≤30 ml/min/1.73 m2, with or without diabetes;  
b. Proteinuria (albumin creatinine ratio-ACR) of 70 mg/mmol or more, 
unless known to be caused by diabetes and already appropriately treated. 
c. ACR 30 mg/mmol or more, together with haematuria. 
The NICE guidelines have been modelled based on the recommendations 
made in the KDIGO 2012 clinical practice guidelines for the evaluation and 
management of CKD. The current referral practice in the UK from general 
practice to Nephrologist is summarised below (4): 
a. By stage 4 CKD (when eGFR is less than 30 ml/min/1.73m2) 
b. eGFR decreasing by more than 3 ml/min/1.73m2/year  
c. At an earlier stage (e.g. CKD3) when urine albumin-creatinine ratio 
(ACR) is more than 30 mg/mmol. 
d. When blood pressure is difficult to control 
e. When there is haematuria, or other findings suggest a primary glomerular 
disorder or secondary disease amenable to specific treatment. 
1.1.9. Unreferred CKD 
Only a few studies look at the burden of unreferred CKD. A study in the UK by 
John et al. showed that the median age of the unreferred population (eGFR ≤ 
30mL/min/1.73 m
2
) was 80 years (range, 18 to 102 years), 53.6% were men, 
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median GFR was 26.3 mL/min/1.73 m
2
 (range, 3.6 to 42.3 mL/min/1.73 m
2
) and 
39.5% of the patients had died over a mean follow-up of 31.3 months. (36) Even 
in advanced CKD, only 35% to 50% of patients are referred, although this may be 
appropriate because of age and comorbidity. (37, 38) In comparison to unreferred 
patients, those under the care of nephrology have not only more advanced CKD 
but also increased comorbidity. (36, 39-42) There is very sparse evidence 
regarding the outcomes associated with unreferred CKD in the medical literature. 
Studies have shown that newly referred, or unreferred elderly patients with CKD 
are more likely to die before reaching ESRD. (43-45)  
1.1.10. Implications of guidelines 
KDOQI Clinical Practice Guidelines for CKD: Evaluation, Classification, and 
Stratification were published in 2002, and over the fifteen years the changes in 
clinical practice, research, and public health as a result of this guideline have been 
substantial. (5, 46). As a consequence of these guidelines, a significant number of 
patients with CKD have been detected. 
1.1.10.1. Policy in the UK 
The Renal National Service Framework (NSF) published in 2004 and set out the 
targets for the care of people with kidney disease, and guidance to help healthcare 
providers detect the condition at an early stage and slow down its progression (47, 
48). The NSF (Part 2) discussed prevention and early recognition of CKD and 
suggested that laboratories should report a formula-based estimation of GFR on 
blood tests taken for serum creatinine measurement in adults. (25) In April 2006 
the Department of Health introduced mandatory eGFR reporting in England using 
the MDRD study equation for all laboratories. Simultaneously, the General 
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Medical Services Contract’s Quality and Outcomes Framework (QOF) introduced 
a register of people in primary care with CKD. The QOF is mostly an ‘annual 
reward and incentive programme detailing general practice achievement results, 
intended to benefit both patients and the National Health Service (NHS). (49) The 
QOF offers financial incentives for the detection and treatment of CKD and 
hypertension in primary care. Since its introduction, the UK has observed a definite 
reduction in numbers of ‘late-presenters’, defined as patients presenting to renal 
services within 90 days of needing RRT, from 31% to 19% in the past few years. (50) 
1.1.10.2. Financial Implications 
The financial consequences of CKD are substantial. Around 1.3% of the NHS 
funding (£1.45 billion) is spent on CKD, with over half of this expenditure for 
RRT. Also, cardiovascular complication management of CKD is a significant 
portion (51). These figures are similar in Australia where CKD- and RRT-
associated costs are estimated to increase by 37% from $1.3 billion in 2012 to 
$1.7 billion in 2020 (1 Australian $ = 0.55 British £, 31
st
 March 2018; Australian 
population 24m vs English population 53m). (52) Given the substantial burden of 
the disease on people and the financial implications of CKD, it is imperative that 
large-scale generalisable studies in CKD are conducted. 
1.1.11. Impact on Quality and Quantity of Research in CKD 
Studies that will lead to better treatments and cures for CKD are essential. Since 
the publication of the KDOQI CKD guidelines, there has been a significant rise in 
the number of studies exploring the various stages of kidney disease. An editorial 
by Coresh et al. stated that the number of articles in the SCOPUS database related 
to CKD research had increased from 188 in the year 2000 to 356 in the year 2002 
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and 4,035 in the year 2011. These CKD-related articles comprised 0.7%, 1.6%, 
and 11.2% of all nephrology research publications in the years 2000, 2002 and 
2011 respectively. (53) Considerable efforts are being made and resources 
allocated to find new treatments for CKD or treatments to slow progression. 
Unfortunately, CKD research has been a challenge, and these issues that have 
been outlined in section 1.1.11.1 below have contributed to the failure to translate 
research into public health practice. (54, 55)  
1.1.11.1. Challenges of CKD Research 
As previously discussed in section 1.1.5, patients with CKD are likely to have an 
increased comorbidity burden and mortality. (17, 56) Patients with CKD are 
likely to have minimal symptoms until it reaches late stages and therefore testing 
treatments to slow the progression of CKD have been challenging. Patients with 
CKD are also likely to be frailer and of lower educational status compared to the 
general population. (56)   In America, a survey conducted between 1999-2008 
showed that 26.7% of adults with CKD had high school education which was just 
below the national average of 28.4%. (56) Both language and illiteracy can lead 
to a lack of understanding of research studies, including their purposes and 
materials (56). The audit also showed that the percentage of adults with CKD in 
America that are disabled was estimated to be 18.3% in comparison with 9.9% in 
the general population, (56) and these people will be more dependent on other 
members of the family to help them attend hospital appointments. The majority 
of CKD patients are burdened with polypharmacy, and by the time they reach 
stage 5 CKD, it is predicted that the typical patient will take 10-12 medications. 
(57) In addition to increasing medications, participating in research increases the 
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number of visits to the hospital for CKD patients, which may serve as another 
deterrent to participating in clinical research. 
All of the above issues in patients with CKD pose a barrier to research in CKD 
patients, and they are often excluded from research trials or refuse to 
participate.(55, 58) These obstacles, in turn, have significant implications upon 
the generalisability of CKD research as the recruited participants are not 
representative of CKD patients in the general population. The consequence of the 
lack of generalisability of research findings of CKD management has added to 
the challenge of translating research into public health practice. (54, 59) There is, 
therefore, perhaps, a particular need to address study design when undertaking 
research to improve the delivery of care to patients with kidney disease (60). 
1.2 Clinical study designs 
With the problem of CKD increasing, research regarding the management and 
treatment of CKD, to improve morbidity and mortality associated with CKD is 
vital. Well-designed studies are of utmost importance to enhance the care we 
deliver to patients with kidney disease (60). 
1.2.1 The Evidence Pyramid 
Study designs regularly used in nephrology research are observational studies, like 
cohort and case-control studies, and interventional studies like randomised 
controlled trials (RCTs) (61). Figure 1.1 depicts the evidence pyramid which can 
be used to understand the certainty of medical evidence. Typically, studies of 
cause and prognosis utilise cohort designs, whereas studies of therapy frequently 
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utilise the clinical trial designs. However, observational study designs using causal 
models can also be used to test the treatment effect.  
 
Figure 1.1: Evidence Pyramid (adapted from “The valuable contribution of 
observational studies to nephrology(62)” 
1.2.2 Randomised Control Trials 
RCTs are considered to represent the gold standard for testing hypotheses in 
medical research. (63) In an RCT, the critical requirement is that the patients are 
randomly assigned to the experimental group (with exposure) or the control group 
(without exposure) by a pure chance process. The randomisation helps to prevent 
selection by the clinician and helps to establish groups that are equal on relevant 
prognostic factors. It should be noted that randomisation does not guarantee to 
make all else equal for measured and unmeasured variables; it ensures that any 
differences occur by chance. Studies may be single-blind (either the patient or the 
clinician does not know who receives the treatment and who does not) or double-
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blind (both the patient and the clinician do not know who receives the treatment). 
In contrast, in open-label RCTs both the researchers and participants know which 
treatment is being administered, an approach which tends to be used for 
comparing two very similar treatments to determine which is most effective. One 
reason for ‘blinding’ is that the patient, as well as the clinician, may act contrarily 
if they know about treatment allocation. A distinct advantage of RCTs over 
observational studies is that they can provide evidence for a causal relationship 
because they have the potential to overcome some forms of selection bias. The 
two groups are followed up for a specified period or until a required number of 
events have occurred and then compared regarding the outcome. 
 
1.2.2.1 Randomised Control Trials in Nephrology 
A recently published systematic review identified that only 1,054 (2.6%) of 
40,970 trials overall, were attributed to nephrology. (64) Between the various 
medical specialities, Nephrology had published fewer RCTs with regards to both 
number and quality. (65) A common concern in nephrology is the lack of RCTs, 
and thus the failure to decisively establish a cause-and-effect relationship between 
exposure and an outcome. A large proportion of these RCTs in Nephrology have 
also had null findings(66, 67). Research also suggests that the quality of RCTs 
within nephrology are suboptimal and that the reporting of results in these RCTs 
is of low quality. (65, 68-72) There has been a lack of decent quality RCTs 
investigating appropriate screening and monitoring in the early stage of CKD. (73) 
A systematic review has determined that evidence on outcomes in patients with CKD 
have been limited, as they have frequently been obtained from post hoc analyses of 
patient subgroups enrolled in RCTs. Negative results from several recent large 
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RCTs have led to a guarded attitude towards designing and conducting RCTs.(74-
81)  
Studies involving patients with CKD, in the past, have produced negative results 
probably as a result of methodological flaws in study design. (82) The absence of 
an agreement regarding the endpoints in Nephrology (doubling of creatinine, a 
decline of eGFR > 25%, requiring dialysis.) have resulted in contradictory results in 
Nephrology RCTs. (83) Also, studies in Nephrology have commonly been 
underpowered due to overeager speculation about event rates and the outcome of 
therapeutic interventions. These issues must be well-thought-out when planning 
RCTs. Good quality, meticulously conducted pilot studies are necessary before the 
design of large adequately powered hard-endpoint clinical trials (84). These issues 
have resulted in some professional guidelines concluding that no firm 
recommendations can be made about the efficacy of many therapeutic 
interventions. (85) As a consequence of the issues highlighted above and in the 
current economic climate,  there is a particular role for well-conducted 
observational cohort studies to inform clinical practice in nephrology. (86)  
1.2.3 Observational studies 
Most of the medical research is observational with nine out of ten research papers 
published in clinical speciality journals describing observational research (87, 88). 
The types of observational study designs are: 
1. Case report or case series: This describes the clinical course of individuals 
with a particular condition or diagnosis.  
2. Case-control studies: This design begins firstly by identifying participants 
with (cases) and without the condition of interest (controls). The exposure 
of interest is determined retrospectively and compared between cases and 
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controls. Exposures that are more common in cases may give clues to 
causal relationships, provided that cases and controls were similar in all 
respects except for the condition of interest. 
3. Cohort study designs: These are increasingly popular in nephrology and 
can be of a quasi-experimental design, combining the essentials of 
observational and interventional research methods. The group of people 
who have a standard feature are recruited and then observed in their 
natural setting as partaking or not having the intervention (or exposure), 
and outcomes are subsequently assessed. In summary, cohort studies, 
begin by identifying exposure amongst a group of people who are free of 
the outcome of interest and evaluating the participants for events of 
interest over time. (89) Cohort studies remain at the top of the ladder of 
observational studies and are invaluable in studying rare exposures, 
examining multiple potential effects of a single exposure, testing multiple 
hypotheses and capturing adverse effects/harm in the long term (89). 
1.2.3.1 The scope of observational research 
Although RCTs represent the gold standard for testing hypotheses in medical 
research, they are not a panacea, and there is a vital role for observational studies 
in understanding disease progression and treatment effectiveness. (90, 91) Also 
due to ethical or other concerns, RCTs may be problematic or impossible to 
conduct (62, 66, 92). Both observational studies and RCTs fulfil a harmonising 
and valuable role in nephrology. When rigorously conducted, cohort studies could 
potentially produce results that are similar to those from randomised controlled 
trials (RCTs). (67, 92) For example, an analysis of 18 randomised and 
observational studies in health services research found that treatment effects may 
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differ based on the research design, but that “one method does not give a 
consistently greater effect than the other.”(93, 94) The treatment effects were most 
similar when the exclusion criteria were similar and when the prognostic factors 
were accounted for in observational studies(95). 
Even if observational studies do not provide a definitive answer; they can be used 
in these settings to refine hypotheses for clinical trials or provide evidence of 
sufficient equipoise to persuade patients and clinicians that randomisation is 
appropriate. This is important as RCTs can answer only one pre-specified question 
and take many years to provide evidence. They also tend to exclude the real world 
population with the condition, and hence the results may not be generalisable. 
An example of an observational cohort study which has informed clinical practice 
is the international, Dialysis Outcomes and Practice Patterns Study (DOPPS). This 
study had collected data from countries in five continents and used an 
instrumental variable approach to explore causal relationships between practice 
patterns and outcomes and influence dialysis practice. (96) 
However, as with clinical trials, a significant challenge to observational research 
is external validity. One approach to deal with this is to collect information on the 
general population from which the study population is taken. For example, in the 
North American Atherosclerosis Risk in Communities (ARIC) study, external 
validity (generalisability) was examined by nesting study patients in communities 
covered by broad surveillance. In the community surveillance component, the 
occurrence of myocardial infarction and coronary heart disease death was 
ascertained for all residents of the communities. (97, 98) The events were 
investigated by review of hospital records and by query of physicians. This helped 
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to understand the representativeness of the study participants to the broader 
community. 
1.3 Validity of research 
It is more than 50 years since Campbell and Stanley published one of the first 
influential papers to raise concerns about threats to validity in research (99, 100).  
Validity can be assessed in two ways – internal validity and external validity. 
1. Internal validity relates to the rigour of study design (how well intervention 
has been performed) and is the degree to which the results are attributable to 
an independent variable and not some rival explanation (X, the independent 
variable, causes Y, the dependent variable). The less chance for confounding 
in a study, the higher the internal validity. 
2. External validity is the extent to which the results of a study can be 
generalised to other situations and other people - 'real world'.  
Internal validity has tended to be considered of higher importance by many 
researchers than external validity. As a result, more attention has often been paid 
to enhance internal validity, with the notion that it is more vital to know if a 
treatment is effective in a study population, than to know if it will be useful in 
every context (e.g. country), setting (e.g. primary/ secondary/ tertiary care) and 
participant case mix (e.g. age, sex, ethnicity, comorbidity and socioeconomic 
status). (101, 102) At the same time funding bodies and journals have placed more 
emphasis on the methodical accuracy of studies (internal validity) than on the 
applicability of results (external validity). As a result, there has been a failure or 
delay in the translation of research findings into healthcare improvement(103, 
104). This has been highlighted by Balas and Boren who found that it takes 
approximately 9.3 years to implement evidence of original research to the benefit 
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of patient care(105). Therefore, researchers should pay adequate attention to 
external validity (generalisability) when designing a study. (106) 
1.3.1 External Validity: Components 
External validity is often used interchangeably with the term "generalisability". 
(106) External validity can be divided into four components. (102) 
1. Population: Population validity is the representativeness of the study 
population to the population as a whole, that is, whether the findings from the 
study sample can be generalised to the population as a whole.  
2. Setting: This refers to the applicability of findings to other contexts, situations 
or locations. Quantitative research typically focuses on a single 
setting/context, or a small number of settings/contexts. To improve the 
external validity of a study, researchers are required to carry out the same 
experiment in diverse contexts. The researchers should consider conducting 
the experiment in different organisational types, countries, cultures, and so 
forth. 
3. Across treatments: Both experimental and quasi-experimental research designs 
involve specific treatments. This component of generalisability refers to the 
characteristics of the intervention - features of the treatment or intervention 
have to be similar when applied to different populations or settings to arrive at 
the same conclusions.  
4. Across time: This component refers to societal and temporal changes. It is 
useful for researchers to consider if the effect of the intervention will continue 
to apply as society changes over the years. For example, will a study 
conducted today still be useful ten years from now? Therefore, when making 
generalisations across time, caution must be exercised to evaluate whether the 
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population, setting and treatments are still relevant or are likely to have 
changed over the period. 
1.3.2 External validity: Threats 
A range of potential threats to the external validity of various clinical study 
designs has been discussed in the literature. (107-111) These threats can arise 
either from the design, recruitment and conduct or the reporting stages of a study.   
1.3.2.1 Threats at the design stage 
When the participants in a study do not represent the population that the 
researcher hopes to make generalisations to, selection bias will result. As a result, 
it will be hard to generalise to the broader population from outcomes that have 
resulted from a biased sample. Studies that have either very selective eligibility 
criteria, with potential participants unrepresentative of patients in the local 
community, or have a single centre or geographic location from which participants 
are recruited, could have poor generalisability(107). Research is also often 
conducted with younger people, with fewer comorbid diseases, less medication, 
and who have low levels of frailty and cognitive impairment.  The real world 
patients are often older, frailer, have multiple comorbidities and likely to die 
sooner (112, 113).  
The extent to which the findings of a study can be generalised across populations 
(section 1.3.1) also depends on the range of the characteristics collected for the 
study sample. Frequently researchers strive to stratify the study population by the 
relevant socio-demographic variables, for example, so that there is a 
representative proportion of both sexes, people of different ages, and so on. 
However, other characteristics of the population are not accounted for such as 
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qualifications, occupation, cultural, social and health service factors. This will 
limit the degree to which results can be generalised across populations. 
The issues related to participant selection when designing the study are perhaps 
one of the most significant threats to external validity as the samples are not 
accurate representations of populations. 
1.3.2.2 Other threats to external validity: retention 
Recruitment into studies can frequently be challenging with older frailer patients 
and those with multiple co-morbidities less likely to agree to participate in studies 
(114). Non-participation can not only affect whether a study can answer the 
questions it is intended to (internal validity) but also the applicability of study 
conclusions to other people and situations (external validity). On the other hand, 
as discussed in section  1.3.1 the recruited participants frequently are different 
from those who are eligible but not recruited regarding age, sex, race, the 
graveness of disease, educational status, social class, and area of residence. (107) 
Selective attrition is also a known problem in research studies as those in 
disadvantaged socioeconomic groups, ethnic minority groups, younger and older 
participants and those at increased risk of poor health are more expected to drop 
out. (115) The loss to follow-up is also typical and occurs when, during the study 
period, participants drop out of the study. Differential loss to follow-up has a 
similar effect. Non-random dropout and loss to follow-up in studies again threaten 
the generalisability of results, as participants who complete the study may differ 
from people who drop out and as a result, the estimates of association are biased 
(116, 117). 
1.3.2.3 Threats due to reporting 
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Study reporting is as critical as the conduct of a study. Transparent reporting of 
studies is needed to better inform the reader on the issues of generalisability and 
selection bias(118). Imperfect and insufficient reporting of research impedes the 
evaluation of the merits and flaws of the research. Some studies fail to report on 
the applicability of the study data to a broader patient population. For example, 
although study reporting often includes the baseline clinical data of patients 
recruited into the study, so that clinicians can assess the applicability of the results 
to their patients, recorded baseline data do not include information on the actual 
composition of the study population (all patients who were eligible to participate 
in the study). This, therefore, is misleading, and the clinician is genuinely unable 
to make generalisations to the study population. It is therefore of importance for 
readers to know if results can be generalised to an individual patient  or groups of 
patients that differ from those enrolled in the study with regard to age, sex, 
severity of disease, and comorbid conditions; and whether similar results can be 
expected at the primary, secondary, and tertiary levels of care. Figure 1.2 
summarises threats to generalisability at the various stages of a study. 




Figure 1.2: Threats to generalisability at various stage of the study. 
1.3.3 Methods to improve external validity 
Several authors have emphasised the importance of controlling for threats to 
external validity. (119-121) The generalisability of a study can be improved in 
several ways. (122) Researchers can enhance the generalisability of their 
conclusions by assessing the representativeness of the sample statistically at the 
design stage. Random selection of participants, although not always feasible, 
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increases the generalisability of findings to the target population, and broad 
eligibility criteria improve the generalisability to other populations.  
Merely addressing issues of sample selection does not improve external validity; 
other threats to external validity must also be addressed. Generalising beyond the 
sample of the study should be based on the size and representativeness of the 
sample, target population, analytic methods and setting. (123, 124) 
Reporting of a study should be in sufficient detail to allow for replication of the 
study to determine if the same results are obtained in other circumstances. (125, 
126) Also by openly acknowledging the limitations of their study, researchers 
assist readers in making informed decisions about generalising findings to new 
settings or populations. Researchers should be cautious in discussing the 
application of their findings from studies that have limited external validity. In 
many studies, small samples might impede generalisability of findings to other 
populations; however, integrating the findings with other similar research studies 
reported in the literature can be useful for positioning the study within the 
knowledge of the discipline. (123) In this way, smaller studies can contribute to 
the theory that can be applied and evaluated in other settings and populations. 
 In summary, there are four fundamental ways in which the results of 
interventional or observational studies can be made more broadly generalisable:  
(1) Optimum design and conduct at recruitment: By having broad inclusion 
criteria and efficient patient recruitment (achieving the sample size)  
(2) Careful follow up of all participants  
(3) Quantification of any selection effect during the recruitment process: by 
accurately recording patient recruitment (using screening logs), and drop out 
(127).  
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(4) Detailed understanding of the setting in which research is performed: by 
describing any peculiarities of the health-care system in which the study took 
place. (125, 128) 
1.4 Summary and scope of the thesis 
This thesis began by describing the burden of CKD and the significant increase in 
research since the introduction of KDOQI CKD guidelines. The chapter 
highlighted the need for high-quality observational studies to contribute to the 
evidence base. However, external validity (generalisability) remains a pitfall of 
observational research. This Doctorate of Philosophy (PhD) adopts a 
methodological approach to understanding and enhancing the generalisability of 
observational studies. The PhD is embedded within the multi-national and multi-
centre European Quality (EQUAL) Study on treatment in advanced CKD funded 
by the European Renal Association and European Dialysis and Transplantation 
Association (ERA-EDTA) for which Bristol is the national coordinating centre in 
the UK.(129) 
The overarching aim of the thesis is to understand generalisability, and issues of 
recruitment in cohort studies: the example of advanced CKD in the elderly 
(EQUAL). The thesis consists of three broad objectives, using EQUAL as a case 
study: 
1. To quantify selection biases occurring during the recruitment to the 
(observational) EQUAL study and their implications for generalisability. 
2. To understand issues underpinning patient recruitment to the 
(observational) EQUAL study. 
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3. To determine if the quality of reporting of observational studies has 
improved after publication of the STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) statement. 
1.5 Structure of the Thesis 
The introduction chapter will be followed by Chapter 2 which describes the 
context and design of this PhD study. It will outline the EQUAL study and types 
of mixed methods study design, and then detail the study design of the thesis.  
The PhD is composed of three sub-studies, each addressing one of the above-
stated objectives. 
Chapter 3 (Objective 1) is dedicated to the first study of the thesis titled “Using 
primary care data to understand the generalisability of clinical cohorts: The 
example of advanced CKD in the elderly.” This chapter explores the threats to 
generalisability at the design stage of a cohort study by quantifying selection 
biases that occur during the recruitment to observational studies and explores how 
participants in a cohort study differ from the wider population of patients that they 
are intended to represent.  
Chapter 4 (Objective 2) is a qualitative study titled “Understanding patients’ 
perspectives that could influence recruitment in kidney studies”. This chapter aims 
to determine the threats to generalisability at the recruitment stage of the study by 
teasing out issues that underpinned patient recruitment to the EQUAL study. Its 
goals are to understand the motivation for participation and any perceived barriers.  
Chapter 5 (Objective 3) is a systematic review titled “Assessing the Design and 
Quality of Reporting of CKD Cohort Studies Assessing Mortality in the Elderly 
Before and After the publication of STROBE: A Systematic Review.” The chapter 
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aims to examine the threats to generalisability at the reporting stage of a cohort 
study. 
The final chapter (chapter 6) of the thesis is a discussion chapter intending to 
bring together the main findings and conclusions of the thesis.
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CHAPTER 2. METHODS: CONTEXT AND DESIGN 
The previous chapter described the burden of Chronic Kidney Disease (CKD) and 
the growth of research in this field. The chapter also highlighted the limited 
number of adequately powered; high quality randomised controlled trials (RCTs) 
in nephrology to allow the establishment of causality (causal conclusions). The 
chapter made a case for good quality observational studies such that they can 
contribute more robustly to the evidence base. However, external validity 
(generalisability) remains a crucial Achilles heel of observational research. This 
Doctor of Philosophy (PhD) was designed to tease out the threats to 
generalisability in observational research by embedding within the multi-national 
and multi-centre European Quality (EQUAL) Study on treatment in advanced 
chronic kidney disease (CKD). This PhD is of a mixed methods design with three 
arms including a. Quantitative b. Qualitative c. A systematic review, aiming to 
explore the threats to external validity in the design, recruitment and reporting 
stage respectively. This chapter gives an overview of the EQUAL study, the role 
of mixed methods study designs and the advantage of using multi-methods to 
explore a research problem. The detailed methods relating to each of the three 
arms of the PhD thesis are contained in the relevant chapters. 
2.1.  EQUAL (European Quality Study on the treatment of 
advanced chronic kidney disease) 
EQUAL is an international prospective cohort study funded by the European Renal 
Association, European Dialysis and Transplant Association (ERA-EDTA). (129), and 
was conceived about ten years ago when representatives of the European registries 
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met to plan the establishment of a CKD register. The best alternative was decided to 
undertake an observational study looking mainly at the timing of the start of dialysis 
in elderly patients with advanced CKD with the purpose of focusing on both the 
quantity and quality of life.  
2.1.1. Design 
EQUAL was carried out in six European countries: Germany, Italy, Netherlands, 
Poland, Sweden and the United Kingdom. The initial plans were for the 
participants to be recruited over two years and followed for a maximum of four 
years.  
2.1.2. Objectives 
2.1.2.1 Primary Objectives 
The primary objectives of EQUAL were to establish the level of kidney function 
(determined by blood results and physical signs or symptoms) at which overall 
quantity and quality of life would be optimised by starting Renal Replacement 
Therapy (RRT) in patients aged 65 years or over. 
2.1.2.2 Secondary Objectives 
1. To determine how uraemic signs and symptoms develop during the 
progression of advanced CKD. 
2. To determine the optimal laboratory measure of kidney function in advanced 
CKD at which to start RRT (regarding optimising quantity and quality of life). 
3. To determine the factors that influence nephrologists, patients and carers when 
deciding whether/ when to start RRT. 
4. To determine whether patients are satisfied with decision making about 
whether/ when to start RRT. 
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2.1.3. Selection of Subjects 
2.1.3.1 Inclusion Criteria 
1. Aged 65 years and over 
2. Attending nephrology clinic with a first eGFR of 20 ml/min/1.73m2 (or less if 
presenting late) within the last six months, regardless of subsequent eGFRs. 
2.1.3.2 Exclusion Criteria 
1. History of dialysis or kidney transplantation. 
2. If the current decrease in eGFR is thought to be due to an acute event (Acute 
Kidney Injury-AKI) with eGFRs before this event not having been ≤ 30 
ml/min/1.73m
2
 for at least 3months. 
3. Patients are unable to give informed consent or have communication problems 
(including limited English language). 
2.1.3.3 Study sites  
In the UK, Bristol (Southmead Hospital) was the national coordinating centre with 
13 other sites used for recruitment. In England, Birmingham (Heartlands & Queen 
Elizabeth Hospital), Liverpool (Royal Liverpool Hospital), Manchester 
(Manchester Royal Infirmary), Oxford (Churchill Hospital), Salford (Salford 
Royal) and Stevenage (Lister Hospital) were the recruiting sites. In Scotland, 
Glasgow (Queen Elizabeth University Hospital) was the only recruiting site. In 
Northern Ireland, Antrim (Antrim Area Hospital), Belfast (Belfast City Hospital), 
Londonderry (Altnagelvin Area Hospital), Newry (Daisy Hill Hospital) and Ulster 
(Ulster Hospital) were the recruiting sites.  
2.1.3.4 Selection of Participants 
The potentially eligible patients were identified retrospectively from the clinical 
renal IT systems, ward lists and clinic lists. The patients were recruited within a 
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six month +/- 6-week window from when they became eligible (first drop in 
eGFR ≤ 20 ml/min/1.73m
2
). 
2.1.3.5 Patient invitation 
Patients who met the inclusion criteria but not exclusion criteria were invited to 
take part in the EQUAL study. The patients were sent the patient invitation letter 
(PIL) (Appendix 2.1) along with the Pamphlet “An introduction for patients” 
(Appendix 2.2) and the patient information sheet (PIS) (Appendix 2.3). Unless the 
patient had contacted the department to decline participation in the study; the 
research nurse would contact the patient within two weeks to see if they would 
like to participate. If so, the initial study visit was arranged. 
2.1.4. Duration of the study 
The study would run for four years from the beginning of patient recruitment in a 
site. The start date would, therefore, define the end date of the study. As 
recruitment would take place over the first two years of the study, individual 
subjects would remain in the study for between two and four years. All sites in the 
UK closed for recruitment in 2015. 
2.1.5. Study Procedures 
2.1.5.1 Case record form 
The case record form included details such as patient demographics and primary 
renal disease (PRD) of the patients according to ERA-EDTA PRD coding system; 
co-morbidity of patients; surgical history; dietary prescription, hospital 
admissions; medications and nutritional status evaluation. 
2.1.5.2 Patient Questionnaire 
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The patient questionnaire included lifestyle questionnaire, Quality of Life, SF-36 
and kidney disease symptom questionnaire; Decision-making, questions about the 
information given to the patients and preferences of patients about treatment; 
Patient satisfaction, Renal Treatment Satisfaction Questionnaire (RTSQ) and Brief 
Illness Perception Questionnaire. 
2.1.6 Follow-up 
The follow-up in EQUAL was designed such that it would coincide with the 
patient’s routine clinic visit. The follow up would be every six months until the 
eGFR was ≤10 ml/min/1.73m
2
. It would then be at three monthly intervals until 
the end of follow-up, or the participant had been on dialysis for six months (when 
follow-up returns to six monthly). Study visits were performed at +/- six weeks of 
the protocol date except for the start of dialysis visit which would need to occur 
within the six weeks leading up to the start of dialysis or within the two weeks 
following the start of dialysis. Patients would be followed until death, renal 
transplantation, discharge from the nephrology clinic to primary care or until the 
end of the study. 
2.2. Mixed Methods design 
Historically, quantitative study designs have dominated health services research. 
However, over the past few decades, qualitative methods have been increasingly 
used by the health research community, with a rise in the publication of qualitative 
studies. (130, 131) As the role of qualitative approaches has been progressively 
acknowledged, there has been a growing interest in combining qualitative and 
quantitative methods. An article by O’Cathain et al. has shown that within 
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England there was an increase in the percentage of studies classified as mixed 
methods from 17% in the mid-1990s to 30% in the early 2000s.(132) 
2.2.1 Definition 
Mixed methods research is a more specific form of multimethod research which 
includes a mixing of quantitative and qualitative methodologies to address a 
research problem. (133-135) 
2.2.2 Reasons for using mixed methods design  
Creswell lists the reasons and situations where a mixed method approach may be 
more appropriate. (136) 
1. When both quantitative and qualitative data, help to provide a better 
understanding of the research problem than either type by itself. A solitary 
approach to understanding a problem is often misleading, so approaching a 
subject from different perspectives or archetypes may help to gain a holistic 
perspective. 
2. Different methodologies offer unique strengths, using more than one helps to 
get a clearer picture of the social world and make an adequate explanation. 
The use of multiple methods enhances construct validity (a form of 
methodological triangulation). Mixed methods are now routinely advocated by 
methodologists. Therefore, mixing or integrating research strategies 
(qualitative and/or quantitative) in any and all research where undertaken is 
considered a standard feature of well-conducted research. 
3. Multi-methodology is associated with pragmatism and practicality. This 
approach is likely to result in multiple viewpoints; biased and unbiased; 
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subjective and objective and therefore likely to significantly enhance the 
validity of the research. 
 
2.2.3 Mixed method study: Types 
Creswell et al. noted that there were nearly forty different types of mixed methods 
studies in the literature. (137) These can be further reclassified into three broad 
categories as detailed by Johnson, Onwuegbuzie, & Turner et al., predominantly 
quantitative, predominantly qualitative and equal status designs. (138)  
2.2.3.1 Predominantly Quantitative 
In this approach, the research study is predominantly quantitative with qualitative 
methods added to supplement the study. For example, Prakash et al. aimed to 
evaluate the association between neighbourhood socioeconomic status and 
barriers to peritoneal dialysis eligibility and choice. (139) Multivariable models 
were carried out to describe the relationship between socioeconomic status and the 
likelihood of peritoneal dialysis eligibility and choice in a prospective clinical 
database of End Stage Renal Disease (ESRD) patients (Quantitative aspect). A 
constant comparative approach was used to explore patient-reported barriers to 
peritoneal dialysis eligibility (Qualitative aspect). This study showed that 
peritoneal dialysis eligibility and choice were not associated with socioeconomic 
status. However, socioeconomic status could influence specific barriers to 
peritoneal dialysis choice. 
2.2.3.2 Predominantly Qualitative 
In this approach, the research study is predominantly qualitative at its core with 
quantitative data added to enhance the study. 
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DePasquale et al. performed a mixed methods study of Americans of North 
African descent and Caucasians of American descent, with CKD and their 
families with mainly qualitative structured group interviews to explore their views 
regarding information that is essential in educational material regarding RRT 
selection decisions. (140) The quantitative element involved each participant 
choosing the three most important features of treatment they thought other 
patients or families confronted with decisions about treatment of kidney disease, 
should contemplate from an itemised list of 36 factors. The study identified 
similar views from Americans of North African descent and Caucasians of 
American descent participants with patients identifying morbidity or mortality, 
autonomy, treatment delivery, and symptoms as essential factors. Family 
members, also, quoted effects of RRT decisions on patients’ psychological well-
being and finances as relevant information. 
2.2.3.3 Equal status designs 
In this approach, the research study equally integrates quantitative and qualitative 
methodologies. For example, a mixed methods study by Sattoe et al. aimed to 
explore the result of a specific form of peer-to-peer support on the self-
management of patients aged 16–25 years with end-stage renal disease (ESRD). 
(141) These young patients had taken part in Camp COOL (CC), a programme 
that aims to aid young Dutch patients with ESRD gain self-management skills. 
The qualitative aspect involved semi-structured interviews with the staff, 
participants, and healthcare professionals. The quantitative aspect involved pre 
and post surveys among participants (n = 62) and observations during two camp 
weeks. The participants reported increased self-confidence, more knowledge of 
their kidney condition, and felt more responsible in managing their kidney 
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disease. The survey showed all participants scored reasonably well on self-
efficacy measures and health-related quality of life after CC. The results of both 
the quantitative and qualitative arm were complimentary. 
2.2.4 Mixed method study: Designs 
Hanson, Creswell and Plano et al. described six different mixed methods study 
designs. (142) Creswell and Plano in their subsequent publication narrowed the 
study designs to four major types. (143)  
2.2.4.1 The Convergent Parallel (triangulation) Design 
The Convergent Parallel Design is the most common and well-known approach 
and is also known as the triangulation design (Figure 2.1). In this design, the 
researcher collects quantitative and qualitative data concurrently followed by 
analysis of the two datasets separately. The integration happens by merging the 
results during interpretation (and sometimes during data analysis). The convergent 
design aids a complete understanding of the two databases and corroborates 
results from the different methods. This study design is also known as concurrent 
triangulation design; quantitative and qualitative data are collected and analysed at 
the same time. Data analysis is usually separate, and integration usually occurs at 
the data interpretation stage. At the point of interface one tries to look for 
convergence, divergence, contradictions, or relationships of two sources of data. 
 




Figure 2.1: Convergent Parallel Design. Adapted from Designing and Conducting 
Mixed Methods Research. Creswell JW & Plano Clark (2007). 
For example, Artsanthia et al. aimed to explore the palliative care needs of 
people living in Thailand with ESRD using a mixed method approach. (144) 
The qualitative arm of the study involved focus groups and interviews with 
patients and family members and adopted a thematic analysis approach. The 
quantitative aspect of the study used the Edmonton Symptom Assessment 
Scale which furnished descriptive data on nine symptoms commonly 
experienced by palliative care patients. The integration point was during the 
discussion phase. The themes discussed were supported by the results of the 
quantitative survey. The findings informed the development of a future 
intervention study. 
Schmid-Mohler et al. intended to explore the presence of self-management 
tasks mastered by patients in the early phase after a kidney transplant. (145) 
To address this research question, a mixed method study design using semi-
structured interviews (qualitative) to explore the perception of self-
management tasks in kidney transplant recipients and a structured 
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questionnaire (quantitative) to evaluate the existence or absence of 44 self-
management tasks that had been identified in previously published reports was 
carried out. The qualitative interviews suggested that the patients found it 
difficult to manage the unpredictability in the early phase of the transplant and 
also to manage emotions such as uncertainty, disappointment, and frustration. 
The survey showed that in 50%, of patients, managing stressful emotions and 
self-perception was the most significant challenge. 
The strong point of this design is that it is intuitive, efficient and lends itself to 
teams. The limitations of this design are that it requires substantial effort and 
expertise for the researcher or research team. There could be issues due to 
having different samples and different sample sizes when merging two data 
sets. In the analysis stage, there could be difficulty converging two sets of 
different data along with the issues of explaining discrepant results should 
they occur. 
2.2.4.2 The Explanatory Sequential Design 
In this design, the researcher starts by collecting and analysing quantitative data 
and as a follow-up to these results collects and analyses qualitative data in a 
second phase (Figure 2.2). The researcher connects the phases by using the 
quantitative results to shape the qualitative research questions, sampling, and data 
collection. The purpose of this design is to explain quantitative results (significant, 
nonsignificant, outliers or surprising results); qualitative results are needed to 
explain the findings. This design can potentially guide researchers to select the 
different patient groups to sample and interview based on quantitative results. This 
design is ideal where participants are available for the second wave of data 
collection; there is adequate time to conduct two phases, and the 
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researcher/research team have limited resources and need to collect and analyse 
one data type at a time.  
 
Figure 2.2: Explanatory Sequential Design. Adapted from Designing and Conducting 
Mixed Methods Research. Creswell JW & Plano Clark (2007). 
Morton et al. in their mixed methods study intended to discover the essential 
factors of dialysis that influence patients and caregivers make decisions about 
treatment. (146). In the quantitative arm, using a nominal group technique, a rank 
of the most critical factors of dialysis on which patients and caregivers make 
decisions about treatment was obtained. Purposive sampling was then used to 
recruit participants into each nominal group. Integration of the two aspects of the 
study occurred following analysis of both phases. This approach helped to 
understand factors important to patients and caregivers about dialysis (treatment 
that enhances survival and can be performed at home). 
Tong et al. aimed to determine patient preferences for how kidneys should be 
allocated for transplantation. (147) Patients on dialysis and renal transplant were 
purposively selected from two centres in Australia to participate in nominal/focus 
groups (Qualitative). Participants then identified and ranked criteria they 
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considered essential for deceased donor kidney allocation (Quantitative). Most 
patients prioritised that matching, wait-list time, medical urgency, the likelihood 
of surviving surgery, age, comorbidities, duration of illness, quality of life, the 
number of organs needed and impact on the recipient's life circumstances were 
important considerations. Supporting their rankings were four central themes: 
enhancing life, medical priority, recipient valuation, and deservingness. 
The limitations of this design type are that it may be challenging to obtain ethics 
approval when the second phase cannot be specified before the first phase 
complete. Although this design helps to theoretically inform patient selection to 
sample for the qualitative study in the different patient groups, it could equally 
create a dilemma regarding whom to sample and criteria to be used for sample 
selection for a qualitative study. For example, in both the above-listed studies had 
there been an extensive list of factors listed regarding dialysis by patients and 
caregivers or criteria essential for deceased donor kidney allocation would have 
caused a dilemma on whom to sample for the qualitative study. Also, the two 
phases require adequate time to implement, and the participants need to be 
contacted for the second round of data collection.  
2.2.4.3 The Exploratory Sequential Design 
In this design, the researcher starts by collecting and analysing qualitative data 
first.  
This is also referred to as instrument development design. The purpose of this 
design is to generalise qualitative findings to a more substantial sample. The 
results of the qualitative data are used to build the subsequent quantitative phase. 
The phases are connected by using the qualitative results to shape the quantitative 
phase by specifying research questions and variables, and / or developing an 
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instrument. (Figure 2.3) This design is useful where important variables are 
unknown, instruments are unavailable, or if new questions are likely to emerge 
from qualitative results.  
 
Figure 2.3: Exploratory Sequential Design. Adapted from Designing and Conducting 
Mixed Methods Research. Creswell JW & Plano Clark (2007). 
 
Tam-Tham et al. conducted a mixed methods study to identify barriers and 
facilitators to conservative care for older adults with chronic kidney disease. 
(148), using an exploratory sequential design. First, they interviewed primary 
care physicians to determine their perspectives on conservative care for older 
adults with stage 5 CKD. They then designed a questionnaire based on the 
findings from the qualitative interviews to be used in a broader survey of 
primary care physicians to determine the prevalence of key barriers and 
facilitators to the provision of conservative care for older adults with stage 5 
CKD. 
Pai et al. used a sequential mixed-method design to explore strategies used by 
families to manage the post-transplant oral medication regimen in adolescents 
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with renal transplants. (149) The qualitative arm involved semi-structured 
interviews assessing tasks used by family members. The qualitative arm 
informed the quantitative arm which involved assessment of pillbox filling, 
calling for refills and verifying that the pillbox was filled correctly. The 
integration of the two arms occurred following analysis of both phases. The 
study highlighted the need to bolster self-management skills among 
adolescents with renal transplants.  
Similar to the explanatory sequential design one should have adequate time to 
conduct two phases as the researcher need to collect and analyse one data type 
at a time. However, the participants in the quantitative study might not all be 
the same individuals who provided qualitative data. The limitations are again 
similar to explanatory sequential design with two phases requiring adequate 
time to implement and difficulty applying for ethical approval as a result of an 
inability to specify quantitative procedures.  
2.2.4.4 The Concurrent Embedded Design 
In this design, the researcher collects and examines qualitative data within a 
quantitative research design or vice versa. The collection and analysis of the 
secondary data set occur before, during, and / or after the primary methods. 
(Figure 2.4). This study design is usually carried out to augment a research 
project, for example, to improve recruitment procedures in a study, examining the 
intervention process or explaining reactions to participation.  




Figure 2.4: Concurrent Embedded Design. Adapted from Designing and Conducting 
Mixed Methods Research. Creswell JW & Plano Clark (2007). 
To explore the palliative care needs of patients with a non-cancer diagnosis (end-
stage heart failure, renal failure or respiratory disease), Fitzsimons et al. adopted a 
mixed method approach. (150) The quantitative aspect of the study used the SF36 
Quality of Life survey and Hospital Anxiety and Depression questionnaire. The 
qualitative arm involved nested interviews and focus groups. Results were 
reported separately with minimal integration during the analysis phase with the 
conclusion that patients dying from chronic illness in this study had several 
concerns and unmet clinical needs. 
The strengths of this study design are that it is appealing to those who are 
accustomed to traditional designs and also lends itself to the team. This design 
offers the capacity to improve the broader design, with supplemental data and also 
gives the researcher the flexibility to publish results separately. The shortcomings 
of this design are that the data from the two separate methodologies might be 
challenging to integrate. 
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2.3.  Doctor of Philosophy (PhD) study design 
The PhD takes advantage of a mixed method design (convergent parallel/ 
triangulation design) to obtain different but complementary data to expand 
quantitative results with qualitative data. The intention was also to bring together 
the differing strengths and non-overlapping weaknesses of quantitative methods 
(large sample size, trends, generalisation) with those of qualitative methods (small 
sample, details, in-depth) to understand more fully the various factors that could 
affect a study’s external validity (generalisability).  
To approach this systematically, it was considered that there were three stages at 
which external validity might be threatened (Figure 2.5): 
1. At the design stage, the threat to external validity could be due to selective 
inclusion criteria, and as a result, the potential recruits are unrepresentative 
of the population. There is a potential of selection bias occurring when the 
study sample does not represent the population that the investigator hopes 
to make generalisations to. 
2. Recruitment into studies can often be problematic, and quite often older 
frailer patients with multiple medical problems are less likely to agree to 
participate in studies. (151-153) Non-participation of specific groups of 
patients can have a poor outcome on a study’s generalisability.  
3. Finally, proficient reporting is essential, and studies should be reported in 
a way that allows clinicians to judge to whom they can reasonably be 
applied. Substandard reporting, therefore, threatens the assessment of the 
external validity of a study. 




Figure 2.5: Threats to external validity at the design, recruitment and reporting stage. 
 
The design was a predominantly quantitative mixed method study of convergent 
parallel/ triangulation design. (Figure 2.6) This figure also illustrates the timeline 
of the various arms of the study.  
The quantitative arm aimed to quantify selection biases and generalisability 
occurring during the recruitment to EQUAL and therefore understand the 
applicability of observational data to the whole patient cohort. This involved a 
retrospective observational cohort study with patients in primary and secondary 
care meeting the same inclusion criteria as EQUAL. 
The qualitative aspect involved semi-structured interviews with patients who 
agreed and who did not agree to participate in EQUAL and thus aimed to 
understand threats to generalisability at the recruitment stage.  
The systematic review aimed to understand the threats to generalisability at the 
reporting stage and to determine whether the publication of the STROBE 
statement has improved the quality of reporting of observational studies. 




Figure 2.6: Mixed methods study design of the PhD using the convergent parallel/ 
triangulation design 
The next chapter is dedicated to the first study of this PhD, the quantitative arm 
which aimed to compare the patients recruited into EQUAL with patients meeting 
the same inclusion criteria but in primary and secondary care.
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CHAPTER 3. USING PRIMARY CARE DATA TO 
UNDERSTAND THE GENERALISABILITY OF 
CLINICAL COHORTS: THE EXAMPLE OF 
ADVANCED CKD IN THE ELDERLY 
The previous chapter set out the broad methodological approach that will be used in 
the Doctorate of Philosophy (PhD), a predominantly quantitative mixed methods 
study with three discreet studies, using the convergent parallel/ triangulation design, 
embedded within the multi-national European QUALity Study on the treatment of 
advanced chronic kidney disease (EQUAL). This chapter covers the first study of the 
PhD which aims to tease out the threat to generalisability as a result of selection 
biases that could have occurred at the design and recruitment stages of the study by 
using quantitative methods. It begins by summarising some of the background 
information presented in Chapter 1  
3.1  Introduction 
The Global Burden of Disease Study showed that chronic kidney disease (CKD) 
was one of the top 20 foremost reasons for mortality (154-157). CKD is prevalent 
in the elderly and is associated with increased morbidity and mortality. (158, 159) 
Even though patients with CKD unquestionably have enhanced the risk of 
advancing to end-stage renal disease (ESRD) (160), their risk of cardiovascular 
(CV) morbidity and mortality are more significant. (161) The EQUAL Study is an 
international prospective observational cohort study funded by the European 
Renal Association, European Dialysis and Transplant Association (ERA-EDTA) 
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on treatment in advanced CKD and to determine when dialysis should be initiated 
in elderly patients. (129)  
Cohort studies are at the top of the ladder of observational studies and are 
invaluable in studying rare exposures, examining multiple potential effects of a 
single exposure, testing multiple hypotheses and capturing adverse effects/harm in 
the long term. (89) The results from some well-conducted cohort studies have 
shown to be analogous to those from randomised trials (RCTs), though caution is 
still required for residual confounding unless the study is a natural experiment. 
(94, 162) Indeed, the international, Dialysis Outcomes and Practice Patterns Study 
(DOPPS), which analysed observational data using an instrumental variable 
approach, has influenced dialysis practice across five continents, more than any 
single RCT. (163) In the existing economic climate, it is also apposite that cohort 
studies are considerably less expensive to perform than RCTs. (86) 
A general challenge of all research and particularly that of a cohort study is 
external validity (generalisability). (107) External validity has been discussed in 
detail in section 1.3 of the introduction chapter. For the results of any study to be 
useful, their relevance beyond the studied population needs to be understood, i.e. 
their generalisability. (107)  
Threats to the generalisability of various clinical study designs have been well 
reported in the literature. (107-110) When designing a study, the researcher has to 
take into account the setting in which the study will be carried out, including any 
peculiarities of the health-care systems. This issue is particularly relevant to 
international studies, where the differences between health-care systems could 
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potentially impact upon the outcome (results) of the study. Furthermore, 
differences between countries with regards to racial differences in pathology and 
natural history of the disease, the methods of diagnosis and disease management 
could also affect the generalisability of studies. (164) Selection of centres and the 
decision whether to recruit participants from primary, secondary and tertiary care 
could also have potential implications for a study’s generalisability. Centre 
selection is likely to influence case-mix and could introduce bias in the measures 
of effect. For example, patients treated in tertiary hospitals (higher volume 
hospitals) are likely to have better clinical outcomes and in epidemiological 
studies can under or overestimate true prevalence of conditions (165-167). 
Patients managed in hospital clinics (secondary care) will differ from those 
managed in primary care as their disease condition is likely to more severe and 
they are more likely to be symptomatic or to have other comorbidities. 
Alternatively, patients who are managed in the community are likely to be multi-
morbid and find it difficult to attend the hospital. The above issues again will have 
an impact on the case-mix of a clinical study. The researcher, therefore, needs to 
decide, based on the research question being addressed, whether recruitment 
should be from all types of centre or can be restricted to one or two types with the 
implications that this might have for generalisability. 
A significant threat to generalisability in cohort studies comes from selection bias. 
Cochrane collaboration defines selection bias as “systematic differences between 
baseline characteristics of the groups that are compared.”(168). For example, those 
recruited vs those not recruited, in RCTs intervention and control groups and in 
cohort studies exposed or unexposed subjects. In comparison with RCTs, where 
this is unusual and may occur as a result of the failure of randomisation or small 
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sample sizes, in cohort studies selection bias occurs due to a non-random sample 
of a population causing some participants in the population to be less likely to be 
included than others(169, 170).  
Miguel Delgado-Rodrıguez et al. in their publication define selection bias as “The 
error introduced when the study population is not representative of the target 
population” which could occur when the participants who agree to take part in a 
study is not representative of the population that the researcher hopes to make 
generalisations to. (171) For example, patients who are frailer and sicker and do 
not take part in studies. (172) alternatively, linguistic or health barriers hinder 
participation, which results in self-selection of participants. (173) Cultural 
differences and socioeconomic status can also impact on willingness to 
participate. Such exclusions mean that the study findings cannot be generalised to 
the patient population that experiences the most morbidity and mortality, 
especially with absolute risk reduction and numbers needed to treat. (174) On the 
contrary, this may not be true for estimates of relative risk where the selection 
itself introduces a bias into the risk estimate rather than the difference between the 
groups for an absolute measure of risk. Because of this, conclusions about 
extrapolating to other populations, geographic locations or facilities need to be 
made with caution. One approach to deal with this is to collect information on the 
general population from which the study population is taken. For example, in the 
North American Atherosclerosis Risk in Communities (ARIC) study, 
generalisability was examined by nesting study patients in communities covered 
by broad surveillance. (97, 98) In the community surveillance component, the 
occurrence of myocardial infarction (MI) and coronary heart disease (CHD) death 
and heart failure (inpatient and outpatient) was ascertained for all residents of the 
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communities. The events were investigated by review of hospital records and by 
query of physicians. The study showed that age-adjusted rates of MI were lower 
than those based on hospital discharge diagnosis code (e.g., 5.60/1000 vs 
11.50/1000 among Forsyth County white men, respectively). Age-adjusted rates 
of definite fatal CHD were similarly lower than rates based on the underlying 
cause of death code (e.g., 2.82/1000 vs 4.52/1000 among Jackson black men, 
respectively).(175) This helped to understand the representativeness of the study 
participants to the broader community. 
3.1.1. Aims and objectives 
The aims and objectives of the first study of the PhD (main quantitative 
component) are as detailed below 
3.1.1.1. Aim 
To develop a methodology that enables us to quantify selection biases 
and generalisability occurring during the recruitment to observational 
studies and therefore to understand the applicability of observational 
data to the whole patient population by using existing primary care and 
secondary care databases. 
3.1.1.2. Objectives 
1. To quantify the extent of selection bias in recruitment to EQUAL and 
interpret the results in the context of the entire population by 
describing the differences in baseline demographics between patients 
in primary care and secondary care meeting the same inclusion criteria  
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2. To enable the understanding of the selection that has occurred at 
recruitment and the generalisability of the findings to the entire 
population by describing differences in outcomes (patterns of 
hospitalization and mortality and morbidity) of CKD patients in 
primary care and secondary care meeting the same inclusion criteria  




3.2  Methods 
3.2.1 Study Design 
A prospective cohort study with retrospective analysis of prospectively 
collected data. 
3.2.2 Data Sources  
3.2.2.1 The Health Improvement Network (THIN) 
In the majority of general practices(GP), records are held in electronic 
format in Electronic Patient Records (EPRs) and are potentially 
available for extraction and analysis. (176) There are currently seven 
GP EPRs in the UK. These seven systems manage the patient data for 
the majority (98.9%) of patients in England, with distinct geographical 
variation in their distribution. (176, 177)  
There are a few datasets that have been derived from primary care 
(GP) EPRs. Primary care patient databases reflect daily care provided 
to patients within a sample of practices and contain demographic 
information, patient-related diagnoses, and prescriptions. (176, 178, 
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179) The strengths of general practice data are that they are 
population-based and derived from a representative subset of the 
population. (180, 181) The four common GP datasets have been 
summarised in Table 3.1. 
The choice of THIN over other GP databases was mainly down to its 
affordability and also notably as it included access to HES linked data 
for the study. The other reason was due to the generalisability of the 
database and its validation for epidemiological studies of CKD.(180, 
182-185). 
The Health Improvement Network (THIN) is one of the top four 
electronic medical record databases and an alliance between two 
companies; In Practice Systems (Vision software) and IMS Health 
who are the guardians of the data for use in medical research. (186) 
The data is captured during the day to day practice and regularly sent 
to THIN. As of January 2014, THIN held longitudinal anonymised 
patient Electronic Medical Records (EMRs) from 588 of the 9,458 
general practices across the UK. The database includes more than 12.4 
million patients, of whom 4.7 million are currently active. The 
database holds information on demographics, diagnoses, prescriptions, 
referrals, hospitalisations, laboratory tests, immunisations, clinical 
measures taken within the practice, and area-level statistics such as 
Townsend deprivation scores. Of the 588 practices, 430 were in 
England, with 157 of these linked with Hospital episode statistics 
(HES). The data from THIN has been organised into clear, flexible 
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structures as four separate files and three linked files. Table 3.2 details 
the various files and the information contained within them. 
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Table 3.1: Summary of General Practice databases in the UK 
NA=Not available, * CPRD and THIN have an overlap of some patients in both datasets. 
Name 












The Clinical Practice Research Datalink 
(CPRD)* (179) 
Vision 674 13.7 5.0 7.1% 2/7/2013 
The Health Improvement Network database  
(THIN)* (180) 
Vision 588 12.4 4.7 6.2% 1/1/2014 
Q Research (187) 
Egton Medical Information Systems 
(EMIS) 
754 13.0 NA 7% 1/5/2014 
Research One (188) System One 400 5.0 NA NA 1/2/2013 




Table 3.2: Summary of the files within the THIN database and information contained within them. 
Name of the file Files type Data contained in the files Details 
Patient file Separate file Data on demographics 
Contains information on patient characteristics and registration 
details 
Medical file Separate file Data on medical events 
Contains details of symptoms, diagnoses and interventions 
recorded by the GP and the primary care team. 
Therapy files Separate file Data on prescriptions 
Contains details of prescriptions issued to patients within 
primary care. 
Additional Health Data (AHD) file Separate file 
Data on prevention, lifestyle 
and diagnostics  
Contains information on lifestyle data, preventative health care, 
immunisations, test results and death details. 
Consult file  Linked file Data on consults 
Consult file provides a record of the patient consultations with 
information on date, time and duration. 
Postcode variable indicators (PVI) Linked file Patients’ ward/location 
Contains anonymous patient postcode-linked, socioeconomic, 
ethnicity and environmental indices for studies using THIN 
Data. 
Staff file Linked file Staff roles linked by staff ID 
Contains details on the sex and roles of the practice staff that 
may have entered the data. 
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All GPs that subscribe to the THIN database use Read codes. 
There are presently approximately 109,000 unique Read codes 
available. (189) The Read codes are a very comprehensive 
coded clinical language. Read Codes are a norm for reporting 
the care and management of patients, such as terms to cover 
observations (signs and symptoms), diagnosis, procedures and 
investigations. There are also codes for innumerable 
administrative purposes. The Read codes were designed and 
expanded by Dr James Read in 1982, for use in General 
Practice. The NHS acquired the Read codes from Dr Read In 
1990 and made them the norm for use in the NHS. (190) The 
NHS has developed the codes further to cover the majority of 
the areas of clinical practice; which encompasses fields such 
as nursing, physiotherapy and health visiting. 
Information on the generalisability of the results of the 
database to the general population is essential and assessed by 
comparing observed demographics, chronic condition 
prevalence, deprivation and deaths with UK national 
estimates. (34) A study looking into the generalisability of the 
database showed that THIN was generalisable to the UK 
regarding demographics and crude prevalence’s of major 
conditions. (180, 183) but THIN and national death rates were 
similar only when adjusted for demographics and deprivation. 
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THIN is, therefore, a reliable and useful data source for 
conducting research and deriving information on UK 
healthcare. The THIN database has also been validated for use 
in epidemiologic studies of chronic kidney disease. (185, 191) 
These studies have ascertained the prevalence of CKD 3-5 
using laboratory reported eGFR and also identified a valid list 
of Read codes to find subjects with moderate to advanced 
CKD. Patient mortality data in THIN comes from information 
which is sent to the patient’s general practitioner upon 
completion of the death certificate. The accuracy of diagnosis 
and death records in the THIN database has been previously 
validated with the agreement of the date of death within one 
day in 95% of cases and cause of death 93%. (182, 184, 192) 
3.2.2.2 EQUAL (European QUALity Study on the treatment of 
advanced chronic kidney disease) 
EQUAL is a prospective observational cohort study which recruited 
patients aged ≥ 65 years; with an incident eGFR of ≤20 
ml/min/1.73m
2
 within the last six months, regardless of subsequent 
eGFRs. In the UK, it recruited from March 2013 and closed 
recruitment in December 2015. (30) The detailed methods of the 
EQUAL study have been described in Chapter 2 (refer to section 
2.1) 
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3.2.3 Study Cohorts 
3.2.3.1 The Health Improvement Network (THIN) 
The following steps were taken to most closely match the THIN 
cohort to the EQUAL cohort. 
3.2.3.1.1 Identifying patients in THIN 
Suitable patients in the THIN database had to meet the 
EQUAL inclusion criteria with the age of ≥ 65 years and their 
incident (first) eGFR reading ≤ 20mls/min/1.73m
2
 after their 
65th birthday. The initial extraction was carried out by IMS 
Health based on the following simple rules. 
1. The THIN database was searched for all patients with 
a code for an eGFR result. 
2. From patients found in step 1, the dataset was 
restricted to patients who were 65 and over between 
01/01/2005 – 31/12/2013 (Thin was formed in 2003, 
but the mortality recording has been reliable since 
2005). 
3. From the patients identified in step 2, only those from 
English GP practices were included (to link to HES 
data). 
4. From the patients found in step 3, the dataset was 
restricted to patients with code 1001400326 (eGFR), 
in the Additional Health Data (AHD) file and a data 
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value  20 ml/min/1.73m2 where the first reading was 
after their 65th birthday. 
If the first reading was “0” or missing, the next reading 
>0 and ≤20 on the same day was looked up. 
5. From patients found in step 4, those with a 
transplantation code were excluded. 
3.2.3.1.2 Inclusion and Exclusion criteria (Including definitions) 
To identify the primary and secondary care cohorts, the full 
patient history which included patient timeline and 
characteristics on THIN was used. Characteristics of the 
patients in the cohorts and reasons for exclusion were defined 
as follows: 
a. Identifying patients with an index eGFR between 
1/4/2007 to 31/12/2012 
The index date was defined as the date of the first 
eGFR reading in the dataset ≤ 20ml/min/1.73m
2
. The 
index eGFR was the eGFR value on the index date. 
The cohort was restricted to patients with their first 
recorded drop in eGFR to ≤ 20 between 1/4/2007 to 
31/12/2012 (Figure 3.1). (The Department of Health 
introduced universal eGFR reporting in England from 
1/4/2007. (25) Hence any reported eGFR readings after 
this date would be based on a standardised method 
Chapter 3: Quantitative Chapter 
81 
 
using Modification of Diet in Renal Disease (MDRD) 
which is based on serum creatinine that has been 
aligned to isotope dilution mass spectrometry 
(IDMS).) The 15 months before the index date was 
used to determine a historical baseline for each patient. 
The period between 1/1/2013 to 31/12/2013 was to be 
used to study outcomes ensuring that all patients 
included had a minimum of 1 year follow up. 
Patients with more than one eGFR reading >20 
ml/min/1.73m2 on the same day as the day that they 






Figure 3.1: Study window for identifying the patients in primary and secondary care 
cohort meeting the same inclusion criteria as EQUAL 
b. Identifying patients with valid patient time in THIN 
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“Valid patient time” in THIN is defined as the time 
between the patient’s start and end dates. Start dates 
within THIN are defined as the latter of; Patient 
registration date (the date the patient registered at the 
GP practice), the Practice Vision date (the date that the 
practice started using the Vision practice management 
software), or the Practice Annual Mortality Rate 
(AMR) date (The AMR date is the year from which the 
GP practice is believed to be reporting all-cause 
mortality correspondingly in accordance with the 
national statistics given the practice’s demographics).  
The end date within THIN is defined as the earliest of; 
the practice last collection date (the last collection date 
for actively registered patients), or the patient transfer 
out date (the date the patient has died or left the 
practice).  
To have a reliable window in which the patient could 
have recorded eGFR ≤ 20mls/min/1.73m
2
 a study 
window was defined for each patient. The start of the 
study window was defined as the latest date out of 
either the start date for the practice or 1/4/2007 (1 year 
after the introduction of mandatory eGFR reporting). 
The end of the study window was the earliest date of 
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either their end date or 31/12/2012 (to ensure all 
patients had a minimum of 1 year follow up to 
31/12/2013). Any patient with an index eGFR reading 
outside the window was excluded. 
Any patients who were not at the practice for at least 
three months before their index date were excluded, 
thereby ensuring that patients had a likelihood of 
having one other blood test (eGFR) before their index 
date. Also, patients who had transferred out of their 
practice within 12 months after the date that they 
reached eGFR of 20 ml/min/1.73m
2
 were excluded. 
c. Establishing a historical baseline 
EQUAL inclusion criteria required an eGFR reading of 
≤30mls/min/1.73m
2
 three months before the index 
event/acute event and have their first eGFR 
≤20mls/min/1.73m
2
 in the last six months in patients 
who are attending nephrology clinic. 
However, for patients in primary care (in our case, the 
THIN database), firstly there was a need to make the 
distinction between patients who have no readings 
before their index date and those with at least one 
eGFR reading. The following algorithm was used to 
determine the patient's historical baseline. 
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i. Any patient who had no historical readings before 




ii. A 15-month window before the index reading was 
chosen to determine a historical baseline. To 
ensure that patients on annual review (12 monthly) 
had the opportunity of having a repeat blood test, a 
further three months added to incorporate patients 
who would have their blood checked late.  
iii. Any patients who only had readings beyond 15 
months ago were excluded.  
iv. If patients had ≥ three readings in the six months 
before their index date an average of their eGFR 
readings were taken. In patients who had <3 
readings in the period six month before their index 
date the average for the last 15 months was taken. 
v. Patients who had an average 
eGFR>30mls/min/1.73m
2
 (in the 6 or 15 months 
before their index date, depending on available 
historical data) were excluded.  
The patients identified by this approach were the 
closest match to those identified by the EQUAL 
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inclusion criteria (without yet applying the rule in 
EQUAL related to attending a nephrology clinic). 
d. Renal Replacement Therapy (RRT) codes before the 
index date 
Patients with RRT related codes (dialysis and 
transplantation read codes) within THIN or 
International Classification of Disease (ICD) 10 and 
Classification of Interventions and Procedures (OPCS) 
codes within Hospital Episodes Statistics (HES) - prior 
to the index date were excluded (refer to Appendix 3.1 
for RRT codes), thereby excluding patients with 
previous history of dialysis or transplantation as per 
the EQUAL inclusion criteria. 
e. Defining the Primary and Secondary care cohort 
There are two ways of identifying speciality referral in 
the THIN database in the medical file: 1. The variable 
“nhsspec”, 2. The variable “medcode (readcode)”. In 
the HES database, speciality referral can be derived 
from the variables “mainspef” & “treatspef” relating to 
the HES OPD speciality code for Nephrology. 
The primary care cohort was defined as a random 
sample of eligible cases from the THIN database not 
attending nephrology services. Within the THIN/HES 
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linked database, this was defined as patients with no 
speciality referral code over the full patient history 
either THIN GP database (nhsspec or medcode 
(readcode)) (Refer to the Appendix 3.2) or HES OPD 
code (mainspef & treatspef). 
The secondary care cohort was defined as a sample of 
eligible cases from the THIN database attending 
nephrology services. Therefore, patients who have 
either a THIN speciality code for Nephrology 
(nhsspec), readcode indicating speciality referral 
(medcode) (Refer to the Appendix 3.2) or HES OPD 
code suggesting patient attendance in a hospital 
nephrology clinic (mainspef & treatspef) were 
allocated to patients attending secondary care.  
3.2.3.2 EQUAL  
The EQUAL cohort was restricted to the first 250 patients recruited 
into the study in the UK. The 250
th
 UK EQUAL patient was 
recruited on the 23/09/2014 and should have completed their 12 
months follow up visit on or around 22/09/2015. However, given 
that follow-up in EQUAL was designed such that it would coincide 
with the patients’ routine clinic visits, a further 6-week window was 
added to ensure all patients had completed their 12 months follow 
up visit. This guaranteed that the majority of the included patients 
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had the opportunity to have completed a minimum of 1 year follow 
up. Data was therefore extracted on 15/11/2015. 
3.2.4 Study Measurements 
3.2.4.1 Deprivation 
Socioeconomic status was estimated using the Townsend 
socioeconomic deprivation score; this is calculated using economic 
and demographic data by the patient’s postcode. (193) In the THIN 
database, Townsend scores and urban classification were attained 
for each area using 2001 census data. Each output area 
corresponded to roughly 150 households (Lower Super Output 
Area-LSOA). The scores were transformed from exact scores into 
quintiles: five groups of identical size, numbered 1 to 5, to specify 
the level of deprivation of the area with one indicating least 
deprived and five indicating most deprived. UK postcodes were 
then matched to output area Townsend deprivation quintile and 
urban classification. The outcome was a table of all UK postcodes 
with a deprivation quintile. The table contains Townsend scores for 
Scotland, Northern Ireland, England, and Wales. Researchers do 
not have access to the patient postcode, and the above matching 
exercise was carried out by IMS Health. 
For the EQUAL cohort, the Townsend quintile scores and urban 
classification was mapped to the EQUAL patient's postcode using 
the subset of postcodes in the THIN dataset. This is an advantage of 
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using IMS Health’s data, and this approach ensured that the method 
of determining the Townsend quintile and urban classification was 
the same in both the THIN and EQUAL datasets. 
3.2.4.2 Laboratory data 
Individual patient laboratory data were determined using the 
relevant additional health data (ahd) codes within the ahd file of the 
THIN database. Refer to Appendix 3.3 for ahd codes related to the 
laboratory data. 
In EQUAL, the index eGFR was defined as the first drop in eGFR 
to 20 ml/min/1.73m
2
 within the six months before the baseline visit, 
regardless of subsequent eGFRs. In the THIN database, this was 
defined as the first drop in eGFR to ≤20mls/min/1.73m
2
 over the 
full patient history. Patients who participated in EQUAL had their 
baseline visit up to 6 months+6 weeks (222 days) after the index 
eGFR. Laboratory data in EQUAL was captured in the case record 
forms (CRFs). To keep the comparison similar to EQUAL, a 
window was created with the start of this window being the index 
date and the end of the window being the earliest of the patient’s 
end date, 31/12/2012 or 222 days from the index date, during which 
the blood tests measured for patients within THIN would be in a 
similar window to the blood tests recorded at baseline for patients 
within EQUAL. 
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Other laboratory data included creatinine, albumin-creatinine ratio,  
haemoglobin, calcium, phosphate, parathyroid hormone, albumin 
and blood pressure. Laboratory data that were recorded on or 
closest to the index date within the window were considered. Units 
of measurement for the laboratory data were harmonised to those 
that were used in the EQUAL study. 
3.2.4.3 Medication 
Individual patient medication history was determined using the 
relevant British National Formulary (BNF) codes (bnfcode) within 
the Therapy file of the THIN database. The BNF is a book 
produced by the British Medical Association and the Royal 
Pharmaceutical Society of Great Britain. (194) It contains vital 
information on the prescribing, monitoring, dispensing and 
administration of medicines in the UK. The therapy file and the 
BNF codes only cover prescription issues in primary care. All 
prescriptions issued by the GP are recorded in the therapy file with 
an associated prescription date (prscdate). BNF codes were used in 
preference to the drug code (drugcode) as there were two or more 
drug codes for a single drug that differed by dosage. To keep the 
comparison similar to EQUAL and in keeping with recommended 
NHS policy restricting prescription length to 4 weeks (28 days), 
any prescriptions issued before 28 days of the index date were 
excluded. (195, 196) An individual patients’ drug count was 
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calculated by summing up all the unique BNF codes in the month 
before the index date. Patients on antihypertensives, lipid-lowering 
medications and anticoagulants/antiplatelet agents were also 
determined by creating an indicator (Binary response: Yes/No) 
(refer to Appendix 3.4 for BNF codes related to the class of 
individual medicines). Medication history in EQUAL was captured 
in the CRFs.This included all the drugs that each participant was 
taking at the baseline visit. 
3.2.4.4 Comorbidity 
Individual patient co-morbidity was ascertained using the variable 
“category” (3=diagnosis) within the medical file of the THIN 
database and the respective Read codes (medcode) associated with 
this. The Charlson Comorbidity Index was used as it has been 
validated to assess comorbidity and predict survival in patients with 
kidney disease. (197, 198) The Charlson weights associated with 
each comorbidity were calculated using the Read code to Charlson 
weight mapping previously described and validated by Khan et al. 
(199). The Charlson comorbidity index (CCI) was calculated for 
each patient by summing the individual weights. (200) CCI was 
used to provide a summary of comorbidity for each patient and to 
adjust for comorbidity burden in the regression models. The co-
morbidity accrued up until the index date was used to calculate the 
CCI. 
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Co-morbidity was captured in EQUAL CRFs mainly as a binary 
(Y/N) response in keeping with the CCI. The CCI for the EQUAL 
cohort was calculated by summing the individual weights attributed 
to the relevant co-morbidities.  
On account of having moderate to severe CKD, all patients in the 
study had a minimum CCI of two. Given the skewed distribution of 
CCI in the study population, for adjustment in the Cox-regression 
models, CCI was grouped into three categories (2–3, 4-5, ≥6) in 
keeping with other peer-reviewed publications. (201, 202)  
Some of the individual co-morbidity components of the CCI were 
grouped for adjustment in the logistic regression models to preserve 
the degrees of freedom. Myocardial Infarction and Congestive heart 
failure were grouped under Cardiac, Diabetes included Diabetes 
without end-organ damage and Diabetes with end-organ damage 
(retinopathy, neuropathy, nephropathy, or brittle diabetes), Stroke 
included Cerebrovascular accident with mild or no residual 
symptoms or TIA and Hemiplegia, Other included Dementia, 
Peptic ulcer disease, Mild liver disease (without portal 
hypertension, includes chronic hepatitis), Moderate or severe liver 
disease and Acquired Immunodeficiency Syndrome. 
3.2.4.5 General Practitioner consultations 
Patient consultations with a general practitioner are recorded within 
the medical file of the THIN database using a unique consultation 
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ID (consltid). The consultations were limited to patients seeing a 
doctor within the practice using the locate variable (locate=A & 
locate=I). (refer to Appendix 5.5 for location codes related to 
consultation locations). This information was not captured in the 
EQUAL study. 
3.2.4.6 Clinical outcomes 
3.2.4.6.1 Mortality 
Mortality data for patients within THIN were obtained from the 
patient file of the THIN database using the variable “deathdat”. 
To calculate the time spent in the study for patients within THIN 
(Primary and secondary care cohort) and to align this with 
patients within the EQUAL study, two dates were defined for 
each patient (start and end date).  
Selective survival bias is defined as “when a series of survivors 
is selected, if the exposure is related to prognostic factors, or the 
exposure itself is a prognostic determinant, the sample of cases 
offers a distorted frequency of the exposure.”(203, 204) The 
following steps were taken to avoid the risk of immortal time 
bias (survival bias). (205) Figure 3.2 illustrates the fix used to 
negate the risk of immortal time bias. 
a. The start of survival time for patients in the primary care 
cohort was the index date.  
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b. For patients in secondary care under the care of a 
nephrologist at the time that they became eligible (eGFR 
≤ 20mls/min/1.73m
2
), the average time spent by 
EQUAL patients from the index date to the 1
st
 study 
visit (116 days) was added to the index date.  
c. For patients within secondary care that were referred to 
a nephrologist after they became eligible, six weeks was 
added to the referral date (the date referred to a 
nephrologist) in addition to the average time spent by 
EQUAL patients from the index date to the 1
st
 study 
visit (116 days). 
The end of survival follow up time (end date) was the date 
of death (deathdat) or 1 year after the start date, whichever 
came earlier. 
In EQUAL, mortality data were captured as a part of the 
CRFs. The start of survival time in EQUAL was the date of 
the first study visit, and the end of survival follow up time 
was the date of death or the end of follow up.  




Figure 3.2: Fix introduced to negate the risk of Immortal Time Bias for each of the 
cohorts 
3.2.4.6.2 Progression to End Stage Renal Disease (ESRD) and 
RRT  
Progression to an eGFR ≤ 10mls/min/1.73m
2
 in the one year 
follow up period after reaching index eGFR ≤ 
20mls/min/1.73m
2
 was calculated using the relevant ahd code 
for eGFR within the THIN dataset. This was taken as the point 
at which patients had reached ESRD. Patients that commenced 
RRT (dialysis or transplantation) in the 12 months after 
reaching index eGFR ≤ 20mls/min/1.73m
2
 were identified using 
read codes within THIN and ICD 10 and OPCS codes within 
HES (Refer to Appendix 3.1 for RRT codes). This analysis was 
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not restricted to patients attending practices linked to HES. 
Instead, HES data were used to improve the sensitivity of 
detecting patients who started RRT. To harmonise with 
EQUAL, RRT starts were calculated for each patient between 
the start date and end date as in the survival calculation. 
In EQUAL, RRT modality and date of the first dialysis were 
captured in the CRFs. 
3.2.4.6.3 Hospitalisation 
Within EQUAL hospitalisations between one study visit and the 
next were recorded retrospectively within the CRFs. 
For calculating the burden of hospitalisations in the primary and 
secondary care cohorts, the dataset was restricted to patients 
attending practices linked to HES. Patient hospitalisations are 
registered within the HES linked file in the THIN database. The 
number of admissions was calculated using the count of unique 
admission dates (admidate). The number of days spent in hospital 
was calculated by subtracting the admission date (admidate) from 
the discharge date (disdat). To harmonise with EQUAL, 
hospitalisation episodes were calculated for each patient between 
the start date and end date. 
A hospital free risk period was calculated for the patients in each of 
the three cohorts, firstly by calculating the risk period by 
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subtracting the start date from end date for each patient, then by 
subtracting the number of days in hospital from the risk period and 
finally by adding the number of admissions to hospital to account 
for the risk on the day of admission. The hospital free risk period 
was used for adjustment in the regression model. 
3.2.5 Power calculation 
The power calculation considered detecting a difference in survival 
between the EQUAL, secondary care and primary care cohorts. 
From Figure 1c in a publication by Hallan et al.,(206) the average 1-year 
survival rate in people with CKD aged ≥65 years was 82%. (206)  
No data exist for secondary care and research participating patients, so 
based on the minimal clinically meaningful difference in survival 
between the two cohorts: 
- primary care not referred to secondary care 82% survive one year 
(206) 
- secondary care 87% survive one year (patients referred to secondary 
care) 
- secondary care recruited to EQUAL 92% survive one year (patients 
attending the renal clinic and agreeing to participate in research) 
Therefore, based on a significance level of 5% and a power of 90% the 
sample size required was worked out as follows:  
- For the primary care and secondary care comparison (i.e. 82% vs. 
87% survival), 821 in each arm. 
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- For the secondary care and EQUAL comparison (i.e. 87% vs. 92% 
survival); 589 in each arm. 
3.2.6 Statistical Analysis 
Normality of the distribution of data was assessed by visual inspection of 
the histogram and normal probability plot. (207) Summary statistics 
were produced using frequencies and proportions for categorical 
variables, and means, standard deviations, medians and ranges for 
continuous variables. Categorical data were compared by χ2 tests. 
Parametric continuous data were compared using a one-way analysis of 
variance and non-parametric using Mann-Whitney tests. 
A logistic regression model was used to identify variables that were 
associated with being in the EQUAL cohort and to determine if the 
patients in EQUAL differed from a broader population of eligible 
patients (secondary care cohort). (208) Therefore in the model 
1=Particpating in EQUAL and 0=Not participating in EQUAL 
(Secondary care cohort) Univariable logistic regression models were 
built for each of the following explanatory variables: age, gender, 
deprivation, urban classification, individual comorbidity, CCI, 
haemoglobin, albumin, blood pressure and drug count. Likelihood ratio 
testing was used to determine whether to include variables from the 
univariable logistic regression model (P < 0.2) in the multivariable 
logistic regression model. Socio-demographics, laboratory variables and 
co-morbidity were added in a stepwise manner in the multivariable 
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stepwise logistic regression analysis. The removal probability for 
multivariable stepwise logistic regression analysis was P values less than 
0.1. A probability of P < 0.05 was considered to be statistically 
significant. 
A Cox proportional hazards regression model was used to compare all-
cause mortality at the one-year post-index date for patients in the 
primary care, secondary care and EQUAL cohort. (209) The predictor 
variables such as sociodemographics (index age as 5-year age bands, 
sex, Townsend score and rurality, laboratory variables (haemoglobin, 
albumin, systolic blood pressure, diastolic blood pressure) and 
comorbidity (CCI) were added in a stepwise manner. (199, 210, 211) 
Predictor variables with log-rank χ2 P values less than 0.1 were included 
in the final models. The final models were checked for the assumption of 
proportionality using the stphtest command in STATA (Schoenfeld 
residuals) to test the proportionality of the model as a whole and also as 
a test of proportionality for each predictor. Predictor variables that were 
not proportional were included as a time-varying covariate (tvc) in the 
model by using the tvc options in the stcox command in Stata. 
Given the over-dispersed count of hospitalisations in the three cohorts, a 
negative binomial regression model was used to model the count of 
hospitalisations with adjustment of variables as in the other regression 
models. (212) The models were also adjusted for hospital free period at 
risk.  
Chapter 3: Quantitative Chapter 
99 
 
All analyses were performed using Stata v13.1 (College Station, TX, 
USA). 
3.2.7 Subgroup analysis 
The following subgroup analyses were carried out  
1. Comparison of socio-demographic characteristics of patients in HES 
linked and non-HES linked practices to review for differences in the 
characteristics of the cohorts. 
2. Comparison of socio-demographic characteristics of the incident 
RRT population (age ≥65 years) from UK Renal Registry (UKRR) 
compared to patients within EQUAL. One of the main aims of 
EQUAL was to understand the timing of dialysis start in the elderly. 
This subgroup analysis intended to look for systematic differences 
between the incident RRT patients over 65 years of age and EQUAL 
participants. 
3. Comparison of socio-demographic characteristics of EQUAL 
participants with those of patients in the primary care and secondary 
care cohorts who were not living in the Strategic Health Authorities 
containing no sites taking part in EQUAL. This analysis was carried 
out to quantify the bias as a result of potential double counting of the 
EQUAL recruited patients in the secondary care cohort. 
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3.3  Results 
3.3.1 Inclusion and exclusion  
Figure 3.3 shows the flow diagram for the initial extraction algorithm used 
by IMS health to identify suitable patients in the THIN database to meet 
the EQUAL inclusion criteria as stated in section 3.2.3.1. There were 
15,564 patients identified by IMS Health using this algorithm from the 
version 1401 THIN database which was the version of the database active 
on the 31
st
 of January 2014.




Figure 3.3: Initial extraction algorithm employed by IMS Health to identify 
eligible patients to meet the EQUAL inclusion criteria from the version 1401 
THIN database.
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Figure 3.4 shows the flow diagram of the various exclusions that were 
performed on the dataset of 15,564 patients defined by IMS Health to 
further refine the patients to be included in the primary and secondary care 
cohorts that met the inclusion criteria of those recruited to the EQUAL 
study (Section 2.1.3.1 and 2.1.3.2 of Chapter 2). 
There were 14,404 patients that had their first recorded eGFR 
≤20ml/min/1.73m
2
 between 1/4/2007 and 31/12/2012. Of these patients, 
anybody who had been with their current practice for <3 months (n=594) 
before their index date was excluded as it would not have been feasible to 
calculate their historical baseline. Patients who had not contributed to 
follow up because of having transferred out of their practice within 12 
months after their index date (508) were excluded. Patients with other 
eGFR readings on the index date that was >20 ml/min/1.73m
2
 (n=44) were 
excluded. Patients with codes (READ, ICD10, OPCS) indicating RRT 
prior to index date (n=340), with no historical eGFR readings prior to 
index date (n=1967), no historical readings in the 15 months prior to index 
date (n=3200), and patients with baseline eGFR readings 
>30ml/min/1.73m
2
 in the 15 months prior to index date were all excluded. 
 
3.3.1.1 Identifying Primary care cohort 
Of the 3,986 patients who met the timeline and eGFR related inclusion 
criteria, 889 patients from non-HES linked practices were excluded as despite 
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having no speciality referral codes within THIN, they could not be reliably 
included in the primary care cohort without confirmation within HES. 
Restricting to HES linked practices ensured that the patients in the primary 
care cohort had not been under the care of a nephrologist at any point over 
their full history. There were 633 patients from practices that were linked to 
HES and had had no referral data to nephrology services both in the THIN 
database (nhsspec or readcode) or in the HES outpatient database (mainspef & 
treatspef), and these patients formed the primary care cohort.




Figure 3.4: Flow diagram of the various inclusion and exclusion criteria to 
further refine the patients to be included in the primary and secondary care 
cohorts that met the EQUAL study inclusion criteria.
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3.3.1.2 Identifying the secondary care cohort 
There were 2,464 patients that were identified as under the care of a 
nephrologist either via a THIN speciality referral code (nhsspec), a 
readcode within THIN (medcode), or who had a HES speciality 
referral code (mainspef & treatspef). Of the 2,464 patients, 1,833 were 
under the care of nephrologist before reaching eGFR 
≤20mls/min/1.73m
2
 (index date) and 631 patients were referred post 
index date. Figure 3.5 shows a breakdown of patients coded as 
attending Nephrology either in THIN (nhsspec or readcode) or HES. 
 
Figure 3.5: Patients with speciality referral code for nephrology in THIN (nhsspec or 
readcode) or HES 
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3.3.2 Patient Characteristics 
There were 633 patients in the primary care cohort, 2,464 patients in the 
secondary care cohort and 250 in the EQUAL cohort. The baseline 
characteristics of the patients in the three cohorts are shown in Table 3.3 
Patients in the primary care, and secondary care cohorts were an average 
ten years and three years older, respectively when compared to patients 
in the EQUAL study. There was a significantly higher proportion of 
male participants in the EQUAL study (60.0%) when compared to 
patients who met the EQUAL inclusion criteria in the primary (34.8%) 
and secondary care cohort (51.4%) (P <0.001). There were a higher 
proportion of patients in the EQUAL study in the most deprived 
Townsend quintile (28.4%) compared to those in primary and secondary 
care cohort (11.2% & 13.6%). EQUAL participants were more likely to 
be living in an urban postcode (86.4%) than patients in the Primary and 
Secondary care cohort (72.4% and 80.3%, respectively). 
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Table 3.3: Distribution of socio-demographic characteristics in the three cohorts 
Patient Characteristics 
Primary care cohort 
N=633 




the χ2 test for 
the difference 
in 3 cohorts 
P value 
Age at index date: mean (95% CI) 86.3 (85.8-86.8) 79.7 (79.4-79.9) 76.6 (75.8-77.4) <0.001 





≥70 - <75 19 (3.0) 426 (17.3) 58 (23.5) 
≥75 - <80 59 (9.3) 571 (23.2) 58 (23.5) 
≥80 - <85 142 (22.5) 654 (26.5) 54 (21.9) 
≥ 85 395 (62.5) 576 (23.4) 30 (12.6) 





1 106 (23.6) 469 (25.5) 44 (17.6) 
<0.001 
2 98 (21.6) 427 (23.2) 44 (17.6) 
3 102 (22.5) 377 (20.5) 43 (17.2) 
4 97 (21.4) 317 (17.2) 48 (19.2) 
5 51 (11.2) 251 (13.6) 71 (28.4) 
Urban Rural 
N (%) 
Urban 330 (72.4) 1482 (80.3) 216 (86.4) 
<0.001 Town & Fringe 91 (20.0) 227 (12.3) 18 (7.2) 
Village & Hamlet 35 (7.7) 136 (7.4) 16 (6.4) 
* 1=least deprived, 5=most deprived 
 




Table 3.4 shows the distribution of the Charlson Co-morbidity Index 
(CCI) in the three cohorts. The range of CCI in the secondary care cohort 
was higher when compared to the primary care and the EQUAL cohort. 
Table 3.5 shows the distribution of the individual component co-
morbidities of the CCI. Primary care cohort had a higher proportion of 
patients with heart disease (myocardial infarction (19.9%) and heart 
failure (32.9%)) compared to secondary care (17.0% & 22.6% 
respectively) and the EQUAL cohort (12.0% & 11.2% respectively). The 
primary care cohort had higher proportion of patients with 
cerebrovascular disease (17.1%) and dementia (7.3%) compared to the 
secondary care cohort (14.7% & 1.9% respectively) and the EQUAL 
cohort (9.6% & 0% respectively). The secondary care cohort had a 
higher proportion of patients with peripheral vascular disease (16.2% vs 
10.6% for primary care vs 10% for EQUAL), chronic pulmonary disease 
(20.6% vs 17.1%  for primary care vs 17.2% for EQUAL), rheumatic 
disease (9.5% vs 8.1% for primary care vs 3.2% for EQUAL), peptic 
ulcer disease (8.8% vs 7.1% for primary care v 2.8% for EQUAL) and 
diabetes mellitus (42.7% vs 24.8% for primary care vs 28.4% for 
EQUAL). The EQUAL cohort had a higher proportion of patients with 
hemiplegia (2.0% vs 0.2% for secondary care vs 0.6% for primary care), 
cancer (20.4% vs 16.9% for secondary care vs 18.8% for primary care) 
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and liver disease (1.6% vs 0.5% for secondary care vs 0.5% for primary 
care) compared to secondary care and primary cohort respectively. 
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Table 3.4: Distribution of Charlson Co-Morbidity Index in the three cohorts 
 
Primary care cohort 
N=633 




the χ2 test for 
the difference 
in 3 cohorts 
P value 
Charlson Comorbidity Index 
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Table 3.5: Individual components of the Charlson Comorbidity Index (CCI) 






the χ2 test for the 
difference in 3 
cohorts 
P value 
Myocardial Infarction N (%) 1 126 (19.9) 418 (17.0) 30 (12.0) 0.017 
Congestive Heart Failure N (%) 1 208 (32.9) 556 (22.6) 28 (11.2) < 0.001 
Peripheral Vascular Disease N (%) 1 67 (10.6) 399 (16.2) 25 (10.0) < 0.001 
Cerebrovascular disease N (%) 1 108 (17.1) 362 (14.7) 24 (9.6) 0.018 
Dementia N (%) 1 46 (7.3) 47 (1.9) 0 (0.0) < 0.001 
Chronic Pulmonary Disease N (%) 1 108 (17.1) 504 (20.6) 43 (17.2) 0.101 
Rheumatic Disease N (%) 1 51 (8.1) 233 (9.5) 8 (3.2) 0.003 
Peptic Ulcer Disease N (%) 1 45 (7.1) 216 (8.8) 7 (2.8) 0.003 
Diabetes Mellitus N (%) 1 157 (24.8) 1051 (42.7) 71 (28.4) < 0.001 
Diabetes with complication N (%) 2 37 (5.9) 429 (17.4) 32 (12.8) < 0.001 
Hemiplegia N (%) 2 4 (0.6) 5 (0.2) 5 (2.0) < 0.001 
Cancer N (%) 2 119 (18.8) 419 (16.9) 51 (20.4) 0.248 
Metastatic Cancer N (%) 6 5 (0.8) 12 (0.5) 5 (2.0) 0.017 
Mild Liver Disease N (%) 1 3 (0.5) 12 (0.5) 4 (1.6) 0.078 
Moderate Liver Disease N (%) 3 0 (0.0) 3 (0.12) 1 (0.4) 0.3 
AIDS N (%) 6 0 (0.0) 1 (0.04) 0 (0) 0.836 
 




Table 3.6 shows the distribution of the medication count in the three 
cohorts and the proportion of patients on drugs to prevent progression of 
CKD such as anti-hypertensives, antiplatelet & anti-thromboembolic 
drugs and lipid-lowering drugs. Although the overall medication burden 
was similar between the three cohorts, EQUAL had a higher proportion 
of patients on antihypertensive (92.4% vs 76.4% for secondary care vs 
73.1% for primary care), lipid-lowering drugs (69.2% vs 49.9% for 
secondary care vs 36.2% for primary care) and 
thromboembolic/antiplatelet drugs (59.6% vs 48.2% for secondary care 
vs 51.7% for primary care) when compared to the secondary care and 
primary care cohort respectively.
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Table 3.6: Distribution of the medication burden and the proportion of patients on medicines to prevent the progression of chronic 
kidney disease in the three cohorts in the four weeks before the index date. 
 
Primary care cohort 
N=633 



















Number on Antihypertensive 
N (%) 
462 (73.1) 1,882 (76.4) 231 (92.4) <0.001 
Number on Lipid-lowering drugs 
N (%) 




327 (51.7) 1,188 (48.2) 149 (59.6) 0.001 
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3.3.5 Laboratory data 
Table 3.7 shows the baseline laboratory data in the three cohorts. 
Although there were statistically significant differences, most of the 
baseline mean laboratory variables and blood pressure readings, the 
absolute values were clinically similar between the three cohorts. There 
was a clinically significant difference in Albumin Creatinine Ratio 
(ACR) with the patients in the EQUAL cohort having ACR two and 
eight times the value compared to the secondary care and primary care 
cohort respectively. This could potentially explain the difference 
between the cohorts with regards to referral to secondary care and 
progression to ESRD.
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Table 3.7: Baseline laboratory variables by three cohorts 


































Albumin Creatinine Ratio (ACR) 
(mg/mmol): 



































Parathyroid Hormone (PTH)  
(pmol/l): 

















Systolic BP (mmHg): 








Diastolic BP (mmHg): 
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3.3.6 General practitioner consultations 
Table 3.8 shows the median number of general practitioner consultations 
in the 12 months before the index date in the primary and secondary care 
cohort. EQUAL was a study based on secondary care, and hence this 
data was not available for EQUAL patients. Patients in the secondary 
care cohort had a higher median number of consultations with their GP 
compared to the primary care cohort (9 IQR (5-15) vs. 7 (IQR 3-13), 
p=0.0001).
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Table 3.8: General Practitioner consultations in the 12 months before the index date in the Primary and Secondary care cohort 
 
Primary care cohort 
N=633 




the χ2 test 
for the 
difference 
in 2 cohorts 
P value 
Number of GP consultations in 12 







Not available 0.0001 
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3.3.7 Variables associated with participation/non-participation in 
EQUAL 
Each variable in Table 3.9 (univariable model) was considered and fitted 
in individual univariable models. All the models shown in Table 3.9 
were restricted to patients with 100% completeness for all variables 
(1,436 patients in the secondary care cohort and 242 patients in 
EQUAL). All variables with P < 0.2 in the univariable models were 
selected for multivariable logistic regression analysis: age, sex, 
Townsend quintile rurality, haemoglobin, systolic blood pressure and 
categorised components of the CCI as described in section 3.2.6 of 
methods section (univariable model in Table 3.9). The multivariable 
logistic analysis identified five main independent factors with P < 0.2 
associated with participation in EQUAL, namely age, gender, Townsend 
quintile, systolic blood pressure and co-morbidity (multivariable model 3 
in Table 3.9). Increasing age was associated with non-participation in 
EQUAL with patients ≥85 years of age 75% less likely to participate. 
Women were 38% less likely to participate, and patients in the 
Townsend quintile 4 were twice and in Townsend quintile 5 four times 
more likely to participate when compared to the least deprived patients 
(Townsend quintile 1). Patients who were less likely to take part in 
EQUAL included those with heart disease (37% less likely), peripheral 
vascular disease (46% less likely), stroke (32% less likely) and 
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rheumatological disease (67% less likely). Patients with a current or 
history of cancer were 55% more likely to participate. 
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Table 3.9:Univariable and multivariable models showing variables associated with participation in EQUAL, odds ratio (OR) and (p-value) 
Secondary care (1,436) * =0 
EQUAL (242) * =1 
Univariable model 
Multivariable Model 1 Multivariable Model 2 Multivariable Model 3 
(Socio-demographics) (Model 1 + Laboratory variables) (Model 2 + Co-morbidity) 
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
Age (years) 
≥65 - <70 1.0 - 1.0 - 1.0 - 1.0 - 
≥70 - <75 0.65 (0.43-0.97) 0.04 0.64 (0.41-0.99) 0.05 0.66 (0.42-1.04) 0.08 0.67 (0.42-1.07) 0.09 
≥75 - <80 0.48 (0.32-0.72) <0.001 0.49 (0.32-0.77) 0.002 0.50 (0.32-0.79) 0.003 0.50 (0.32-0.79) 0.003 
≥80 - <85 0.39 (0.25-0.59) <0.001 0.36 (0.23-0.56) <0.001 0.37 (0.24-0.58) <0.001 0.37 (0.23-0.59) <0.001 
≥ 85 0.25 (0.15-0.40) <0.001 0.25 (0.15-0.42) <0.001 0.26 (0.16-0.43) <0.001 0.25 (0.15-0.43) <0.001 
Gender male (ref) 0.71 (0.54-0.92) 0.009 0.65 (0.49-0.87) 0.004 0.63 (0.47-0.84) 0.002 0.62 (0.46-0.84) 0.002 
 
1 1.0 - 1.0 - 1.0 - 1.0 - 
Townsend 2 1.10 (0.71-1.70) 0.68 1.28 (0.80-2.03) 0.30 1.31 (0.82-2.09) 0.25 1.40 (0.87-2.24) 0.16 
Quintile 3 1.21 (0.78-1.89) 0.39 1.30 (0.81-2.08) 0.28 1.37 (0.85-2.20) 0.20 1.46 (0.90-2.36) 0.13 
1=least 5=Most 4 1.61 (1.05-2.49) 0.03 1.78 (1.12-2.84) 0.02 1.95 (1.22-3.10) 0.005 2.12 (1.32-3.40) 0.002 
deprived 5 3.02 (2.01-4.53) <0.001 3.48 (2.23-5.44) <0.001 3.69 (2.37-5.74) <0.001 4.17 (2.65-6.57) <0.001 
Rurality 
Urban 1.0 - 1.0 - - - - - 
Town/Village 0.64 (0.44-0.94) 0.02 0.78 (0.52-1.18) 0.24 - - - - 
Hemoglobin (g/dl) (≥ 10 (ref), <10) 0.72 (0.51-1.03) 0.06 - - 1.36 (0.94-1.98) 0.10 - - 
Albumin (g/l) (≥ 35 (ref), <35) 1.04 (0.76-1.42) 0.82 - - - - - - 
 
<120 0.73 (0.47-1.41) 0.17 - - 0.73 (0.46-1.17) 0.20 0.76 (0.47-1.23) 0.27 
Systolic BP ≥120 - ≤140 1.0 - - - 1.0 - 1.0 - 
(mm Hg) >140 1.77 (1.33-2.35) <0.001 - - 1.76 (1.30-2.39) <0.001 1.69 (1.24-2.30) 0.001 
 
<70 0.97 (0.72-1.30) 0.84 - - 
 
- - - 
Diastolic BP ≥70 - ≤80 1.0 - - - - - - - 




2-3 1.0 - - - - - - - 
4-5 0.69 (0.52-0.91) 0.009 - - - - - - 
≥6 0.68 (0.46-1.0) 0.05 - - - - - - 
Individual CCI 
components 
Cardiac (ref=absent) 0.53 (0.38-0.73) <0.001 - - - - 0.63 (0.44-0.90) 0.01 
PVD (ref= absent) 0.58 (0.38-0.88) 0.007 - - - - 0.54 (0.34-0.86) 0.009 





0.80 (0.57-1.13) 0.22 - - - - - - 
Diabetes (ref= absent) 0.94 (0.72-1.22) 0.65 - - - - - - 
CVA (ref= absent) 0.75 (0.51-1.13) 0.16 - - - - 0.68 (0.43-1.06) 0.09 
Cancer (ref= absent) 1.41 (1.03-1.93) 0.04 - - - - 1.55 (1.08-2.22) 0.02 
Rheumatology (ref= 
absent) 
0.31 (0.15-0.65) 0.0002 - - - - 0.33 (0.15-0.72) 0.005 
Other (ref= absent) 0.34 (0.18-0.66) 0.0002 - - - - 0.30 (0.15-0.61) 0.001 
Drug count 
(quintile) 
Q1 - - - - - - - - 
Q2 1.36 (0.95-1.96) 0.1 - - - - - - 
Q3 0.94 (0.66-1.33) 0.72 - - - - - - 
Q4 0.99 (0.70-1.41) 0.94 - - - - - - 
* All the models included patients with 100% completeness for all variables  
  




Figure 3.6 and Table 3.10 show the unadjusted mortality at one year for 
the three cohorts. The EQUAL cohort had a higher proportion of patients 
alive at one year (90.7%) when compared to secondary care (85%) and 
primary care cohort (69.6%). All the analysis were restricted to patients 
with 100% completeness for all predictor variables. 
 
Figure 3.6: Kaplan Meier survival estimates of EQUAL, Secondary Care and Primary 
Care cohorts 
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Table 3.10: Patient survival at one year in the EQUAL, Secondary Care and Primary 
Care cohort 
Cohort 
Patient survival at one year 
Yes No 
N (%) N (%) 
EQUAL 225 (90.7) 23 (9.3) 
Secondary Care 1913 (85) 338 (15) 
Primary Care 321 (69.6) 140 (30.4) 
 
Table 3.11 shows the output of the final unadjusted and adjusted multivariable Cox 
regression models which only included predictors that were significant (P <0.2) in the 
univariable model. Townsend quintile of deprivation was not significant in the 
univariable model. However, as the THIN database had a higher proportion of 
patients living in the most affluent areas, Townsend was retained in all the 
multivariable models. Only systolic blood pressure was included in the final models. 
Multivariable model 1 included adjustments for age, sex and Townsend deprivation 
quintile; model 2 included an adjustment for haemoglobin, albumin and systolic 
blood pressure in addition to the predictor variables included in model 1 and model 3 
included adjustments for all predictors included in model 2 and CCI. 
In the unadjusted model, in comparison to EQUAL, the unadjusted hazard ratio (HR) 
of all-cause mortality was 1.7 (95% CI 1.1-2.7, p=0.02) and 3.48 (95% CI 2.1-5.7, 
p=<0.001) in the secondary care and primary care cohorts, respectively. In 
multivariable model 3, the HR reduced moderately upon adjustment for socio-
demographics, laboratory variables and comorbidity. Age was the most influential 
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predictor of mortality - in model 3, for every five years increase in age, there was an 
18 per cent increase in the mortality (p=0.001). In multivariable model 3, patients 
with haemoglobin <10g/dl had a 31% higher risk of death at one year compared to 
haemoglobin ≥10g/dl (p=0.06). Similarly, in multivariable model 3, patients with 
albumin <35g/l had a 37% increased the risk of death compared to albumin ≥35g/l 
(p=0.02). In multivariable model 3, patients in the highest CCI category (≥6) had a 
58% greater risk of death compared to category 2-3. 
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Multivariable Model 1 Multivariable Model 2 Multivariable Model 3 
(Socio-demographics) (Model 1 + Laboratory variables) (Model 2 + Comorbidity) 
Cohort HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
EQUAL (n=236) * 1.0 - 1.0 - 1.0 - 1.0 - 
Secondary Care (n=1,203) * 1.71 (1.10-2.65) 0.02 1.61 (1.03-2.52) 0.04 1.52 (0.97-2.38) 0.07 1.47 (0.94-2.31) 0.09 
Primary Care (n=183) * 3.48 (2.12-5.71) <0.001 2.80 (1.65-4.75) <0.001 2.52 (1.47-4.32) 0.001 2.41 (1.40-4.14) 0.001 
Index age  
5-year bands - - 1.19 (1.08-1.30) <0.001 1.17 (1.07-1.28) 0.001 1.18 (1.08-1.29) 0.001 
(years) 
Gender (male (ref), Female) - - 0.74 (0.58-0.94) 0.02 0.75 (0.59-0.96) 0.02 0.79 (0.62-1.01) 0.06 
 
1 - - 1.0 - 1.0 - 1.0 
 
Townsend 2 - - 0.91 (0.64-1.29) 0.60 0.87 (0.61-1.24) 0.45 0.88 (0.62-1.25) 0.48 
Quintile 3 - - 0.97 (0.68-1.38) 0.85 0.95 (0.66-1.35) 0.76 0.95 (0.66-1.36) 0.77 
1=least 5=Most 4 - - 0.93 (0.64-1.35) 0.70 0.91 (0.63-1.33) 0.63 0.90 (0.62-1.31) 0.58 
 
5 - - 1.07 (0.73-1.56) 0.74 1.07 (0.73-1.56) 0.75 1.04 (0.71-1.53) 0.83 
Haemoglobin  
(≥ 10 (ref), <10) - - - - 1.32 (1.00-1.75) 0.05 1.31 (0.99-1.74) 0.06 
(g/dl) 
Albumin  
(≥ 35 (ref), <35) - - - - 1.38 (1.06-1.81) 0.69 1.37 (1.04-1.79) 0.02 
(g/l) 
Systolic BP  






- - - - 1.06 (1.00-1.13) 0.05 1.06 (1.00-1.13) 0.05 
Charlson  2-3 - - - - - - 1.0 - 
Comorbidity 4-5 - - - - - - 1.16 (0.88-1.53) 0.28 
Index ≥6 - - - - - - 1.58 (1.13-2.19) 0.007 
* All the models included patients with 100% completeness for all variables  
** Systolic BP was included as a time-varying covariate as the variable was not proportional and as the effect of a systolic BP is likely to change over time 
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3.3.9 Progression to ESRD and RRT 
Table 3.12 shows the percentage of patients whose renal function had 
deteriorated to eGFR ≤10mls/min/1.73m
2
 in the 1-year follow up period 
after the start date but not had commenced RRT. Progression rates were 
slower for the patients in the primary care cohort with only 3% dropping 
to eGFR ≤10mls/min/1.73m
2
 when compared to 5.3% for patients in 
secondary care cohort (p <0.001). 
Table 3.12: Percentage of patients who had dropped to eGFR ≤10mls/min/1.73m
2
 at 
one year in the secondary care and primary care cohort but were not on RRT 
Cohort 
Percentage of patients who had fallen to eGFR 
≤10mls/min/1.73m
2
 at one year 
Yes No 
N (%) N (%) 
EQUAL NA NA 
Secondary Care 117 (5.3) 2086 (94.7) 
Primary Care 14 (3.0) 447 (97.0)  
NA: Not available 
 
Table 3.13 shows the percentage of patients who commenced RRT in the 
1-year follow up period after the start date. EQUAL had a higher 
proportion of patients starting RRT compared to those in the secondary 
care cohort (8.1% vs. 2.1%, p <0.001). There were no patients who 
started RRT in the primary care cohort in this one year follow up period. 
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Table 3.13: Percentage of patients on RRT at one year in the EQUAL, secondary care 
and primary care cohort 
Cohort 
Percentage of patients on RRT at one year 
Yes No 
N (%) N (%) 
EQUAL 20 (8.1) 228 (91.9) 
Secondary Care 48 (2.1) 2203 (97.9) 
Primary Care 0 (0) 461(100) 
 
3.3.10 Hospitalisation 
Table 3.14 shows the percentage of patients having zero, one, two, three 
or four or more hospital admissions in the 1-year follow up period after 
the start date. Patients in the secondary care cohort had a higher 
proportion of patients having three or four or more admissions (6.7% & 
7.8%) compared to the primary care (2.8% & 5.0%) and the EQUAL 
cohort (2.8% & 1.6%). 
Table 3.14: Percentage of patients having hospital admissions in primary care, 
secondary care and EQUAL cohorts 
Number of admissions 
Primary Care Secondary Care EQUAL 
N (%) N (%) N (%) 
0 287 (62.3) 639 (58.3) 163 (65.7) 
1 97 (21.0) 195 (17.8) 51 (20.6) 
2 41 (8.9) 104 (9.5) 23 (9.3) 
3 13 (2.8) 73 (6.7) 7 (2.8) 
≥ 4 23 (5.0) 85 (7.8) 4 (1.6) 
Table 3.15 shows the output of the final unadjusted and adjusted 
negative binomial regression models which only included predictors that 
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were significant (P <0.2) in the univariable model. All the models 
(Model 1 to 4), were adjusted for a patient’s hospital free period at risk 
(as defined in section 3.2.4.6 clinical outcomes). Patients in the primary 
and secondary care cohort had over twice the rate of hospital admissions 
compared to patients in EQUAL. Increasing age was associated with 6% 
(IRR 0.94, 95%CI 0.86-1.02) fewer hospital admissions in the fully 
adjusted model (model 4). Females were 23% (IRR 0.77, 95%CI 0.61-
0.78) less likely to have a hospital admission in the fully adjusted model 
(model 4). Albumin (<35 g/l) was associated with risk of admission in 
the fully adjusted model (model 4). Charlson categories (4-5 and ≥6) 
were associated with 35%, and 50% respectively increased the risk of 
admission in the fully adjusted model (model 4). 
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Table 3.15: Unadjusted and adjusted 1-year hospitalisation, incidence rate ratio (IRR) and (p-value), for EQUAL, Secondary Care and Primary Care 
patients 
 
Model 1* Model 2* Model 3* Model 4* 
(Unadjusted Hospital free 
risk period) 
(Model 1+Socio-demographics) (Model 2 + Laboratory variables) (Model 3 + Comorbidity) 
Cohort IRR (95% CI) p value IRR (95% CI) p value IRR (95% CI) p value IRR (95% CI) p value 
EQUAL (238) ** 1.0 - 1.0 - 1.0 - 1.0 - 
Secondary Care (625) ** 2.13 (1.59-2.86) <0.001 2.55 (1.90-3.44) <0.001 2.50 (1.68-3.74) <0.001 2.28 (1.68-3.10) <0.001 
Primary Care (229) ** 1.76 (1.27-2.47) <0.001 2.52 (1.74-3.65) <0.001 2.58 (1.92-3.55) <0.001 2.16 (1.44-3.23) <0.001 
Index age  
5 year bands - - 0.92 (0.85-0.99) 0.03 0.91 (0.84-0.99) 0.001 0.94 (0.86-1.02) 0.12 
(years) 
Gender (male (ref), Female) - - 0.73 (0.60-0.89) 0.003 0.73 (0.58-0.91) 0.02 0.77 (0.61-0.98) 0.03 
 
1 - - 1.0 - 1.0 - 1.0 - 
Townsend 2 - - 1.30 (0.96-1.77) 0.09 1.29 (0.92-1.82) 0.14 1.21 (0.86-1.70) 0.27 
Quintile 3 - - 1.21 (0.88-1.66) 0.23 1.14 (0.81-1.63) 0.45 1.15 (0.81-1.63) 0.44 
1=least 5=Most 4 - - 1.28 (0.93-1.75) 0.13 1.41 (0.99-1.99) 0.06 1.38 (0.98-1.94) 0.07 
 
5 - - 1.12 (0.79-1.58) 0.52 1.16 (0.80-1.69) 0.44 1.07 (0.74-1.55) 0.73 
Haemoglobin  
(≥ 10 (ref), <10) - - - - 1.18 (0.88-1.57) 0.26 1.18 (0.89-1.57) 0.24 
(g/dl) 
Albumin  
(≥ 35 (ref), <35) - - - - 1.31 (1.00-1.72) 0.05 1.35 (1.03-1.76) 0.03 
(g/l) 
Charlson  2-3 - - - - - - 1.0 - 
Comorbidity 4-5 - - - - - - 1.52 (1.18-1.95) 0.001 
Index ≥6 - - - - - - 1.55 (1.10-2.19) 0.01 
* All models were adjusted for hospital free period at risk 
** Patients with 100% completeness for all variables included in the model 
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3.3.11 Sub-group analysis 
3.3.11.1 Characteristics of patients in HES linked and non-HES 
linked GP practices 
This analysis was carried out to look for any differences in the 
characteristics of patients in the HES linked and non-HES linked 
GP practices. Characteristics of patients in the HES linked and 
non-HES linked GP practices are shown in Table 3.16. Patients 
registered at HES-linked practices were more likely to be older 
than those in non-HES linked practices (mean age=82.0 yrs vs. 
79.5 yrs, p <0.001). A similar pattern was seen when age was 
analysed as five-year categories. Patients in HES-linked practices 
were also less likely to be men (45.2% vs. 52.2%, p <0.001), with 
some small differences in co-morbidity, GP consultations and the 
average number of drugs being prescribed.
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Table 3.16: Comparison of socio-demographic variables between people registered at HES-linked and non-HES linked practices. 
Patient Characteristics 












Age at index date: mean (95% CI) 82.0 (81.7-82.4) 79.5 (79.1-79.9) <0.001 
 ≥65 - <70 133 (7.2) 121 (9.6) 
<0.001 
Index age ≥70 - <75 221 (12.0) 224 (17.3) 
categories ≥75 - <80 337 (18.3) 294 (23.2) 
N (%) ≥80 - <85 462 (25.1) 334 (26.5) 
 ≥ 85 687 (37.3) 284 (23.4) 




1 326 (24.4) 250 (26.0) 
0.34 
2 303 (22.7) 222 (23.2) 
3 281 (21.0) 198 (20.7) 
4 259 (19.4) 155 (16.2) 
5 169 (12.6) 133 (13.9) 
Urban Rural 
N (%) 




185 (13.8) 133 (13.9) 
Village & 
Hamlet 
110 (8.2) 61 (6.4) 








Number of GP consultations in 12 8 (4-15) 9 (5-15) 0.03 
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* 1=least deprived, 5=most deprived  
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3.3.11.2 Comparisons of socio-demographic variables of EQUAL and 
incident dialysis patients submitted to the UK Renal 
Registry (UKRR) 
Table 3.17 gives comparisons of socio-demographic variables 
between the patients recruited into EQUAL and incident dialysis 
patients submitted to the UK Renal Registry (UKRR) aged ≥ 65 
years in EQUAL and non-EQUAL centres between 2013-2015. 
This sub-group analysis aimed to examine the differences between 
patients recruited into EQUAL and incident dialysis patients 
submitted to the UKRR in the EQUAL recruiting centres and non-
EQUAL centres. Patients in EQUAL were on an average 1.3 years 
older when compared to incident dialysis patients both in EQUAL 
and non-EQUAL centres (p <0.001). There were, however, no 
differences seen in the gender and socio-economic distribution.
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Table 3.17: Comparision of the socio-demographic variables of patients in EQUAL with incident dialysis patients submitted to the UK Renal 


















1 vs. 3 
Age at index date: mean (95% CI) 76.6 (75.8-77.4) 75.3 (74.8-75.8) <0.001 75.3 (75.0-75.5) <0.001 




Index age ≥70 - <75 58 (23.5) 152 (25.4) 613 (24.3) 
categories ≥75 - <80 58 (23.5) 156 (26.0) 649 (25.8) 
N (%) ≥80 - <85 54 (21.9) 101 (16.9) 411 (16.3) 
 ≥ 85 30 (12.6) 40 (6.7) 202 (8.02) 









2 44 (17.6) 107 (18.0) 392 (15.6) 
3 43 (17.2) 106 (17.8) 453 (18.1) 
4 48 (19.2) 98 (16.5) 532 (21.2) 
5 71 (28.4) 182 (30.6) 786 (31.3) 
* 1=least deprived, 5=most deprive 
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3.3.11.3 Characteristics of the patients in the three cohorts having 
excluded patients from the secondary care cohort who were 
in the Strategic Health Authority (SHA) of EQUAL 
recruitment sites. 
Table 3.18 shows the baseline characteristics of the patients in the 
three cohorts having excluded patients from the secondary care 
cohort who were in the Strategic Health Authority (SHA) of 
EQUAL recruitment sites. This analysis was carried out to quantify 
the potential dilution because of double counting of the EQUAL 
recruited patients in the secondary care cohort.  Reassuringly, there 
were similar differences in the socioeconomic distribution among 
patients in EQUAL, primary care and secondary care cohort as 
shown in Table 3.3.  
Considering the issue of double counting, patients in the secondary 
care cohort had their first recorded drop in eGFR ≤ 
20ml/min/1.73m
2
 between 1/4/2007 to 31/12/2012. The first 
EQUAL patient was recruited in May 2013 with their qualifying 
index eGFR in December 2012. Therefore, the risk of double 
counting the EQUAL recruited patients would have been minimal 
and if so the results show that there has been no change in the 
differences observed between the cohorts.
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Table 3.18: Distribution of socio-demographic variables in the primary, secondary care cohort who were not in the Strategic Health 
Authority (SHA) of EQUAL recruitment sites and EQUAL  
Patient Characteristics 
Primary care cohort 
N=633 
Secondary Care cohort 










Age at index date: mean (95% CI) 86.3 (85.8-86.8) 79.9 (79.5-80.2) 76.6 (75.8-77.4) <0.001 
 ≥65 - <70 17 (2.7) 115 (8.7) 47 (19.0) 
<0.001 
Index age ≥70 - <75 19 (3.0) 233 (17.5) 58 (23.5) 
categories ≥75 - <80 59 (9.3) 312 (23.5) 58 (23.5) 
N (%) ≥80 - <85 142 (22.5) 343 (25.8) 54 (21.9) 
 ≥ 85 395 (62.5) 326 (24.5) 30 (12.6) 





1 106 (23.6) 253 (23.1) 44 (17.6) 
<0.001 
2 98 (21.6) 251 (22.9) 44 (17.6) 
 
3 
102 (22.5) 232 (21.2) 43 (17.2) 
4 97 (21.4) 191 (17.4) 48 (19.2) 
5 51 (11.2) 168 (15.3) 71 (28.4) 
Urban Rural 
N (%) 
Urban 330 (72.4) 905 (82.4) 216 (86.4) 
<0.001 Town & Fringe 91 (20.0) 120 (10.9) 18 (7.2) 
Village & Hamlet 35 (7.7) 74 (6.7) 16 (6.4) 
* 1=least deprived, 5=most deprived 




This study examined whether patients participating in an observational cohort 
study of elderly people with advanced CKD (EQUAL) were similar to “real-
world” patients regarding baseline characteristics, hospitalisation and survival. 
Patients in EQUAL were more likely to be younger, male and from an urban 
setting compared to the primary and secondary care cohort patients. EQUAL 
patients were also less likely to have cardiovascular, cerebrovascular, peripheral 
vascular, rheumatic diseases and dementia. EQUAL patients were more likely to 
start RRT and had a higher probability of being alive at one year compared to 
primary and secondary care patients. The overall better health of EQUAL patients 
likely explained the observation that they were less liable to be admitted to 
hospital for illnesses. 
3.4.1 Age 
Patients in EQUAL were three and ten years younger than patients in the 
secondary care cohort and primary care cohort respectively. There were 
decreasing odds of participation; for every 5-year age band increase, the 
likelihood of participation reduced significantly (patients in age band ≥85 years 
had 75% lower odds of participating p <0.001). 
It has been recognised that patients recruited into a study may differ from the 
target population and be younger and healthier than referred and registry patients. 
(213, 214) This is a common problem in research, with a middle-aged group of 
patients more likely to enrol and patients at the extremes of ages (youngest and the 
oldest groups) less likely to participate (215). Often the study sample 
disproportionately excludes the elderly(216, 217) who have a higher burden of co-
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morbidity and therefore higher expected mortality(218). Such patients may also 
differ from younger participants regarding treatment effects.  
The implications of this are that ‘evidence-based’ research findings based on 
younger patients are applied to elderly patients with comorbidities, through 
clinical practice guidelines. (152) The reason for the underrepresentation of 
elderly in studies could also be because patients who are relatively healthier and 
more functional are less likely to agree to participate. (219, 220) Studies have also 
shown that older participants who participate in research studies may be less 
typical of their age cohort. (221)  
Solutions such as liberal inclusion criteria, improved communication, reducing 
respondent burden, provision of travel support or data collection in the home, 
involving members of the target population or gatekeepers (general practitioners) 
in the recruiting process in the community and to coordinate logistical challenges 
may facilitate the participation of older people in research. (153, 222) 
Unfortunately, despite these measures, as the older patients increase as a 
proportion of the population, those who agree to participate in RCTs and 
observational studies may be less representative.  
3.4.2 Gender  
Women were less likely to be represented in EQUAL in the UK with only 40.0% 
of participants in EQUAL being women when compared to 48.6% and 65.2% in 
the secondary care and primary care cohort (OR 0.62 (0.46-0.84) p=0.002). A 
probable explanation for a lower proportion of women in the EQUAL cohort 
could be due to slower progression rates in women. (223) The slower progression 
rates mean that there will be a smaller cohort of women reaching an incident 
eGFR of ≤ 20mls/min/1.73m
2
 or commencing RRT as shown in Table 3.3. 
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The recruitment of women in research studies is an essential issue for researchers. 
Medical research results cannot be extrapolated between genders as the 
pathophysiological process varies. For example, cardiovascular disease and some 
of the cancers are affected by hormones. As a result, much of our understanding of 
illnesses and its treatments is based on research conducted disproportionately with 
men. (224) However, an article by Mastroianni et al. argues that there is 
insufficient evidence available to determine whether women have participated in 
the whole of clinical studies to the same extent as men. (225, 226) It may be more 
complicated, however, with women no more likely than men to decline to 
participate in studies but merely underrepresented in target populations. (227) So 
if there has been no selection bias in the study, there would be fewer women in the 
study, but the percentage would be the same as men in the non-responder group. 
For example, lung cancer and cardiovascular disease are more common in men, 
even though they are equally severe when they affect women. More men get lung 
cancer than women, mainly due to patterns of smoking. With regards to 
cardiovascular disease, it is primarily influenced by smoking and sedentary 
lifestyle, and significant heart disease and stroke happen earlier in men than in 
women. For these reasons, it should perhaps not be surprising that we see higher 
numbers of men in these studies. 
The variation in gender seen in EQUAL could also be explained by the variation 
incidence of CKD amongst men and women. Most other studies report more CKD 
in women and more RRT in men, however a UK based population study of the 
incidence of CKD by Nicholas Drey et al. showed a male preponderance which 
was significant in all ages (40 years or older) and increased with age. (228) 
Chapter 3: Quantitative Chapter 
140 
 
However, this does not explain the gender differences seen between EQUAL, 
primary care and secondary care, using the same inclusion criteria. 
3.4.3 Socioeconomic status 
There was a higher proportion of patients within EQUAL in the most 
deprived Townsend quintile. In the multivariable logistic regression 
model with sociodemographic factors, Townsend quintiles 4 and 5 were 
two and four times more likely to participate in EQUAL, respectively. 
This can be explained on the basis that epidemiological studies of CKD 
have shown a higher prevalence of CKD with increasing deprivation. 
(229, 230). However, similar to gender this does not explain the 
socioeconomic differences seen between EQUAL, primary care and 
secondary care, using the same inclusion criteria. The pattern of 
socioeconomic status seen in the primary and secondary care cohort was 
the opposite of what was observed in patients recruited into EQUAL. 
This is in keeping with the population covered by the THIN database 
with a higher proportion of patients living in the most affluent areas than 
the national average. Therefore any analysis required adjustment for 
deprivation so that the estimates were closer to national death rates. (180) 
Socioeconomic deprivation has been associated with poorer outcomes in 
various chronic diseases. (231-234) Research has also shown that there is 
under-representation of patients in the lower socioeconomic strata in 
epidemiological studies, which therefore limits the generalisability of 
these studies.(235, 236) Negative beliefs about trials, lack of knowledge, 
influence of faith, healthcare provider influence (physician's lack of 
knowledge regarding clinical trials and poor communication skills), and 
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friends' or relatives' participation in clinical trials were identified as the 
main barriers to participation in a systematic review. (237) However, the 
distribution pattern of socioeconomic deprivation in EQUAL is 
reassuring and in keeping with the pattern of disease prevalence rather 
than different rates of participation across the socioeconomic groups. 
3.4.4 Rurality 
An important observation was that there was a more significant 
proportion of patients in the secondary care cohort who lived in urban 
areas compared to primary care populations (80.3% vs 72.4%). This 
raises the possibility of referral differences between patients residing in 
urban and rural areas. 
The recruiting sites in EQUAL were mainly academic hospitals in large 
cities (Birmingham, Manchester, Liverpool, Oxford, Glasgow, Bristol 
and Belfast), though the organisation of renal services in the UK means 
that they will also cover the rural areas around those cities. In the 
unadjusted logistic regression models, patients who lived in a town or a 
village were 36% less likely to participate in EQUAL (secondary care vs. 
EQUAL cohort). This could potentially be explained by the catchment 
population of the EQUAL sites. Alternatively, this observation could be 
due to the poor participation of patients residing in rural areas. 
There is evidence to show that involvement in clinical trials can be low 
in patients living in rural communities.(236, 238, 239) Barriers as a result 
of access to healthcare may also prove to be barriers to research 
participation. (239, 240) Possible reasons for such hesitation include 
cultural beliefs, lack of knowledge, and personal attitude. To minimise 
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this, patient education about research, reimbursement of the cost of travel 
and study visits to patients' homes may be potential solutions to be 
incorporated when designing a research study. (232) 
3.4.5 Co-morbidity 
Patients in EQUAL were less likely to have cardio-/cerebrovascular 
disease and rheumatological disease. In the univariate logistic regression 
model, higher CCI was associated with lower odds of participation in 
EQUAL, with patients with CCI ≥ four 30% less likely to participate in 
EQUAL (secondary care vs. EQUAL cohort). There was a higher 
proportion of patients in the unreferred primary care cohort with 
ischemic heart disease (19.9%), cerebrovascular disease (17.1%) and 
heart failure (32.9%) compared to patients in secondary care (17.0% 
14.7% and 22.6% respectively) and EQUAL (12.0%, 9.6% and 11.2% 
respectively), suggesting that patients with higher co-morbidity burden 
are less likely to be referred to a nephrologist (secondary care). Patients 
with current or a history of cancer were 55% more likely to participate in 
EQUAL. An interesting point to consider is that as cancer (which 
contributes towards the CCI) appears to increase odds of participating in 
EQUAL (unlike all the other co-morbidities) the usefulness of using a 
composite index could be reduced. 
The differences observed are probably not surprising as patients with 
ESRD have an increased risk of ischemic heart disease, cerebrovascular 
diseases and congestive heart failure, but fails to explain the differences 
between the three cohorts. Equally, all of these comorbidities are also 
likely to be present in patients over 80 years of age as in the primary care 
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cohort. (241) Patients in the primary and secondary care cohorts had their 
mean age close to 80 years in comparison with a mean age of 76 years 
for EQUAL. In the multivariate logistic model, increasing age rather than 
comorbidity was significantly associated with non-participation. Also, 
the co-morbidity pattern seen in this study is in keeping with other 
published literature of elderly patients with advanced CKD, bearing in 
mind that all of these cohort studies may have suffered from similar 
selection biases to the EQUAL study. (242, 243) 
3.4.6 Health outcomes 
Patients in the non-referred primary care cohort and secondary care 
cohort had over twice the risk of hospitalisation compared to patients in 
EQUAL. These patients also had increased mortality at one year.  
The findings of this study are consistent with prior reports in other study 
designs showing that patients participating in trials have better survival 
not only on account of being healthier but perhaps also reflecting the 
better medical oversight.(151, 244, 245) The hazard ratio of death in the 
non-referred primary care cohort compared to the referred secondary care 
cohort was very similar to publications by John Robert et al. (2.41 (1.40-
4.14) vs 1.47 (0.94-2.31)).(36, 223, 246).  
There was a higher proportion of EQUAL participants starting RRT 
compared to secondary care patients. The potential explanation for this 
finding could be that they represented a cohort of patients who had a 
quicker rate of progression of their kidney disease and were more likely 
to have had a pre-dialysis education. Due to quicker progression, this 
group of patients was probably under more active surveillance, which 
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could have resulted in earlier detection (reaching an incident eGFR of ≤ 
20mls/min). The EQUAL patient invitation letters mentioned, 
“treatment” and “dialysis” which might have resonated more with 
patients who were informed about treatments for advanced chronic 
kidney disease such as dialysis and made them more likely to agree to 
participate in the EQUAL study. 
Patients in the primary and secondary care cohort had over twice the rate 
of hospital admissions compared to patients in EQUAL. The most 
obvious explanation for this finding could be because EQUAL patients 
were younger and had a significantly lower co-morbidity burden in 
comparison with the patients in primary and secondary care cohort. An 
alternate explanation for this finding could be attributed to the source of 
the hospitalisation data. EQUAL hospitalisation data came from the 
nurse collected CRFs whereas the THIN data came from the HES 
linkage. It could be possible that HES linkage could have identified more 
hospital admissions. Also, hospital admission rates vary a lot between 
renal units, so it is also possible that EQUAL centres have lower rates of 
hospital admissions. An interesting observation was that increasing age 
was associated with fewer hospitalisations. A potentially be explanation 
could be that older patients are likely to have longer hospital admissions 
and therefore less likely to be admitted as often as younger patients. 
3.4.7 Challenges with the use of routinely collected data 
In the era of 'big data', research using routinely collected data offers more 
significant potential and has underpinned research in recent years. (247) 
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The strengths of general practice data are that they are population-based 
and are derived from a representative subset of the population. (178, 180) 
However, the choice of GP database has to be considered prudently 
especially when generalising to routine care. (248) There has been 
relatively little research done to compare different computer systems and 
their advantages and disadvantages. (249, 250) Also, details about the 
research methods employed by researchers using primary care databases 
are often not described in sufficient detail to ensure replicability. (251) 
Payments to GPs can distort coding practice. (248) As a result of 
inaccurate reporting and recording of morbidity, it makes it tough to 
calculate a reliable denominator for calculation of incidence and 
prevalence. (252, 253) In summary, validation and generalisability 
studies of GP databases, are essential to aid researchers in choosing 
databases for epidemiological studies. 
3.4.8 Strengths and Limitations 
3.4.8.1 Strengths 
This study is unique and has used routinely collected primary 
care data to understand the generalisability of an observational 
cohort study. This has therefore not necessitated the recruiting 
of patients who have declined to participate in a study and 
overcome the complex ethical issues of re-approaching patients 
who have already refused to take part in a study. Attempting to 
recruit “EQUAL declined” patients (EQUAL-D) would almost 
certainly still have resulted in a selected cohort. This use of 
routine primary care or registry data could be extended to 
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understanding the generalisability of other observational and 
intervention studies. 
3.4.8.2 Limitations 
There were several limitations to this study. Identification of the 
appropriate comparison control group was crucial to an 
inference of the study as any observational design will always 
be limited by unmeasured confounding. (254)  
The potential limitations were:  
1. Although this study did not directly assess the 
generalisability of EQUAL data by understanding the 
differences in baseline socio-demographic and outcomes 
between EQUAL agreed and EQUAL-D, routinely 
collected data has shown the differences in EQUAL 
patients and patients in secondary care meeting the same 
eligibility criteria. A better comparison would have been 
the consent of all patients who declined EQUAL-D for their 
routine data to be used and for them not to participate in a 
study, rather than using primary care data. This approach 
would also be troubled with selection bias; for example, 
research nurses often choose not to invite patients because 
they are too ill at the time of invitation to participate in the 
study or they live far from the hospital.  
In the context of this PhD, recruitment of EQUAL-D 
patients would have several issues:  
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i. A major ethics amendment would have been required to 
the EQUAL study, which was already underway.  This 
could, however, be considered for future observational 
studies. 
ii. Patients would have had to sign and return a consent 
form. The process of consenting would have had 
financial implications, as the costs of mailing the 
consent letters and also the self-addressed envelopes. 
iii. As per the power calculation, it would have been 
necessary to recruit over 2000 patients into the 
EQUAL-D arm to have sufficient power to detect a 
difference in mortality between the two cohorts. One in 
three eligible patients who were approached agreed to 
participate in EQUAL. EQUAL recruited 500 patients 
in the UK and so even if all of the EQUAL-D patients 
were recruited, this would still have left a shortfall of 
the number needed to detect the expected difference in 
mortality between the groups.  
iv. It might have been ethically challenging to re-approach 
patients who have already refused to participate in 
EQUAL to consent them for their data to be used. This 
would be less of an issue if done at the same time as the 
original approach. 
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v. There would have been a further selection bias as the 
patients recruited into EQUAL-D would likely still have 
been different to the actual real-world population. 
vi. Recruitment of EQUAL-D patients would have had an 
additional burden to the research nurses and could have 
had implications for recruitment to the primary study 
(EQUAL). 
2) The other issue that was considered was applying for section 
251 (Section 60 of the Health and Social Care Act 2001 as re-
enacted by Section 251) approval which grants access to and 
use of patient identifiable information for purposes of 
medical research without individual patient consent. (93) At 
the time of drafting this PhD proposal, the Health Research 
Authority was currently reviewing its process for approval of 
section 251 support. This would have potentially resulted in 
delays to the PhD timelines. 
3)  The use of ineligible secondary care cohort subjects could 
result in bias concerning prognosis, as a result of not being 
able to correctly apply all the eligibility criteria as one would 
be able to in a prospective cohort study. 
4) Multiple biases as a result of differences in data capture 
methods between THIN and EQUAL and resultant 
misclassification of the THIN subjects. The data in EQUAL in 
the setting of a study and would have been captured with 
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significantly more rigour in comparison with routinely 
collected GP data. 
5) This study looked at health outcomes at one year, and these 
short-term estimates in the EQUAL cohort may be somewhat 
optimistic in comparison with the primary and secondary care 
cohort. Some of the positive results seen in the EQUAL cohort 
could be explained due to the self-exclusion of patients from 
participation in EQUAL as a result of increased comorbidity 
and performance status.  
6) THIN (primary and secondary care cohort subjects) had a 
higher proportion of patients living in the most affluent areas 
than the national average. These consistent biases could have 
resulted in a less fair comparison between EQUAL and THIN 
patients concerning survival. However, adjustment for 
deprivation indices in the regression models would have 
resulted in the accurate comparison between the cohorts and 
mitigated some of the biases. 
7) The eligibility period for the EQUAL and THIN cohorts was 
non-overlapping. Ideally, understanding the generalisability of 
patients in EQUAL would require a comparison between 
EQUAL and the general secondary care population at the same 
time as the observational study is conducted. The eligibility 
period for THIN was between 1/4/2007 and 31/12/2012. The 
250 EQUAL patients were recruited between 30/05/2013 and 
22/10/2014. This issue potentially is simultaneously a 
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limitation and strength of this study. Patient referral patterns 
from primary to secondary care would have potentially changed 
over the period and also the management of patients with 
advanced CKD would have evolved over this time.(223, 255, 
256) These changes are likely to have had an impact on patient 
outcomes and hence upon the observations drawn from this 
study. Equally the fact that the eligibility period for the two 
cohorts was non-overlapping meant there was no double 
counting of patients in the secondary and EQUAL cohort and 
resultant dilution of effect. 
3.4.9 Conclusion and recommendations 
This analysis has provided empirical evidence concerning how 
participants in EQUAL differ from the broader population of patients that 
they are intended to represent. Older and sicker patients were less likely 
to be recruited to EQUAL, and this was supported by follow up data on 
health outcomes with patients in EQUAL more likely to be hospitalised 
and alive at twelve months. This selection pattern is likely to be found in 
most observational studies of chronic diseases as most chronic diseases 
have associated comorbidities. However, in a majority of observational 
studies, the classification errors, selection bias, and uncontrolled 
confounders and the uncertainty introduced by these types of biases are 
seldom quantified. Therefore, future studies would require a comparison 
between experimental and the eligible study population at the same time 
as the study is conducted as was done in the North American 
Atherosclerosis Risk in Communities (ARIC) study were generalisability 
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was examined by nesting study patients in communities covered by broad 
surveillance. (97) Alternatively using statistical techniques such as 
probabilistic sensitivity analysis (Episens model, Orsini et al.) may help 
to quantify the effect of bias and researchers can report results that take 
into account the systematic errors and hence avoid overstating their 
certainty about the effect under study. (257, 258) 
The next chapter seeks to understand the threats to generalisability that occur at the 
recruitment stage. The chapter describes a qualitative study that aimed to tease out 
issues underpinning patient recruitment to the EQUAL Study.
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CHAPTER 4. UNDERSTANDING PATIENTS’ 
PERSPECTIVES THAT COULD INFLUENCE 
RECRUITMENT IN KIDNEY STUDIES: THE 
EXAMPLE OF EUROPEAN QUALITY STUDY ON 
TREATMENT IN ADVANCED CHRONIC KIDNEY 
DISEASE-EQUAL 
The previous chapter explored threats to generalisability due to selection biases that 
could have occurred at the design stage of the study, and how participants in EQUAL 
differed from the broader population of patients that they are intended to represent. 
This chapter explores threats to generalisability that occurred at the recruitment stage 
of EQUAL by describing the methods and findings of a qualitative study that 
explored the thoughts and experiences of eligible patients about the recruitment 
process, their motivations for participation, and any perceived barriers. 
4.1  Introduction 
4.1.1 Recruitment to studies 
The most challenging task in undertaking clinical research is participant 
recruitment and retention. (259) Recruitment into RCTs is often much lower than 
anticipated (260-262). This can be due to the study design, participants 
characteristics such as demographics and personal preferences, investigator 
features, collaboration with clinicians (115), and other barriers to patient 
participation, including additional demands of the study, issues with travel and 
costs, patient preferences and concerns about information and consent. (240) It is 
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often believed that full disclosure of information, regarding both the content and 
the techniques and styles of delivery, could be a significant predictor of 
recruitment success. (263). These obstacles have been extensively studied in 
randomised control trials but not as robustly in observational studies. (264) In a 
systematic review by Lacey et al. only five of the 32 included papers discussed 
strategies to improve cohort follow-up, and none addressed strategies to enhance 
recruitment in observational cohort studies. (264) Furthermore, systematic reviews 
have identified many barriers but few robust interventions to improve recruitment 
(260, 263, 265, 266). Therefore it is not only essential to understand recruitment 
issues within observational studies but identifying strategies to enhance 
recruitment are of utmost importance. 
Previous studies note that several factors may negatively influence the recruitment 
of older adults to clinical research, such as patient risk factors (age and 
comorbidity), vulnerability (frailty and cognitive difficulties) and increased 
clinician workload (to recruit and deal with older patients). (267-269) However, 
most studies have failed to seek the personal views and experiences of those in 
this group. Instead, many of the factors identified are based on a priori supposition 
or subjective observation by medical and research staff. A robust qualitative 
investigation is lacking. (269) 
4.1.2 Older adults in clinical research 
The World Health Organization (WHO) state: “The number of people aged 65 or 
older is projected to grow from an estimated 524 million in 2010 to nearly 1.5 
billion in 2050, with most of the increase in developing countries. (270) It is 
therefore essential that there is equity throughout the generations when it comes to 
inclusion in clinical research.  
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The issue of older adults participating in clinical research has been a cause for 
debate and growing concern for more than a decade. Some believe that age has 
been a cause for systematic and unethical exclusion from research and trials and 
an extensive amount of research suggests there is some unease about older adults 
being involved in clinical research.(267, 271, 272) Gonzalez et al.  found that 
recruitment and retention of older adults were difficult, time-consuming and 
expensive. (273) Jacelon et al., in her paper, focuses on the challenges that 
researchers face when including older adults within their cohort. Jacelon suggests 
that the uneasiness surrounding the inclusion of older adults in clinical studies is 
to do with a number of apprehensions, namely: “negative stereotypes, perceived 
lack of competence, complications in obtaining consent, belief that they are likely 
to decline an invitation to participate, and the additional time needed to include 
them as participants”.(272) High profile and official attempts have been made to 
promote the inclusion of older individuals. This has been achieved through 
governmental and advisory documents that have set recommendations for the 
inclusion of older adults in research. (274-276) The established preference against 
the inclusion of older adults in studies and trials seems to be slowly shifting. (277)  
It is unsatisfactory that the results of clinical trials which consider treatments for 
certain conditions cannot reliably be extrapolated to older patients because the 
participants who take part in the studies are younger and healthier(112, 269, 278) 
and often do not have the complications of polypharmacy and co-morbidity that 
exist in older patients. (268, 279) When examining reasons for older people not 
being included in research, Witham & McMurdo list several key factors including 
study protocols, communication, attitudes and the influence of others. They then 
move on to list several strategies to aid the inclusion and retention of this age 
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group in research. Many of the key factors found by Witham & McMurdo have 
been influential in the enrollment of older adults. (269) Levy et al. in his 
systematic review found that fifty-three per cent of health-risk behaviour clinical 
trials excluded adults over the age of 65, with only two and a half per cent 
including those only over 65 years of age. (271)  
There is much more yet to be done before we can see a continuing trend of 
research open to involving older individuals in studies. (267, 280) Such a shift 
would likely prove beneficial to patient care. 
4.1.3 Use of qualitative research methods to understand and 
optimise recruitment 
Patient recruitment in clinical studies can be a challenge. Non-participation can 
affect not only the validity of the study but also have a financial impact. (281) 
About 50% of RCTs fail to recruit to target and only 50% of those that 
successfully recruit do so promptly. (282) Qualitative research has been frequently 
used in the setting of RCTs aimed at identifying barriers to recruitment and to 
optimise recruitment. (283, 284) The use of Qualitative research methods has 
proven to be the most promising. (283) The ORRCA project (Online Resource for 
Recruitment research in Clinical triAls) brings together published evidence in the 
field of recruitment research. (285)  
The qualitative research has used interviews (semi-structured; in-depth), focus 
groups and audio recordings not only to explore barriers to recruitment but also 
explore reasons for low recruitment and attempt to improve recruitment rate by 
implementing changes suggested by qualitative findings. (286)  
A few interesting examples of the use of Qualitative research to identify barriers 
to recruitment are  
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i. Lack of clinician time for research (287) 
ii. conflicting roles of clinicians and Principal Investigators (288),  
iii. training needs of healthcare staff (289),  
iv. perceived barriers of clinicians to introduce RCTs (290),  
v. Doctors attitude to patient participation in trials (291) 
vi. clinicians understanding of the trial (292) 
vii. Patients strong preferences for a particular treatment (293, 294) 
viii. Communication of the RCT and clear explanation of the paucity of 
evidence to participants. (295, 296) 
 
Several approaches to using qualitative research to optimise recruitment have been 
discussed below. (297, 298) Donovan et al. showed that the integration of 
qualitative research methods within a trial allows us to understand the recruitment 
process and elucidate changes necessary to the content and delivery of 
information to maximise recruitment and ensure the effective and efficient 
conduct of a trial. (299, 300) In the ProtecT study, the development of a complex 
intervention to improve recruitment was derived from the use of qualitative 
research and the data from interactions in on-going trial recruitment appointments. 
(300) The information from the interviews helped inform a set of interventions:  
i. Consistent refresher training for all staff and training for new staff 
in the beginning. (301) 
ii. Regular reviews of the targets for each of the centres are recorded. 
iii. Pamphlets to offer guidelines and information.  
iv. Individual feedback as needed.  
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Implementation of the complex intervention in ProtecT resulted in a marked 
improvement in the frequency of instantaneous embracing of allocation 
gradually (from 65% to 81%) with the preservation of high randomisation 
rates (over 65%) (300). 
The QuinteT Recruitment Intervention (QRI) methodology was developed by 
researchers at the School of Social and Community Medicine at the University 
of Bristol after the above set of interventions were refined in several 
RCTs.(302) The QRI aims to understand the recruitment process of the RCT 
in the recruiting centres so that reasons for recruitment problems can be 
recognised and suggestions made to change aspects of design, conduct, 
organisation or training that could then lead on to improvements in 
recruitment. The QRI methodology investigates the delivery of information to 
patients by way of audio recordings and anonymous feedback to the 
individuals recruiting into the RCT. A training intervention (QRI 
methodology) for health professionals to recruit into challenging randomised 
controlled trials. This intervention had a positive impact on the self-confidence 
of healthcare professionals in discussing RCTs with patients and also a 
positive impact on recruitment practice. (303) This methodology has been 
used in specific RCTs and has been shown to improve recruitment in some 
cases. (302, 304)  
A potential issue to the use of embedded qualitative research is trials is the 
extra time, money and personnel needed to carry out the qualitative research. 
Therefore, the use of qualitative methods in pilot or feasibility trials before a 
full study would be more cost-effective by defining interventions that could be 
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fully incorporated into subsequent trials. (305) Although qualitative methods 
have mainly been used to create interventions to improve recruitment to RCTs, 
these methods can be transferred to other settings such as cohort studies to 
have a positive effect on recruitment. 
4.1.4 Qualitative Research methods 
While quantitative research is widely known for generating objective, reliable and 
generalisable information (306), qualitative data can complement and refine this 
by producing rich, in-depth data on complex issues such as subjective 
experiences, perceptions and motivations that are difficult to quantify. (307) The 
use of qualitative research is invaluable in narrowing the gap in knowledge that is not 
easily accessible via the uses of quantitative research methodology. (308, 309) 
Qualitative research lacks a single definition: Strauss and Corbin defined it by 
what it is not, merely stating that “by the term ‘qualitative research’ we mean any 
research that produces results that have not been obtained by statistical 
methodology or other means of quantification.”(310) Although the use of numbers 
in qualitative research is controversial, the distinction between quantitative and 
qualitative research is not entirely down to this. (311) Qualitative methods are 
typically inductive, in that theory and hypotheses are formulated as a result of the 
observations and findings. Mohr et al. described the characteristic difference between 
the two methods with respect to the ‘mental model’:  
1. Quantitative research assumes a ‘variance theory’ approach. This methodology is 
associated with the analysis of the role and also the differences between the 
various variables. 
2. The qualitative research implements a ‘process theory’ method. (312) This 
technique produces knowledge by studying the method by which some actions 
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impact on others and provide a circumstantial and illustrative, appraisal. (307, 
311)  
Qualitative methods provide a way of tackling difficult topics, which are 
problematic or hard to measure for instance ‘how’ and ‘why’ questions. 
Qualitative approaches also permit wide-ranging themes to be explored, as there 
is less constraint placed on the information collected. This method does not 
impose a limitation on the variables that are collected, and these variables need 
not be rigidly defined. The method facilitates thorough scrutiny of the 
phenomena using subjective information. Henceforth, the method is invaluable 
for hypothesis generating or exploratory research. (307) Ormston et al. (313) 
have stated that qualitative research includes the following vital elements stated 
in Table 4.1 
Table 4.1: Elements of Qualitative Research 
No Elements 
1 
Qualitative research provides an in-depth and interpreted understanding of the social 
world of participants who take part in research. 
2 
Qualitative research aids enhanced understanding of the participants social and 
material circumstances, their experiences, perspectives and histories. 
3 
Qualitative research uses non-standardized, flexible approaches to collecting data.  
This data takes account of the context (social) of the study. 
4 Qualitative data is comprehensive, rich and complex. 
5 
Qualitative analysis retains complexity and nuance and respects the uniqueness of 
each participant or case as well as recurrent, cross-cutting themes. 
6 
Qualitative research aids openness to embryonic categories and theories at the 
analysis and interpretation stage. 
7 
Qualitative research produces outputs that include detailed descriptions of the 
phenomena being researched. 
8 Grounded in the perspectives and accounts of participants. 
9 
A reflexive approach, where the role and perspective of the researcher in the 
research process are acknowledged. For some researchers, reflexivity also means 
reporting their personal experiences of ‘the field’. 
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Quantitative and qualitative research methods have their distinctive merits and 
demerits. Instead of the methods conflicting, both the approaches should be 
considered in a harmonising role to each other. (314) Four possible approaches to 
combine qualitative and quantitative methods have been suggested by Steckler et al. 
(314):  
1. Qualitative methods can be employed to assist the generation of quantitative 
measures and tools. 
2. Qualitative methods can be used to get an in-depth understanding of the 
quantitative results. 
3. Merging quantitative approaches to enhance a principally qualitative study. 
4. Qualitative and quantitative research methods can be used together, equitably 
and in parallel. 
When effected rationally, qualitative and quantitative methods together can yield 
fuller and wide-ranging results. Also, qualitative research methods are therefore 
often used by healthcare researchers to examine institutional and social practices 
and processes and to identify barriers and facilitators to change (315). 
This thesis not only utilises the strengths of quantitative and qualitative research 
approaches, but the qualitative study also explores facilitators and barriers to 
participation in research. In this current climate, where patient-centred care and 
patient safety is strongly advocated (316, 317), a better understanding of patients’ 
perceptions and experience of participation in research will undoubtedly be 
invaluable in guiding researchers to improve the process of inviting eligible 
participants to take part in research. 
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4.1.5 Aims and ObjectivesAim 
To understand issues that underpin patient recruitment to the European QUALity 
Study on treatment in advanced chronic kidney disease (EQUAL study). (129) 
4.1.5.2 Objectives 
A qualitative interview study was nested within the EQUAL study, an 
observational study of advanced CKD in the elderly, and intended to recognise 
possible barriers to participation in research and to investigate possible resolutions 
to overcome the barriers. 
4.2  Methods 
4.2.1 Participant Eligibility  
Patient interviews were conducted at three of the ten EQUAL recruitment sites, 
selected using recruitment data from the first few months of the study to include 
centres with high, medium and low recruitment rates (Bristol, Salford and Oxford 
respectively). Eligible participants were identified using the screening logs 
maintained by the local team for the EQUAL study. Eligible patients were all 
individuals aged 65 and over who had been approached to take part in EQUAL 
and had either declined or agreed. 
4.2.2 Sampling Strategy 
Sampling in qualitative research does not intend to detect a statistically 
representative set of participants. (311) Several methods of sampling exist for 
interview based qualitative research studies, which can overlap or be intentionally 
combined. Convenience sampling is probably the least rigorous approach, 
involving the opportunistic sampling of the readily available subjects for 
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participation (318, 319). It can be associated with minimal research costs and may 
be appropriate for hard-to-reach groups, but can result in weak data quality which 
lacks credibility, and findings which lack transferability (318). 
An alternative approach is purposive sampling which involves the selection of 
participants according to particular characteristics or experiences related to the 
research question of interest (318). Before sampling, the researcher will typically 
identify features of interest that might influence an individual’s contribution to the 
research based on the researcher’s practical knowledge of the area and sometimes 
knowledge of the existing literature (319). Purposive sampling also involves 
selection of deviant cases defined as “highly unusual cases of the phenomenon of 
interest or cases that are considered outliers, or those cases that, on the surface, 
appear to be the 'exception to the rule' that is emerging from the analysis” (320-
322). Analysis of deviant cases may revise and widen the patterns emerging from 
data analysis.  
A further approach is theoretical sampling. The iterative process of much 
qualitative research means that samples are often theory-driven to a greater or 
lesser extent (319). Theoretical sampling involves “building interpretative theories 
from the emerging data and selecting a new sample to examine and elaborate on 
this theory.” (319). It involves selecting participants to test the theory, emerging 
themes or developing hypotheses, or to explore a specific concept further. 
Although theoretical sampling can be thought of as a type of purposive sampling, 
it must be undertaken alongside the data analysis. Theoretical sampling is the 
primary sampling strategy in the Grounded Theory approach (319, 323), discussed 
later. 
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Snowball sampling, in which one participant is asked to suggest someone else 
who may be willing to participate, can be employed in all sampling strategies 
(318). In qualitative interview studies using purposive or theoretical sampling, the 
sample size is typically decided by attainment of theme saturation, when limited 
or no new concepts are emerging (324, 325), and when it is considered that no 
further data collection will add any new insights (323). 
In this study, a purposive sampling approach was adopted for patient interviews 
(data collection) to achieve maximum variation regarding age (65-74 & 75 above), 
co-morbidity (0-2 & ≥3), and participation status (agreed and declined). (326-
328). Care was taken so that the sample included elderly co-comorbid patients 
who have refused but importantly also those who have agreed to participate, the 
latter being ‘deviant cases’ for comparative analysis. Participants from the 
‘agreed’ and ‘declined’ groups were interviewed with a roughly even distribution 
of cases in the age and co-morbid category across the three sites. The exact 
numbers in the groups and the sub-strata were however determined by the number 
required to achieve a consistent understanding across a varied group and where 
further interviews were not yielding any substantially new themes. 
4.2.3 Recruitment 
Only the local research teams had access to patient screening logs. The research 
teams at Oxford and Salford invited the eligible participants for qualitative 
interviews. In Bristol, AR was part of the research team and invited the patients 
for the interviews. The eligible participants were mailed the patient invitation 
letter and patient information sheet. The research teams in each of the centres 
contacted the eligible participants both in the agreed and refused group until the 
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required number of participants with the defined features of interest were 
recruited. 
Participants who were open to being interviewed had their contact details passed 
on to the investigator (AR). The investigator contacted the participants to arrange 
a suitable venue for the interview. Interviews with participants were coordinated 
with the outpatient clinic or follow up visits in the renal unit/hospital that usually 
supervises the care of the patient to reduce inconvenience to the patient. 
Participants were also offered the option of a home visit or telephone interview. 
4.2.4 Data collection method 
Interviews are a standard mode of acquiring information in a qualitative study. 
(329) Interviews are of three main types: structured, semi-structured and 
unstructured. Structured interviews allow the interviewer to ask the same 
questions in the same way and very much like a questionnaire with closed 
questioning. Therefore, a minimal range of responses is elicited. On the other end 
of the spectrum, unstructured interviews have very little structure and aim to 
discuss a limited number of topics (one or two). 
For this study, it was decided that semi-structured interviews would best suit the 
requirements. The format of semi-structured interviews would provide the 
opportunity to ask open questions and to allow participants to talk privately and at 
length (detail) about their participation decision. This interview style would lend 
itself to the use of cues or prompts to encourage the interviewee to consider the 
question further. Other methods such as focus groups would not have been 
feasible as the participants were elderly and co-morbid. The logistics of 
coordinating such a focus group would therefore have been complicated. 
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Most interviews took less than an hour to complete. Following the interview, no 
further participation was required.  
A topic guide was used to ensure consistency and that the research aims were 
satisfactorily addressed, but participants were encouraged to raise the issues they 
considered necessary with minimal prompting, including any additional areas. 
This ensured that data collection was grounded in their experiences. Probing was 
used to clarify salient points and encourage reflection. The first draft of the topic 
guide was constructed to include issues drawn from a broad range of articles taken 
from the literature searches carried out. (330-334) Possible prompt questions were 
devised to access topics (Appendix 4.1 and 4.2), but in actuality, the conversation 
mostly moved naturally into each of the topic areas. This required a degree of skill 
in steering the discussion informally, replicating natural patterns of conversation. 
Participants could tell their own stories in their own, albeit guided, ways. This 
meant that the answers sought were frequently not provided in the order that 
questions were laid out on the form yet, through careful listening, the investigator 
could identify the pertinent data. 
Given that the potential participants of the qualitative interviews were elderly and 
comorbid, it was anticipated that they would be accompanied by their spouses, 
other relatives or friends. It was also predicted that families and friends would 
answer on behalf of the participants on a few occasions but also on the rare 
occasion express their view on the matter. Responses from spouses, relatives or 
friends are denoted in quotations by an observer (O). On the occasions the family 
members responded to the discussion, they would be allowed to speak for the 
participant with efforts made to elicit the participants’ views first-hand in their 
own words or at least to seek confirmation that the family member provided an 
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accurate account. Only data (quotes) in which friends or family assist in 
describing the views, experiences, beliefs, perceptions of the primary participant 
and on the odd occasion if it was felt that friends or family’s views were relevant 
to patients’ participation decisions were included in the analysis. Any personal 
opinions of the friends or family are not reported in the results. To illustrate a few 
examples: 
“I: What are your thoughts on medical research? 
O: I think it should be done, for the future of the children, 
grandchildren.” OXF_DNA_16 
 
“I: When did you first come about to hear about this study called 
EQUAL? 
R: I do not really know. 
O: If we declined it though I think at the time he was probably so 
poorly we did not want to do it.” BRL_DNA_10 
 
Patient interviews involved a broad range of topics including factors guiding the 
decision to participate or not, factors about the study that appealed/did not appeal 
to the patient, patient ideas about research, barriers to participation at the patient 
healthcare interface, other obstacles to the patient involvement, patient concerns 
and economic incentives. Other related topics included patient satisfaction with 
the renal unit, patient understanding of their illness and treatment preferences. 
Interviews were conducted in small batches with parallel analysis, allowing 
insights and questions from earlier batches to inform the focus of later interviews. 
The topic guide evolved with each batch with emerging themes being added and 
redundant topics removed (Appendix 4.3 & Appendix 4.4). Interviews were audio 
recorded and transcribed verbatim with participants’ consent, a practice 
recommended by Silverman. (335)  
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4.2.5 Ethical Considerations  
Before commencing with data collection, it was necessary to seek and gain ethical 
approval for the study from the NRES Committee South West - Central Bristol. 
This was done by submitting a substantial amendment to the EQUAL study (REC 
reference:13/SW/0015; Amendment number: 3, 06/12/2013; Amendment date:06 
December 2013). 
Individuals were given up to two weeks to consider participating. Voluntary 
participation was emphasised. Invited individuals were informed in the patient 
information sheet that they could withdraw at any time, without giving a reason. 
They were also informed that if they did not decide to take part, their clinical care 
would not be affected in any way. The participants signed a consent form at the 
time of the interview. Consent was obtained by myself in line with local policies 
and following GCP guidelines. Any clarifications required by the patients were 
given before the consenting process. Explicit consent for the audio recording of 
the interviews was requested, and participants were assured that all information 
would be confidential, and all data would be stored securely as per the Data 
Protection Act. Participants provided consent for the use of anonymised quotes in 
presentations and publications. Adults who were deemed unable to consent for 
themselves (English not first language & cognitive impairment), or to belong to 
vulnerable groups (mental health issues) were not approached for participation in 
the study.  
If the patients found the interviews to be distressing, they would be allowed to 
pause, break, reconvene later or terminate the interview, though in practice this 
did not happen. Transcripts were stripped of all patient identifiers.  
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4.2.6 Data Analysis Method 
The general fundamentals of grounded theory underpinned the appraisal of 
this study and and steered the data collection and analyses. (336)  
Glaser and Strauss developed grounded theory in 1967. ‘Pragmatism and 
Symbolic Interactionism’ are the conceptual foundations of Grounded theory. 
(337) Pragmatism deduces that ‘knowledge is created through action and 
interaction’. Symbolic interactionism aims to ‘explore behaviours and social 
roles to understand how people interpret and react to their environment’.(337) 
Grounded theory provides a methodical means of scrutinising qualitative data 
and ensures the progress of a theory that is ‘grounded’ in the realism of the 
data. (336) The grounding of impressions in the data guarantees theory-
observation compatibility and protects against experimenter bias (researcher 
performing the research influences the results). (338) Theoretical sampling, an 
iterative approach and constant comparisons during data analysis are the three 
fundamental processes of grounded theory research (Figure 4.1). (337) In 
grounded theory, research data collection and analysis are interconnected 
simultaneous processes. (338)  
In this study, an iterative approach was adopted for data collection and 
analysis (thematic analysis). The iterative method of grounded theory consists 
of a series of concurrent data collection and analysis. The results from the 
previous cycle of data analysis advise the subsequent cycle of data collection. 
(339) Following this approach, interviews in this study were conducted in 
small batches interspersed with a preliminary analysis. Findings from early 
batches were used to refine the topic guide for the next set of interviews.  
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Using the iterative approach enabled pertinent ideas to be recognised. As the 
study continued, some of these ideas were challenged, expanded, evolved, 
polished and explored in depth. (338) Over a period, ideas accrued in number, 
which became more abstract and enabled for various categories to be formed. 
(338) Well-defined categories offer the explanatory power to enable the 
development of a theory. (338) 
With every cycle of sampling (interviews) generated more data which built on 
the previous analysis up until each of the categories got to the point of 
‘saturation’.(337) Although ‘total saturation’ of data was improbable to be 
entirely attained, in this study ‘data saturation’ was taken as the stage in data 
collection when new information did not add any significant further 
awareness. (337) 
 
Figure 4.1: Concept of grounded theory approach (337) 
In qualitative research, coding forms the foundation of data scrutiny. The code 
refers to “a word or short phrase that symbolically assigns a summative, 
salient, essence-capturing, and/or evocative attribute” for a segment of the 
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data. (340) There are three types of coding which are used in grounded theory: 
opening coding, axial coding and selective coding. (338) The process of open 
coding involves a comparison of the issues of interest for parallels or variances 
following which codes are then allocated to the raw data. Axial coding 
attempts to create a relationship between the categories and codes as the codes 
and categories develop. In the later stages of analysis, selective coding merges 
all the pertinent categories around a ‘core’ category. (338) 
In this study, thematic analysis using the constant comparison approach was 
selected as the most appropriate approach to organise the coded data. (341) 
Thematic analysis is a principle adopted from grounded theory. The long list 
of different codes was sorted into potential themes with some codes forming 
main themes or sub-themes. Thematic analysis is a commonly used method of 
analysis in qualitative research that can be used with any theory the researcher 
chooses. This allowed the participants’ experiences to determine how the 
themes were identified from the interview data. Astin & Long comment that, 
in general, the intention in data analysis is not to impose an external 
structuring on the data but rather to use the frames or themes emerging from 
within the participants’ comments and observations of their actions, or from 
other participants in other studies. (342) The research analysis, therefore, 
began by reading through the data (transcripts) several times and creating 
provisional labels for sections of data based on the meaning that emerged from 
the data (open coding). From this broad list of issues (labels), a categorical 
structure was developed consisting of several sub-topics or themes (axial 
coding) and identifying connections among the issues. The sub-topics were 
developed by listing the responses to each question (in abbreviated form) and 
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then highlighting the overall subjects of each answer. Where answers were on 
similar themes, they were given the same sub‐ topic. A random subgroup of 
interviews was independently double coded by Dr Helen Cramer, a National 
Institute for Health Research (NIHR) post-doctoral research fellow in the 
School of Social and Community Medicine to ensure reliability. Codings were 
compared, and an agreed coding frame was derived that could be applied 
consistently to all transcripts. Any disagreements about the coding were 
resolved by discussion. Any new emerging themes (the raw data extracts) and 
its interpretation, including iteration to the coding framework was clarified 
with Dr Lucy Biddle, Senior Lecturer in Medical Sociology at supervision 
meetings. Figure 4.2 illustrates the initial coding framework extracted from 
NVivo. These themes were then collated under the umbrella of eight main 
headings (see Table 4.3, below). NVivo software (QSR International) was 
used to aid analysis.




Figure 4.2: Coding framework generated from NVivo for agreed (top) and decline groups (bottom)
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The use of figures and statistics in qualitative research has been a subject of 
ongoing dispute. Although some qualitative researchers value the use of 
quantitative data to supplement the research (338, 343, 344), apprehensions 
about the aptness of its use persist (307, 345, 346). The use of quantitative 
data in qualitative research can lead to an inference of the generalisability of 
the conclusions with research appearing more precise, rigorous, and scientific. 
However, in trying to improve the rigour of qualitative research, quantitative 
data can lead to reducing the importance of the logic of the study and thus 
misrepresents the actual basis for the conclusions and ultimately has the 
danger of quantifying the amount of evidence. (311) It can jeopardise 
enforcing the ‘variance theory mental model’ on the study which theoretically 
weakens the strong point of the ‘process theory’ that qualitative research 
proposes (section 4.1.4). (311) As a result of the above discussions, this 
qualitative study has opted to use the verbal statements/terms such as ‘some’, 
‘several’, ‘many’, ‘often’, ‘typically’, ‘sometimes’ in making any qualitative 
assertions. On a few instances where it was felt that there was a need to 
substantiate reporting of qualitative data, quantitative data was quoted to add 
more weight. 
4.3 Results 
4.3.1 Interviewer Characteristics 
The interviews were carried out by the writer of this thesis, Dr Anirudh Rao (AR) 
(Qualifications MBBS MRCP). The investigator was a 36-year-old male, of 
Indian ethnicity, with a respectable command of English. He was a researcher at 
the UK Renal Registry (UKRR) and a doctor working in a large tertiary referral 
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hospital specialising in renal medicine. AR had received formal training in 
Qualitative Methods, Qualitative Appraisal and the use of NVivo (347) for 
qualitative analysis, on taught courses at the University of Bristol. He also 
received guidance from Dr Lucy Biddle, Senior Lecturer in Medical Sociology, 
and other medical sociologists and anthropologists at the School of Social and 
Community Medicine, University of Bristol. In his role as a hospital doctor, the 
researcher was involved in the recruitment to the study in Bristol. He introduced 
himself to interviewees as a ‘kidney doctor who is involved in the EQUAL study’ 
and explained that all queries not related to the interview would be answered at 
the end of the interviews. Mindful of the possible effect of his expert role as a 
doctor (348), he stressed that he was not involved in participants medical care and 
had no access to their medical data. Therefore, the participant’s general 
practitioner (GP), supervising consultant nephrologist, or the clinical director were 
informed of any relevant information disclosed in the interview for continued 
follow-up. 
4.3.2 Interview context 
The semi-structured interviews were conducted between May 2014 and July 2015 
about six to eight months after EQUAL recruitment had commenced in each of 
the three sites (Bristol, Salford and Oxford). Participants for the interviews in the 
agreed group had been in the EQUAL study for at least six to eight months. 
Participants of the agreed group had either just been followed up or had up to 6 
months elapsed since their last follow up. The participants in the declined group 
were interviewed after 4-8 weeks following their invitation to participate in 
EQUAL. The timing of the interview could have influenced the participant 
(agreed and declined) understanding or recollection of EQUAL. 
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4.3.3 Interview Setting 
Face-to-face semi-structured interviews were conducted at the participants’ homes 
between May 2014 to July 2015. Although it was envisaged that the interviews 
would be in the renal unit or hospital, coordinated with the outpatient clinic or 
follow up visits, in reality, most patients preferred home visits given the length of 
the interviews. Also, the difficulty of room availability in the hospital for the 
duration of the interview meant that home visits became the default option. Some 
participants had either their spouse, children, or other family members present at 
the interviews (6/17 agreed group, 7/17 declined group). On the occasions, the 
family members responded to the discussion this was handled as stated in the 
section 4.2.4 of the methods section. 
4.3.4 Participant Characteristics 
In the agreed group in EQUAL, all the participants that were invited to take part in 
the qualitative interviews decided to participate. Recruitment was more difficult in 
the declined group with only 1 in 4 participants agreeing to participate in the 
interviews. Despite this, every attempt was made to represent both genders and 
comorbidities in this declined group. Table 4.2 shows the number of interview 
participants by EQUAL participation status in the three sites. 
Table 4.2: Distribution of patients in EQUAL sites by participation status 
Participant characteristics 
EQUAL participation status 
Agreed to participate Declined to participate 
N=17 N=17 
Bristol (high recruitment site) 5 8 
Salford (medium recruitment site) 6 3 
Oxford (low recruitment site) 6 6 
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Table 4.3 gives a breakdown of the interview participants’ age and co-morbidity 
by EQUAL participation status. There were a higher proportion of participants 
aged ≥ 75 in both the agreed and declined group. In the declined group there was a 
more significant proportion of women compared to men. This correlates with the 
EQUAL recruitment data which showed that 60% of those declining to participate 
were women. The distribution of comorbidity was evenly distributed in both the 
agreed and declined groups. 
Table 4.3: Participant characteristics 
Participant characteristics 
EQUAL participation status 
Agreed to participate 
N=17 
Declined to participate 
N=17 
Age (years) 
65-74 7 5 
≥ 75 10 12 
Gender 
Male 10 7 
Female 7 10 
Comorbidity 
(Charlson’s count)  
0-2 7 7 
≥3 10 10 
 
4.3.5 Interview Themes 
Eight major themes emerged from interviews describing factors influencing 
participation and non-participation in research, the majority containing some sub-
themes (Table 4.4). They are discussed below alongside illustrative data extracts. 
There were no significant differences in the themes by site (high, medium and low 
recruiting sites) and the initial recruitment rates were more likely related to the 
resources at these sites and competing studies. 
Table 4.4: Themes describing factors influencing participation & non-participation in 
the EQUAL study 
Major theme Subtheme 
Healthcare related issues and patient 
activation 
Satisfaction with care 
Forthcoming with non-related symptoms 
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Awareness of renal condition and its 
treatment 
Awareness of medical condition 
Actions taken when unwell 
Impact of health problems 
Burden of hospital appointments 
Barriers: Vision, Hearing and memory 




Caring responsibility  
Mobility 
Reliance on friends and family 
Home visits 
Transportation 
Help with decision  - 
Medical Research 
Perception of research 
Previous experience 
Worthwhile 
Personal and beliefs 
Early life 







Reaction to invitation 
Manner and method of approach 
Timing of approach 
Clarity of invitation/information 
Trust 
Source of contact 
Confidence in approaching person 
Privacy 
 
4.3.5.1 Healthcare related issues and patient activation 
As mentioned in section 4.1.2, there is a vast amount of literature which argues 
that participants who take part in studies are younger and healthier and less likely 
to have the complications of polypharmacy and co-morbidity that exist in older 
patients. This theme captures the impact of the burden of health, and its relation to 
participation in EQUAL. This theme is mainly descriptive and reveals differences 
between the two groups about awareness of healthcare related issues, which could 
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have a bearing on the participation decisions. The evidence emerging from the 
theme also suggests that patients who engaged in their healthcare and thus were 
more activated were more likely to agree to participate in research. Patients’ 
perceptions of health and healthcare can have an impact on the choice to 
participate in research.  
A patients’ understanding of their health condition or lack of it can have a 
significant influence on participation in research. A couple of participants made a 
direct link between their awareness of their health condition and their decision 
whether or not to participate in EQUAL, as illustrated in the two quotes below. 
“I: So, you got the letter and what happened did somebody gets in 
touch with you? 
R: No, only me, only me made up my mind, I thought well I ain’t going 
to bother with that. Thinking, I have got no idea of the kidney trouble 
or what it is all about.” BRL_DNA_15 
 
“I: What did you think when you received the letter? 
R: Yeah, there was no definite other reason why I didn’t join it, you 
know, I just it wasn’t worth it from your point of view, you know….as 
far as I knew, there wasn’t anything wrong with me you know, there’s 
nothing physically wrong, let’s put it that way. Moreover, that seemed 
to me to be; that is what I felt, that I was wasting your time.” 
OXF_DNA_05 
 
Further quotes related to this theme and its sub-theme are illustrated in Table 4.5 
below. 
4.3.5.1.1 Satisfaction with care 
The sub-theme ‘Satisfaction with care’ captured the relationship between EQUAL 
participation and the interviewees’ overall satisfaction with their healthcare. This 
theme was explored in fourteen of the seventeen participants in the agreed group, 
all of whom were satisfied with the care that they had received at the renal unit 
and overall from the NHS. In the declined group only six of the sixteen 
participants were happy with their care. Despite this, they had other overriding 
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circumstances that had caused them to refuse participation. Seven in the declined 
group had neutral responses, and three were dissatisfied with the care that they 
had received. 
Three of the participants in the agreed group felt that their experience of the renal 
unit influenced their decision to participate. 
“R: The renal unit, I see. I have found up there; it is a different 
situation than the cardiology where I go, it is um, very friendly.  You 
know, it’s quite um, like when what’s the doctors name, they all call 
him Dr X.  You know, and everyone, different one I’ve seen, we’ve um, 
what can I say, we’ve just, I’ve told them different silly stories and 
then, and it’s been very relaxed.  Moreover, of course, I think what 
helps, although they have moved, the smallness of the place is far more 
intimate so to speak.  However, I have found the staff so very different 
than they are in cardiology.  They are very helpful and very, they seem 
to care more about you, you know?  Yes, and a good atmosphere, my 
partner always says that good atmosphere in, here isn’t it?  I said 
“Yeah”.” BRL_AGREE_12 
 
4.3.5.1.2 Forthcoming with non-related symptoms 
The data coded under the subtheme of ‘Forthcoming with non-related symptoms’ 
explored participants’ ability to volunteer concerns about their health during 
consultations when not directly questioned about these. The majority of the 
participants in the agreed group (7/8) would bring up any non-related health 
concerns they might have at a consultation with their GP/Renal physician. The 
group that did not agree to participate seemed less likely (4/7) to bring up other 
health concerns not directly relating to the consultation. 
4.3.5.1.3 Awareness of renal condition and its treatment 
The sub-theme ‘Awareness of renal condition and its treatment’ captures 
interviewees’ awareness of their renal condition (CKD) and the potential 
treatments for this. Although the connection between this awareness of renal 
condition and participation was not explicitly explored in the interviews, the two 
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groups were different about this theme with the majority of the participants in the 
agreed group being aware of the cause of their kidney failure in comparison to 
those in the declined group. The theme indicates that patients who agree to 
participate are more aware of their illness and hence this generates self-interest 
which drives them to participate. BRL_AGREE_10 was a negative case, contrary 
to the majority, who agreed despite little awareness of their renal condition. It was 
their altruistic moral of “help and benefit to others” (section 4.3.5.2) that had 
motivated them to participate in EQUAL. 
“I: Do you want to tell me about your kidney problems? 
R: Well I do not know what you mean by that cos as far as I know they 
do not bother me. 
I: OK. So, you have no symptoms what so ever of with your kidneys? 
R: Well no not as far as I know.” BRL_AGREE_10 
Nine of the 17 participants in the agreed group and only 4 of the 14 participants in 
the declined group were aware of the potential of requiring dialysis should their 
kidney disease progress. All patients recruited into EQUAL had to have an eGFR 
less than 20 ml/min/1.73m
2
. Across the UK this is when the patients are likely to 
have received a dialysis-related education and therefore to be aware of its 
potential need. The majority of patients commence dialysis when they reach a 
mean eGFR of 8 ml/min/1.73m
2
. 
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Table 4.5: Sub-themes coded under ‘Healthcare related issues and Patient activation’ with illustrative quotes in the agreed and declined groups 




Satisfaction with care 
“I: What has your experience been so far?   
R: Renal Unit, is thoroughly relaxed, sometimes non-medical if you 
like, everyone’s friendly, even the nurses taking the blood……it is a 
nice atmosphere in the, in the unit itself, it is not too medicalised if 
you like. 
I: Did your experience at the Unit have a bearing on your decision 
to participate in this study? 
R: I suppose in a way because it was relaxed and the whole Unit 
seems to be run on a nice relaxed, friendly basis rather than purely 
medical. It is informal, and it puts you at ease.” BRL_AGREE_11 
“I: So, this whole experience for the last year or so how … and how 
would you summarise your thoughts? 
R: Rubbish. I do not consider that anybody is taking me seriously 
about what I can do and what I cannot do.” OXF_DNA_06 
Forthcoming with non-
related symptoms 
“I: If there is something else bothering you about your health do you 
bring it up yourself without being asked? 
R: Oh usually. I am not one of these that soldier on keeping it to 
myself.  I have had too many things go wrong …. I mean I had a 
problem the other week with my bladder, discomfort and I thought 
“Right I am going to get it checked out, I have had cancer twice, I 
want to get it sorted” SAL_AGREE_08 
“I: If you are seeing the doctor, like your kidney doctor, or your GP, if 
something is in the back of your mind, or if something is bothering 
you, although it is not related to why you are seeing them, do you 
bring it up at these meetings? 
R: Not particularly, no.” OXF_DNA_01 
Awareness of renal 
condition and its 
treatment 
“I: So, what have you been told is wrong with your kidney?  
R: It is got... I even know what it is called. I’ve got a staghorn stone 
in the right kidney, and the kidney is shrunk round it.” 
SAL_AGREE_06 
 
“I: Okay, for example, should your kidneys fail, do you know what 
can be done? 
R:  I know I asked her about the dialysis, and that is when she 
explained to me….” BRL_AGREE_01 
“I: So when you did get this letter through the post from Nurse M, 
asking you to take part in this big kidney study, what was your initial 
thoughts? 
R: My initial thought was; I don’t know that I’ve got anything wrong 
with my kidneys.  I mean there is nothing obvious, I wasn’t being 
treated for anything, and I suggested to her that I’d probably be a 
waste of money or a waste of time, you know, if it went on for four 
years was it, or something?” OXF_DNA_05 
Awareness of medical 
condition 
 “I: And do you know what each of your medications is for and what 
it does? 
R: It will be easier when I show you.  I can never understand the 
medical names. These two basically cover the blood pressure.  The 
consultant at renal put me on this one instead of the statins; he said 
it was a better one for it.” OXF_AGREE_02 
“I: And do you know what each of your medications is for and what it 
does? 
R: I presume; I forget what they all are for now (laughter) get so 
many.  I got a load of bloody tablets.” BRL_DNA_10 
Actions taken when 
unwell 
“I: If you were feeling breathless, for a couple of days, okay, how 
would you take that forward? 
R: Wait and watch. If it got too bad, I would consult Dr X and say 
look, this is not, I do not seem very well. I do realise with this that I 
am getting short of breath, but I thought, after I went onto dialysis, 
“I: On a given day you are not feeling well, what steps do you take? 
R: I just want to sit down and go to sleep. 
O: Mum is … she will suffer in silence.  … while I’m proactive and try 
and say, “Look, you need to see the doctor – we need to get you to the 
doctor.”  She will say, “Oh, I have not felt well the last week – I feel a 
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the breathing would get better, but it does not seem to have got that 
much better. I saw Dr X last week, I went to the clinic last week, and 
I said that and he said things take a bit of time, but that is about it 
really.” OXF_AGREE_03 
bit dizzy,” so I get her to the doctor and try and sort it out.” 
BRL_DNA_04 
Impact of health 
problems 
“I: OK. How do your medical problems affect you? 
“R: You just learn to live with things, don’t you? I do most of 
the things myself – cooking, and sometimes I have not washed the 
pots properly, and I’m not too sure... There is no sensation in my 
fingers to check them… I think it is just ageing, arthritis.” 
SAL_AGREE_07 
“R: I come over tired all the time, and I cannot do what I want to do.  
Because I used to do all this gardening, even now, clean all the 
windows at my age – a very independent woman, and I cannot do it…. 
Otherwise, I have been fit all my life, and I have gone downhill.” 
BRL_DNA_04 
The burden of hospital 
appointments 
 “R: Well what it was, with all the clinics. I mean this is sort of like 
injections, foot clinic, diabetic clinic, renal clinic and the eye clinic, 
everybody seems to want blood….. I cannot remember, I was 
panicking (laughter) it is all sort of more visits and more blood……It 
was “help, please, no more” …... was my reaction.” OXF_DNA_17 
Barriers: Vision, 
Hearing and memory 
“R: Well I think I’ve had one like that [Patient Information Sheet] 
but I don’t think I read it all it’s such a lot to read, and my eyesight 
isn’t quite so good as it used to be, and um it takes me a long time to 
read anything nowadays…I’ve got trouble with my eyes because I go 
to the eye hospital and um I’ve had laser treatment on one eye and 
twice on the other eye.” BRL_AGREE_10 
 
“R: And so hearing the phone is not good, you know, sometimes it is a 
low frequency, low signal strength and I have difficulty understanding 
it.  Um, and that is another reason why I, am frightened of going in for 
interviews and things in case I mishear or do not hear at all.” 
BRL_DNA_13 
 
“I: How were you contacted, so you just received a letter did you to 
say? 
R: I had a letter. However, I have not got around to reading it because 
reading is difficult. 
R: So somebody rang me up, and I said that I had not read it.” 
OXF_DNA_17 
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BRL_AGREE _12 again was a negative case who had agreed to participate to benefit 
others. She expressed that the questions in the EQUAL questionnaire were not 
relevant to her. This suggested that the participant’s assessment of their condition did 
not coincide with the relevance of the questions in the EQUAL study questionnaire. 
“R: Well I did say to Nurse when she came after the first and left 
me with this thing to go through and I said to her, course a lot of this 
the answers or the questions here, really don’t apply to me because 
this is, questions for people who are really suffering because of kidney 
problems failure and then they were talking about how would you feel 
about dialysis and things like that, so well I said to Nurse “the thing is 
I’m not that advanced” so you understand a lot of the questions were 
for people who were on their way into dialysis really, so I said to her 
“there are, there are quite a few questions here that don’t apply to me 
at all”. BRL_AGREE_12 
 
4.3.5.1.4 Awareness of other medical conditions 
This theme describes interviewees’ awareness of their co-existing medical 
conditions and the medications are taken for these. As described above (Table 
4.2), the agreed and the declined group were balanced in the comorbidity burden. 
However, the interviewees in the EQUAL agreed group were more aware of their 
health conditions and medications compared to the declined group. 
4.3.5.1.5 Actions are taken when unwell 
This sub-theme describes patients engagement with healthcare and the 
management of their health. A majority of interviewees in the agreed group said 
that they would consult their GP or engage with their nephrologist if they 
continued to feel unwell beyond a few days in comparison to the declined group.  
4.3.5.1.6 Impact of Health problems 
This theme describes differences between the groups with regards to the potential 
impact of their health problems. Most of the patients both in the agreed and declined 
group had a significant impact on their ability to function because of their morbidity. 
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However, despite the level of morbidity, participants in the agreed group were more 
mobile (see section 4.3.5.3.2), while the declined group were affected much more 
significantly. Participants in the agreed group appeared to be more functional overall, 
and those with reduced functional status were less likely to participate. 
A few of the participants in the agreed group were still pursuing their hobbies, 
reflecting their physically active state. 
“R: I have retired, and like I said my main hobby is golf twice a week. 
Apart from that it is just like anyone else would do; television and 
computer. Nothing out of the ordinary, nothing exceptional.” 
SAL_AGREE_05 
 
4.3.5.1.7 The burden of hospital appointments 
Participants, particularly those in the declined group, had a significant number of 
hospital appointments because of their co-morbidities. In the agreed group 9/17 
and the declined group 13/17 participants were affected by the burden of hospital 
appointments.  
4.3.5.1.8 Barriers: Vision, Hearing and memory 
Barriers such as vision, hearing and memory can affect eligible patients' 
interpretation of study material such as the patient invitation letter and information 
sheet. This is mainly an issue if the eligible patients are invited by letter or by 
phone rather than face to face. However, despite such barriers, some of these 
patients had agreed to participate in EQUAL. Although there was no difference 
between the two groups, this sub-theme observes that these difficulties can be 
barriers to participation. 
4.3.5.2 Altruism and self-interest 
4.3.5.2.1 Altruistic morals 
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This theme captured the reasons most overtly motivating for individuals to 
participate in EQUAL study. Many of the interviewees conveyed altruistic morals 
which had driven them to take part in the EQUAL study or which they perceived 
as the most influential reason for taking part in research in general. For example, 
participant SAL_AGREE_08 commented: 
“I: So, you are a busy man with all your research participation? 
R: Yeah well, I don’t mind you know I mean the treatment I’ve had off 
NHS because like I say, I’ve had my large bowel removed …I’ve had 
sepsis, I’ve had diabetes, I’ve got arthritis but all this being looked 
after, so I have no complaints so I can put a bit back you know.  If it 
helps somebody else later in life well why not?  You know, somebody 
has obviously done it to help me you know. It is – well it is like 
anything else, isn’t it?  You do not – you do not get to know – you 
cannot – you cannot advance knowledge without you doing these sorts 
of things.” SAL_AGREE_08 
 
The altruistic morals were along the lines of wanting to help benefit others, benefit 
the family, assist knowledge, and payback the National Health Service (NHS). In 
general, they aimed to help others with the illness, help the researchers to find a 
‘cure’ or advance medical knowledge.  Patients who agreed to participate in 
EQUAL often explained their decision with reference to altruism. However, the 
circumstances which motivated some individuals to agree to participate in 
EQUAL were very subjective.  
The concept of altruism was less forthcoming in the interviews of the group that 
did not agree to participate. To illustrate this point, there were 37 quotes (17 
participants) that were coded under the various sub-themes of altruism in the 
agreed group, In comparison only 13 quotes (11 participants) in the declined 
group. The declined group participants explained their decision not to participate 
in the face of altruism mainly as a result of the burden of medical illness, but a 
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couple of participants expressed that they perceived no immediate benefit to them 
as a result of participation. 
“R: Um, and I can, I know that it won’t help my case, but research has 
got to take place to help people in the future, I’m well aware of that, 
but I’m not just an ordinary kidney patient, I’ve got another problem 
as well you see, and I thought I couldn’t set myself up for all this.” 
_BRL_DNA_13 
 
“R: Well I really cannot see the point of it because (pause) if it is me 
personally, I have got something wrong and they were trying to help 
me, then go ahead and do it.  I know it is for the future for other people 
as well, but, it does not actually help me, does it? At the time.” 
_BRL_DNA_15 
 
The altruistic moral of “help benefit others” was the most widely acknowledged, 
appearing in the accounts of nearly all (15/17) participants in the agreed group. 
This altruistic moral also had 77 quotes coded under it and was consistently 
expressed across the participant characteristics (age and comorbidity). The moral 
of “assist knowledge” was one of the other consistent reasons given for wanting to 
take part in EQUAL and captured reasons such as an intention to assist in the 
development of the knowledge base for healthcare professionals and thereby 
benefit future patients. The altruistic moral of “benefit family” captured the 
perceptions of participants who expressed that EQUAL participation would 
influence the medical care their family would receive should they go on to 
develop kidney disease in the future. The moral coded as “National Health Service 
(NHS)” captured the participant's gratitude for the care they had received from the 
NHS and a feeling they should or wanted to give something back in return. Table 
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Table 4.6: Altruistic morals and illustrative quotes 
Altruistic moral Illustrative quote 
Help and benefit to 
others 
“I: And what did you think you would gain from 
[participation]it? 
R: Well I did not think medically, I would gain anything 
like that…  It was just basically agreeing to make things 
better, perhaps, in the future.” OXF_AGREE_02 
Benefit family 
“I: Once you read the letter, what did you think about it? 
R: Well I thought it would be a good thing, you know, it’s 
not just me in the family it affected, it’s, it was my sister as 
well (pause) and I’ve got loads of children, well 
grandchildren and great-grandchildren and that and so the, 
you know if anything can help that, plus helping anybody else 
if possible.” OXF_AGREE_14 
Assist knowledge 
“I: What influenced your decision to say yes, to take 
part? 
R: Well because, I said, because research needs bodies 
and I mean, I am not in your field, but in engineering, we 
have a need to do research, is that piece of metal going to 




“I: So, when they came and asked you, how did you decide to 
say yes versus no? What made you say yes? 
R: Well, I think I have an interest and the fact that I have 
taken a fortune out of the NHS. If I could put that little bit 
back, it would make me feel better.” SAL_AGREE_07 
 
4.3.5.2.2 Self-interest/Personal Gain 
The converse of the theme of altruism is the theme of Self-interest/Personal Gain. 
Self-interest was an important feature that came out during interviews regarding 
patients’ decision-making and motivation for research participation. This theme 
encoded the opposite of the feelings of altruism expressed under the theme of 
altruism (section 4.3.5.2.1). Ten of the 17 participants in the agreed group 
quoted self-interest as a reason for participation. The theme of altruism and 
self-interest often jointly emerged in the same interview, suggesting that they 
might be interconnected. However, Altruism was more potent with fifteen of 
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the seventeen participants in the group that agreed to participate expressing 
this.  
 As illustrated by the quote below self-interest could have negatively influence 
participation. 
“R: Well I really cannot see the point of it because (pause) if it is me 
personally, I have got something wrong and they were trying to help 
me, then go ahead and do it.  I know it is for the future for other people 
as well, but, it does not actually help me, does it? At the time.” 
_BRL_DNA_15 
 
As illustrated in the following quote (BRL_AGREE_12) it is often difficult to 
disentangle altruism from self-interest and which of these is an overriding 
motivation for participation in research. 
I: Were there any parts of the study that drove you to decide to 
participate? 
R: No, no I never had that negative attitude at all. I was very keen on it 
because if my condition gets worse, I shall need all the research that’s 
done and all the progress they have made.” BRL_AGREE_12 
 
The below quote made by BRL_AGREE_09 was less straightforward. Although this 
reads as self-interest, it is more inclined to altruism with a sense of pride the 
individual gets from being altruistic 
“I: What prompted you to participate? 
R: Well as I said to you in the very beginning really, I have, I am 
very keen, especially in the medical world, you come across anything 
that you can be of help.  Years and years ago when I was a blood 
donor, they had the Anthony Nolan Trust, and they were getting, 
wanted extra blood for him, I straight away volunteered my blood, but 
unfortunately, it was not a match.  However, um, I, I believe in helping 
if you can, and it does me no harm, and I feel I get a proudness really 
from being able to take part and maybe benefit other people in the 
future.  That is my basic reason... I have always had an interest in 
health matters, and I feel that um, my input would be of use, would be, 
you know, I would be useful, I would not be a waste of time.” 
BRL_AGREE_09 
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In some instances, this was less straightforward. OXF_AGREE_02 felt that they had 
nothing to lose from participation. This is different compared to self-gain, and it is 
likely that they perceived participation to be low cost to them but not necessarily a 
benefit. 
“I: What influenced you to say yes, to taking part? 
R: Well, I would not say influence, the point was, I was obviously 
having treatment for my kidneys, so just find out a little bit more, what 
was going on, you know?  So, I mean there was no point in just 
ignoring it, you just go along with it, at least you can find out a bit 
more, and you have got nothing to lose, you know?” OXF_AGREE_02 
 
Emphasising the importance of self-interest, a lack of perceived personal gain was a 
reason for non-participation.  
“I: When you first got the letter (EQUAL invitation letter), how did 
you feel?   
R: (Long pause) Read like say half of it and thought “Oh well that is 
nothing to do with me, that is not really of any interest”.  Not really 
interested, you know? Well, I really cannot see the point of it because 
if it is me personally, I have got something wrong and they were trying 
to help me, then go ahead and do it.  I know it is for the future for other 




Under the theme of convenience, a wide variety of sub-themes were noted, which 
were overall demotivating to participation in EQUAL. The theme was divided into 
caring responsibility, mobility, reliance on friends and family, home visits, 
transportation (driving and parking) and convenience issues while in hospital. 
Although the majority of the centres offered home visits, the perception of having 
to travel to hospital for the research study was a significant barrier to participation.  
4.3.5.3.1 Caring responsibility 
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Caring responsibility was an important issue to emerge from the interviews. This 
significant barrier to participation was elicited mainly in the declined group (7 vs 
3 in the declined and agreed group respectively). This reason was also 
significantly expressed by the interviewees aged ≥ 75 years of age. (7 vs 3 in the ≥ 
75 years vs 65-74 years of age respectively), but was quoted almost equally by 
women and men (6 vs 5).  
“I: When you were approached to take part in the EQUAL study 
you did mention that there was too much on at that time, would you 
mind elaborating? 
R: Well I have got as I said my husband does not endure very 
good health, he is a diabetic, he is under the urinal clinic, he has had 
heart surgery, he is having problems even with his sugar levels at the 
moment, and I have to do a lot for him.  I have to help him dress, I help 
him to wash, and it is all happening now.  Up until this year, he was 
quite independent, so these sorts of things were all going through my 
mind.”   BRL_DNA_09 
 
“R: Well as I say I can’t go very far because of him, you know, I’ve 
got make sure he’s ok, he fell in the greenhouse and we had to call the 
ambulance…. we don’t go out very much now, we used to, but we don’t 
go out now because he can’t walk very far.  He could not; he cannot 
walk from there to there without getting out of breath….. You see I do 
not have time really (Referring to participating in the EQUAL study), I 
know I’m here all the time, but I still don’t have, and I can’t just dart 
off and go there and go here, I’ve got to plan it, and I don’t want to 
start doing that now.” BRL_DNA_14 
 
The following quote was elicited from the son of one of the participants in the 
group that did not agree to participate in the EQUAL study. The son explained 
that the reason for non-participation was due to the poor state of health of his 
mother which was a result of the burden of the caring responsibilities. 
“I: So you read the letter, what did you think of the letter? 
R: Well there was quite a lot to take in I think… 
O: I think Mum … in principle she would be up to do it.  Maybe just 
medically she was not … 
O: My Dad, had dementia.  Of course, she was trying to care for him 
as well, so I think the whole thing just got too much for her and I think 
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it sort of triggered the sort of more rapid deterioration that was 
probably lurking in the background.” BRL_DNA_04 
 
4.3.5.3.2 Mobility 
Declining mobility is usually regarded to be a consequence of deteriorating 
health discussed in section 4.3.5.1. Healthcare related issues and patient 
activation. There appeared to be a link between self-reported mobility and 
participation status, those participating reporting better mobility. Fifteen of the 
seventeen participants in the group that declined to participate in EQUAL 
described mobility issues. In comparison in the agreed group, only seven of the 
seventeen had mobility issues. The eligibility criteria for EQUAL was the elderly 
(≥ 65 years of age) where the prevalence of mobility issues is likely to be higher.  
“I: And your mobility, how is that? 
R: Not very good. I cannot walk very far. 
I: And the times you must get to the clinic, how do you manage? 
O: I, take him there. 
R: It is dreadful.  
O: to get him back in the car is an issue because of his legs; his 
legs will not bend.” BRL_DNA_10 
 
One participant explicitly linked mobility to their decision whether or not to 
participate. 
R: It is because, this, this is not to do with my kidneys; this is 
purely to do with the fact that I cannot balance…..and, I do feel very 
vulnerable. Moreover, that is frightening….Moreover, the fewer times I 
have to go out of that front door the better it is for me.……I know that 
it won’t help my case, but research has got to take place to help people 
in the future, I’m well aware of that, but I’m not just an ordinary 
kidney patient, I’ve got another problem as well you see, and I thought 
I couldn’t set myself up for all this. Because of my balance, I am 
frightened I will fall.  If I fall and break an arm, I am in real serious 
trouble” BRL_DNA_13 
 
4.3.5.3.3 Reliance on friends and family 
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Patients in the group that did not agree to participate were overall more reliant on 
their family for support. This reliance was linked to reduced mobility, with ten of 
the fifteen patients who reported mobility as an issue also reporting increased 
reliance on friends and family. Although an explicit connection was not made 
between reliance on friends and family and non-participation, this was implicit in 
what the participants quoted during the interview. All of the patients in the group 
that agreed to participate who had mobility issues and expressed reliance on 
friends and family had expressed altruistic morals which had driven them to 
participate in EQUAL. 
“R: I cannot… I have not got transport; I have a taxi. All my family is 
at work, and I do not want them to lose their job because they have got 
to have time off to take me somewhere. So I have a taxi from home 
down to the surgery, not far away but I have still got to have a taxi, 
and I have been going in for blood tests” OXF_DNA_06 
 
“R: So, my son always, he’ll always take me anywhere if I wanted to 
go, but as I say, I don’t like to be a nuisance, so I don’t like to keep 
worrying people…it does limit you to what you can do, you know, you 
have to rely on people and you have to rely on transport to get you to 
the hospital” OXF_DNA_05 
 
4.3.5.3.4 Home visits 
Amongst those who agreed to participate, three said their decision had been 
swayed by being offered a home visit. However, in the group that did not agree to 
participate, 10 of the 12 who were asked this question felt that they would have 
agreed to take part in EQUAL had they been made aware of the option of home 
visits at the time of invitation. 
 “R: I thought I had enough problems getting up to the hospital for 
treatment. I did not want to have to go even more often than I already 
am. 
I: Okay. If I were to tell you that as a part of the study, there is a 
facility to see you at home, or we only arrange to see you when you are 
attending a clinic appointment. Would that have swayed your 
decision? 
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R: If you mean someone is coming here to interview me, then there 
is nothing wrong in that. My biggest complaint is that I would have to 
get out there and get out to the hospital, by one method or another and 




Issues relating to transportation were one of  the most significant concerns and 
commented on by the majority of interviewees. 
“I: So, when did you first come about to hear about this study called 
EQUAL?   
R: Well I think it was a lady is not it that came on the phone? 
I: Yes. 
R: And I said to her, what did it entail?.... Going out there, and I 
thought Jesus, I cannot, I cannot, just cannot put up with this, it is 
enough to go out there when I have got to go out there.” BRL_DNA_10 
 
“I: How were you asked to take part in this EQUAL study? 
R: It was at the renal clinic, and one of the nurses came and asked me 
would I take part in it. Moreover, I said, “I will take part in anything 
as long as it is not a venue I have to get there too because I cannot get 
there.” SAL_AGREE_07 
 
Patients in the group that agreed to participate had overall retained the 
independence of driving despite their co-morbidities compared to the declined 
group.  
“I: Do you drive? 
R: Yes, yeah…the eyesight, after the cataract, has been pretty 
okay?” OXF_AGREE_04 
 
“I: Do you drive? 
R: I am used to having a car and driving. 
R: I have lost my car, I can no longer drive, I cannot get anywhere, so 
I am frustrated.” OXF_DNA_17 
 
Parking in the hospital was quoted as an issue in a couple of interviews and 
related to the issue of participation.  
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4.3.5.4 Help with decision 
Interviews explored the process of decision-making. Family opinions and attitudes 
could have an overt influence on participants’ decisions about whether to take part 
in the research. This could be either a positive or negative influence. The majority 
of patients who were approached to take part in the interviews in whom this theme 
was explored said that they had consulted with their family. (60%, 8 out of 14 in 
the agreed group and 7 out of 11 in the declined group). Of the eight in the 
agreed group who had discussed with the family, four had mutually 
decided to participate. In three cases the participants’ the family had left 
the decision to them, while one had a positive influence.  
“R: I spoke to my wife, and she said well, you do what you want to do. 
Did not consult anybody else other than that.” OXF_AGREE_03 
 
“I: Was it a decision taken with your wife or would you have said yes 
regardless? 
O: We were there together, so I was there. 
R: She had my arm up my back.” OXF_AGREE_17 
 
“I: What did your family think of your decision to participate in the 
study? 
R: Nothing to do with them. It is my body…. I just tell them. I am the 
head of the family.” SAL_AGREE_06 
 
Of the seven in the declined group who had discussed with their family, 
three had come to a mutual decision not to participate, three of the 
participants appeared to have had a negative influence from their family 
member and one had received a positive influence from the family but 
decided against participation due to other commitments. 
 
R: I have got to say that my daughter in law who works in a hospital in 
the path labs and ugh she said mum do it, she said it is very 
advantageous if I go – it will help you a lot, and you are helping other 
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people as well.  So, she recommended me to proceed with it. However, 
there was so much going on” BRL_DNA_09 
 
“I: So at the point that you received the letter, how did you approach it 
once you had read it?  Did you discuss it with your other half, did you 
speak to anybody? 
R: Well I showed it to wife … I mean, you can remember reading it, 
can’t you?  
O: Yes. 
R: As my wife said, at the time I was absolutely so overloaded with the 
hospital visits and blood tests and what have you.” OXF_DNA_01 
 
“I: how did you come to a decision not to take part? Was it yours to 
make or did you speak to your son? 
R: Well I mentioned to him, and you know, I said, this was something 
new. 
O: From our point of view, I stood there as a neutral person saying, 
“Look Dad do you want to take part in this research or not?”  You 
know at the end of the day it is something that one is not used to and 
for the reasons given etcetera, etcetera, privacy effectively you know, 
we declined.” OXF_DNA_12 
4.3.5.5 Medical Research 
This theme collated several sub-themes relating to participants’ perceptions of 
medical research, such as the need for this, the importance of research and their 
previous experiences of participation in research (if any). 
4.3.5.5.1 Perceptions of research 
The attitude to research was positive in the group that agreed to participate in 
EQUAL.  
“I: And what are your views on medical research? 
R: Well they need to do that don’t they to get to cure things, you know 
things what peoples got. It is like diabetes. I mean they try to get a cure 
for that but it will never be in my lifetime I should not think.  ‘Cos I 
have had it since I was 20.” BRL_AGREE_10 
 
BRL_AGREE_12 had a couple of family members who had died due to a 
congenital heart condition, and she owed the fact that she had lived up to the 
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age of 65 years down to research and the improvement in healthcare that 
research had facilitated.  
“my heart condition is inherited, as you know, and my father died at 
fifty, and my brother died at forty-two, and I am the only one out of 
three of us that have survived, and that is all down to research.” 
BRL_AGREE_12 
 
Altruistic morals (discussed in section 4.3.5.2) were strongly linked to participants 
perception of research. 
 
“R: I believe in research. I believe in you know, there’s a way forward 
for, like there’s so much for cancer now, I mean we’ve all felt that one 
way and another, and I mean we can do so little, because we’re not in 
the medical field, but we have the benefits from all this……if I can do 
one little thing, that is going to help the people with the knowledge and 
the know-how get to that place, in the end, we’re all responsible for 
that aren’t we.  Everybody should be responsible for that.  Cannot just 
leave it to the professors and the, can you, we have to chip in as well.  
So that is my reasons for being quite happy about research……I have 
had much help over the years medically wise, and um, (clears throat) 
having lost family because it was not so advanced as it is for me, and 
have allowed me to live a longer life, I am all for research” 
BRL_AGREE_12 
 
Only three patients in the declined group felt that research was useful. The husband of 
OXF_DNA_17 had been recently diagnosed with Huntington’s, and her son was also 
the carrier of the gene. She was, therefore, hoping that a cure for Huntington’s would 
have been found before her son or grandson developing it. 
“R: I do think medical research is important.  I mean I am hoping the medical 
research will have done its wonders by the time my son’s or my grandchildren 
come to developing Huntington’s, I do not know.” _OXF_DNA_17 
 
BRL_DNA_10 felt that research was essential for younger people, as they would 
benefit the most, but felt this was not the case for people of their age. 
“I: what are your thoughts on research? 
R: Well obviously it is a good thing, especially for probably 
younger people because they have got a chance of new things turning 
Chapter 4: Qualitative Chapter 
197 
 
up and helping them to keep their health. At my age, I do not expect 
anything is going to change any different, you know.” BRL_DNA_10 
 
The majority of the participants in the declined group were neutral, and one expressed 
a negative feeling that research was a waste of time.  
“I: what are your thoughts on medical research? 
O: Well obviously, it is important to you people that are doing the 
work, but, we are really done, we are getting to the age where we have 
not got much patience, do you know what I mean?  About things that 
do not really concern us, well we do not feel it does.  My wife seems 
pretty good with her, her, kidney situation; it has not been getting any 
worse.” BRL_DNA_14 
 
 “I: what are your thoughts on medical research yourself? 
R: I feel it is a waste of time…. I feel those people that are doing the 
surveys they could be doing a better job at looking after the patients.” 
OXF_DNA_06 
 
4.3.5.5.2 Previous experience 
This sub-theme captured interviewees past involvement in medical research or 
other activities promoting or related to research. Many of the interviewees who 
had agreed to participate in EQUAL had been involved with research in the past. 
Thirteen of the 15 participants in the agreed group, in whom this theme was 
discussed, were involved either directly in medical and non-medical research or 
activities similar to research such as questionnaires. In comparison, only two of 
the nine participants in the declined group had previously participated in research 
or similar activities.  
The husband of participant BRL_AGREE_10 said that although none of them had 
been involved in any research, they contributed actively to charities involved in 
research. These intentions suggested altruistic morals which had driven them to 
participate in EQUAL.  
“M: I am all for it, to be honest, we do give to some certain charities… 
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R: We give to too many. 
M: British Heart Foundation….do the um cancer one in it, and I do the 
blind. 
R: We do the Lifeboats. 
M: Lifeboats.  Foot and Mouth people, you know we’ve got certain 
other ones you know but I don’t – I don’t give every – I only choose 
two every month, pay monthly, the other ones I do as I you know I send 
a cheque off regularly you know, but we take it in turns more or less 
you know.” BRL_AGREE_10 
 
Several factors can have a bearing on the altruistic intent of participants – for 
example, where there may be an element of risk such as in a drug trial. Participant 
OXF_AGREE_17 expressed that a drug trial was something that they drew the 
line at. The interviewee had been invited to participate in a randomised control 
trial of sodium bicarbonate but chose not to take part as she was apprehensive of 
taking a new drug as it could potentially interact with the drugs she was already 
taking. She was, however, happy to take part in EQUAL which was a far less 
invasive observational study. 
“I said ‘basically that is a… I have just been looking for the 
information now’, and I said, ‘you do realise that I am high blood 
pressure, diabetic and some other things like you know, you put on a 
tablet, might happen’.  I said ‘I am already on medication, so 
everything is going quite nicely at the moment in time with my 
medication and everything.  So, I do not want to take something that I 
do not need.” OXF_AGREE_17 
 
Only two of the participants in the declined group had previously taken part in 
research. Participant BRL_DNA_03 had previously taken part in a stroke study after 
his admission to hospital with a stroke. However, he refused to participate in EQUAL 
quoting that his mobility was not the same anymore.  
“I: The stroke study you took part in it for two years and then the study 
ended, is that correct? 
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R: It was the end of the story, really, you know.  They said that you 
would not be getting a final report because there is not one, you know 
what I mean, outside of the … that the tests were being withdrawn. 
I: And did that have a bearing on your general feeling of what 
research meant? 
R: What, a negative feeling? 
R: No.  I mean, the only reason I am not particularly interested in 
doing the renal one is that you know, a lot of my time is taken up with 
my other medical issues, you know.” BRL_DNA_03 
 
4.3.5.5.3 Worthwhile 
A key factor when deciding whether to take part in a research study is whether the 
individual feels that the study itself is of value. For example, for 
BRL_AGREE_09, the potential value of the research was the primary motivating 
influence: 
 
“I: Do you know what it (EQUAL study) involves for the future and 
how long you are going to be participating? 
R: I know it could be a matter of three or four years or so, or even 
more, as long as I am alive and obviously can still talk to people, I 
would be happy for, for it to continue. Yes, I would, I am quite happy 
with that. Because, as I say I think it is a very good, worthwhile thing 
that you are doing, and I agree with it, totally and I wish that more 
could be done for so many more problems, you know.” 
BRL_AGREE_09 
4.3.5.6 Personal and beliefs 
This theme explored how participant life experiences, personal characteristics and 
beliefs may have motivated research participation. 
4.3.5.6.1 Early life 
Five of the seven participants in the agreed group had displayed a humanitarian, 
giving personality since early in life or had worked for the national health service, 
which was influential in them agreeing to participate in research. In the group that 
did not agree to participate there was no such evidence demonstrated in their early 
life through the interviews. 
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“R: I am a widow now, We had four children, and then we had, we 
fostered four, …. this one here, (girl’s name) she died when she was 
thirty.” OXF_AGREE_14 
“I had given blood from when I was old enough at eighteen to start, to 
help other people and it has just carried on that (pause) any survey 
that’s been necessary or I thought would be helpful to other people; I 
have contributed to it, you know.” OXF_AGREE_17 
4.3.5.6.2 Family and Friends’ health experiences 
Several of the participants (ten) in the agreed group in comparison to three in the 
declined group, had witnessed their close family members experience significant 
adverse health conditions including kidney disease, which could have influenced 
their decision to take part in medical research(EQUAL) though they did not make 
this explicit connection. 
OXF_AGREE_14, quoted the various health experiences of her family, initially 
referring to one of her foster daughters and then her sister followed by her 
husband. 
“This one here, (girl’s name) she died when she was thirty.  Down in 
Bristol, she had a bad heart.  I had a sister, I had two sisters, but the 
eldest one of those died through, with this same kidney condition sort 
of thing. My husband um, had diabetes, he must have had it for years 
before it was ever picked up. He had part of one foot amputated and 
then he had, uh, the other one below the knee amputated. Moreover, 
then it was, uh, oh diabetes infecting it and he went totally blind, um, 
all that sort of thing and when we were at the hospital once, he, when 
he was getting really poorly, the consultant there said about dialysis 
for him” OXF_AGREE_14 
 
SAL_AGREE_08 is referring to his brother-in-law commented that people are 
more willing to participate in research when they are desperate. This could be a 
potential explanation of why cancer research is eliciting better participation than 
research in other fields. 
R: “…..sometimes you are prepared to try it out because you are on 
death's door, like my brother-in-law, he is dying with cancer you know, 
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and he is quite happy to try things out which you know you would do 
wouldn’t you? SAL_AGREE_08 
 
Participants in the group that did not agree to participate had also had close family 
members experience health issues. However, when compared to the agreed group, 
this group had other mitigating circumstances for declining to take part in 
EQUAL. For instance, for the agreed group their family health experiences had 
driven them to participate in research (EQUAL) whereas for the group that had 
refused participation in EQUAL the experiences might have had the opposite 
effect and made them averse to anything remotely connected with healthcare. 
For example, OXF_DNA_05’s wife had died of oesophageal cancer a few months 
before having received the invitation to participate in EQUAL. Over the years of 
his wife’s illness, they had moved away from medically related discussions. 
Although this was not overtly expressed, this could have influenced the decision 
not to participate. 
“She had cancer of the oesophagus, which she was treated for and she 
lived for another 20 years, and after that, when she cleared of having 
that cancer, she lost one of her breasts.  So in a way, all that she had 
been through, she would not even watch hospital things on the 
television, you know, it sort of, she did not talk about it.  It might be 
mentioned, but that was it, we never went into deep discussions over 
anything like that.” OXF_DNA_05 
 
4.3.5.6.3 Proactive 
This sub-theme captured the participants’ eagerness with regards to healthcare 
related issues and overall decision making. It is probably unsurprising that the 
participants’ in the agreed group were overall more proactive. 
“R: I mean; in fact, they would not have needed to tell me why they 
picked me.  So, long as I knew it was something relating to my health.  
Like I say, I have attended two seminars….I would not have attended 
them if I’d not been interested in my health and what is being done 
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about it and what is new on the market because every time there is one 
we go.  Well, every time you learn something new.” SAL_AGREE_05 
 
4.3.5.6.4 Mindset 
The interviewees who had agreed to participate in EQUAL overall had a very 
positive outlook towards life despite their illness and co-morbidities compared to 
the EQUAL non-participants. This reflected in their enthusiasm to participate in 
research. The declined participants were overall more overwhelmed with their 
health care related issues. 
“R: I know that it won’t help my case, but research has got to take place to 
help people in the future, I’m well aware of that, but I’m not just an 
ordinary kidney patient, I’ve got another problem as well you see, and I 
thought I couldn’t set myself up for all this…. not because I didn’t want to 
help, but it’s just that it’s me, my situation is different from other 
people’s….. Because if I fall and break an arm, I am done for…. I am not 
dizzy, but I am unstable……And that is frightening….. And the fewer times 
I have to out of that front door the better it is for me.” BRL_DNA_13 
 
4.6.4.6.5 Privacy 
Only one interviewee commented about privacy and quoted this as an issue for 
non-participation. The son felt that his father was a very private person and that 
this was one of the main reasons for not participating in the study. 
“ I: And what are the reasons for you not to take part? 




Under the broader theme of ‘Study-related’, a wide variety of subthemes, or 
categories, were noted. These were: why chosen, study understanding, reaction to 
the invitation, the experience of renal unit, manner and method of approach and 
clarity of invitation/information. 
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4.3.5.7.1 Why chosen 
This sub-theme was mainly descriptive and collated participants’ perception of 
why they were chosen. Nine of the 13 participants in the agreed group and nine of 
the ten participants in the declined group were not aware of the reason why they 
had been invited to join in the EQUAL study. 
Not aware 
The patients were not aware of the fundamental reason behind why they were 
invited to participate in EQUAL and the reasons behind what made them eligible.  
“I: Do you know why specifically you were being asked to take part? 
R: No, I just thought I was just one of the millions if you like.” 
BRL_AGREE_01 
 
“I: And did they tell you why they had asked you to take part? Why you 
specifically? 
R: It was when you get to a certain age, and you have problems, and 
they are doing a study that can help people in the future. It is no use to 
me now, but it will help other people.” SAL_AGREE_07 
 
BRL_DNA_15 felt that they were not relevant to the study. 
 
I: Okay. Um, when you first got the letter, how did you feel?  When you 
looked at it? 
R: Read like say half of it and thought “Oh well that is nothing to do 




Some of the participants in the aware group had only a vague understanding of 
why they had been chosen to participate. 
“I: And do you know why they asked you particularly, to take part? 
 R: I think it is just because of the chronic kidney function.” “I am just 
wondering whether they did not actually say, I am not sure whether it 
would have been an age thing or not, whether they were taking it.” 
OXF_AGREE_02 




“I: How did you first come to hear about the study that you are taking 
part in? 
R: “Saying my name was flashed up because I was the right sort of age 
and the right level, with the bloods or whatever it is.” 
OXF_AGREE_14 
 
4.3.5.7.2 Study understanding 
This sub-theme again was mainly descriptive and captured the participants 
understanding regarding what participating in the study entailed. Nine of the 17 
participants in the group that agreed to participate had no understanding, six were 
partly aware and only 2, fully aware.  
“I: And was it clear to you why this specific study was being done? 
R: Only in so much that you need the information to probably change 
things, from what is already in the public domain at the 
moment.” BRL_AGREE_01 
 
“I: Okay. Now, having read all the information that you were given, 
was it immediately clear to you what was going to happen for 
the duration of the study? 
R: Not really, no.  Well, it is that long since I read it, to be honest, you 
know……. 
R: You read something, you forget it, you know.  
I: But having refreshed your memory now…… 
I:  About what was going to happen for the study?  How long you are 
going to be followed up, things like that?   
R: No, that does not bother me because as I say I’ve done similar 
studies.” OXF_AGREE_17 
 
One participant said that she was aware of what participating in the EQUAL study 
meant but on probing further became upset. She was unable to differentiate 
between her routine clinic visits and visits relating to the study and was not aware 
that she was participating in EQUAL. 
“I:  And having read it was it clear to you what was going to happen 
once you agreed to take part in this study? 
R:  Yeah more or less yeah. 
I: What it would entail, what would happen at each step of the study - 
that is what I meant. 
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R: Do you think it is worth me doing it?  Because I am not very 
helpful.” 
 
“I: Have you, had to take extra blood tests or have you had to 
complete questionnaires? 
R: Right when I go to the clinic first thing they do is um got to be 
weighed, and ugh take my urine and then ugh I get to go and have my 
blood took, and then I go in to see the doctor.” 
I: Oh, I was more talking about the study. 
M: But basically, in the study, this is as far as you have done as we 
are concerned, they have not asked anything apart from that.” 
 
“I: Have you filled out any questionnaires? 
M: Ugh which questionnaires – I cannot remember we got.  Which 
questionnaires was it? 
I: Questionnaires that asked about the questions relating to how 
you are feeling, about your physical health and things like- 
R: No. 
M: I think so well yeah  
R: I cannot – I have had so many forms.” BRL_AGREE_10 
 
One of the participants who had agreed to participate had limited awareness of 
what participating in the study meant but had a poor understanding regarding the 
relevance of the study to their current illness. This issue also relates to limited 
awareness of the renal condition which is discussed in section 4.3.5.1.3 above. 
“ Well I did say to nurse X when she came after the first and left me 
with this thing to go through and I said to her, course a lot of this the 
answers or the questions here, really don’t apply to me because this is 
uh, questions for people who are really suffering because of kidney 
problems failure and then they were talking about how would you feel 
about dialysis and things like that, so well I said to nurse X “the thing 
is I’m not that advanced” so you understand a lot of the questions 
were for people who were on their way into dialysis really, so I said to 
her “there are, there are quite a few questions here that don’t apply to 
me at all.” BRL_AGREE_12 
It is noteworthy that although some participants did not have much awareness, this did 
not deter them from participation. 
“I: having read this was it clear to you what was going to happen throughout 
the study?  Did you have any questions? 
R: No, I suppose not.  Um, I was not bothered about all this information 
goes here, there and everywhere, because that is the whole intention and it 
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does not matter if my name came into it, I am not bothered about that.  
However, I am interested in the results at the end of it.”  
“I: What they are actually hoping to achieve?  
R: No, I really do not.  I do not know whether, well, I do not know research 
seems to involve many things, does not it.  I suppose.  I do not know; I do not 
really know an awful lot about kidneys, I was actually in hospital with a young 
lady who actually put herself on dialysis, ………. I know it is to do with the 
waste product and everything like that, but I do not really even know 
whereabouts it is.  I’m a bit silly like that; I do not get too serious about it.” 
BRL_AGREE_12 
Of the 17 patients in the declined group, 16 were asked the question relating to 
study understanding, 13 had no understanding of what the EQUAL study involved 
with only 3 participants being partially aware of what taking part in EQUAL 
meant. This would suggest that understanding of study purpose was lesser 
compared to the agreed group and could have had an influence on participation. 
This accurately reflected the patient understanding of EQUAL as the interviews 
were conducted fairly soon after they had agreed or declined to participate in 
EQUAL (time of decision-making). 
“I: What did you hear about the EQUAL study? 
R: I know nothing about it at all. I do not know what it is all about. 
R: I can imagine sitting just in a room talking about it; that is all.” 
BRL_DNA_14 
 
4.3.5.7.3 Reaction to invitation 
Included under the umbrella of this theme were questions intending to explore 
patient’s reactions to an invitation to the EQUAL study. Overall, participants from 
the agreed group did not express much of a surprise about the invitation, and one 
participant (SAL_AGREE_07) was ‘thrilled’ that she was invited to take part. 
However, participants in the ‘did not agree’ group expressed a sense of shock, 
disbelief and felt overwhelmed that they were being asked to take part. This could 
be related to the timing of the approach discussed in section 4.6.4.6.6. 
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SAL_AGREE_07 was happy that she was invited. She felt indebted to the NHS 
due to the care she had received over the years and also understood the purpose of 
research. She had developed myeloma and had been offered thalidomide as a trial, 
and that cured her of the disease. 
“R: It might not seem much to some people, but I was thrilled to 
bits when I was asked.” SAL_AGREE_07 
 
4.3.5.7.4 Manner and method of approach 
Across most centres, all eligible patients were invited to take part in EQUAL via 
an invitation letter and information sheet sent in the post. This was then followed 
up with a phone call to confirm whether they were willing to participate. 
Six participants in the agreed group felt that the friendly method of invitation had 
a role to play in the decision to participate in EQUAL. 
“I: What was, what was good about the way she went about asking 
you to take part?  What is it that appealed to you the most? 
R: That her mannerism was very good, you did not, you felt at 
ease all the time, there was, she said if there are questions you do not 
want to answer, do not answer, she said, I quite understand, so yeah” 
OXF_AGREE_03 
 
The majority of the participants both in the agreed and did not agree group did not 
remember getting the letter; one must, however, bear in mind that the qualitative 
interviews were conducted a few weeks or on occasions, a couple of months after 
the invitation to participate in EQUAL had been made. 
I: Did you remember getting this letter?  Do you remember reading it?   
I: I show it to you.  Does that ring a bell? 
R: Well I think I have had one like that, but I do not think I read it 
all because it is such a lot to read, and my eyesight is not quite so good 
as it used to be, and um it takes me a long time to read anything 
nowadays.  BRL_AGREE_10 
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The majority of the participants in the agreed group felt that it did not matter how they 
were approached though they preferred the approach to be face-to-face. Five of the 
seventeen participants in the declined group felt that a telephone call might not have 
been the best method of establishing contact. A few felt that they were often harassed 
with cold calls from salesman over the phone and therefore a telephone invitation 
would put them off. This could prevent them from engaging in further conversation. 
Had they been invited face-to-face this would have influenced their decision to 
participate. Inviting participants to take part in the qualitative sub-study at times 
proved to be a challenge as I was frequently mistaken to be a salesman. 
“O: And of course, the other problem is, with the old people, is you get 
so many, you know, bogus callers and of course, at the end of the day, 
she picks up the phone and if she hears somebody she doesn’t 
recognize and she thinks, “Oh, well, that’s not family, and it’s not the 
doctor or something – I don’t wanna …” you know, so it’s almost not 
giving the person who’s trying to make the phone call, to make the 
communication … giving them a chance to say something, you see, and 
probably also not quite understanding what it is all about.” Son of 
BRL_DNA_04 
 
“R: Well, for me, not forms, make a contact that I can respond 
immediately to that question. When paper lands on my desk, being in 
business, I get lots of paper, you know, and at that specific time, I 
might be too busy, you know, because other things are falling about my 
ears, and I have got to answer someone else. 
I: Sure, but I think, so personally you feel a personal contact 
would work better for you? 
R: For me, yeah.” BRL_AGREE_01 
 
“R: Well, I only heard about this one when actual fact the young 
woman phoned me up…..What happened in actual fact, if I am doing 
something like this I prefer to sit in front of somebody so if I have a 
problem I can ask a question SAL_AGREE_05 
 
4.6.4.6.6 Timing of approach 
The timing of the approach was one of the key factors that influenced the decision 
of whether to participate in EQUAL or not. In at least half of the participants who 
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had declined to participate in EQUAL, the invitation had come at an inappropriate 
time usually when the patient was unwell. 
For example, BRL_DNA_03 had been approached at a time when their illness 
was accelerating. Regardless of the patient's perceptions of the research, this 
overruled any thoughts regarding participation. 
“I: What did you think of the way the lady that called you asked 
you to take part in the study?   
R: It was just a polite follow-up to her letter, ….I had just been 
told that I would probably be going on dialysis then, and I thought … 
well, it was not a matter of, “No, I am not doing it – it is a waste of 
time.”  It was a matter of, “Hang on, I am starting to get a little bit ill, 
and I would like to know how it is going and what is happening before 
I take on any other commitments for the hospital.” BRL_DNA_03 
 
“I: Okay.  So, when did you first come about to hear about this 
study called EQUAL? 
R: I do not really know, it is just, I say it caught me at a wrong 
time 
O: If we declined it though I think at the time he was probably so 
poorly we did not want to do it.” BRL_DNA_10 
 
Illness experience in the family could also contribute to it being the wrong 
time to be approached (section 4.3.5.6.2) 
“R: Well last year was a very bad year, I discovered my husband 
had Huntington’s disease, um, I had to leave my home he had to go 
into a care home, and then I came down here, which was all very 
traumatic.” OXF_DNA_17 
 
4.3.5.7.5 Clarity of invitation/information 
The wife of a participant (BRL_DNA_10) who had not agreed to participate in 
EQUAL felt that the letters had to be more explicit. Her husband who had 
developed a general aversion to hospitals as a result of a previous experience 
refused to participate in EQUAL after seeing the letter with the hospital’s name on 
it and therefore assumed that participation would result in increased visits to the 
hospital.  
Chapter 4: Qualitative Chapter 
210 
 
“I: …. Now coming back to the study itself and the way we invited you, 
what do you think was good or bad, what could we have done better? 
O: I think they need shorter letters. 
O: And maybe make it more explicit.  That it could be done in your 
home.  I think people like him would just see the word [hospital name] 
” BRL_DNA_10 
 
On the other hand, a daughter (BRL_AGREE_12) felt that the invitation letter was 
well laid out. 
R: It [information sheet] is quite clear, you know, what the purpose is 
and how you were approached and whether you want to or not. 
I: But, did you think in any way it was elaborate or sufficient?   
R: I’ll tell you, my daughter was here when (clears throat) I was 
reading this because she, the field she is in, she is trying to make all 
this kind of thing, even a prescription, understandable for people with 
Alzheimer’s, DSA and that, and so actually she, she’s still got it.” 
BRL_AGREE_12 
 
On any of the study materials, it is mandatory to have the details of the lead 
site/sponsor of the study. One of the participants who agreed to participate in 
EQUAL felt initially a bit panicked at the thought of having to drive down to 
Bristol from Oxford for the study visits.  
“I:       When you received the letter did anything go through your 
mind?  ….. was there anything that you thought about, or you just said, 
fine yes go ahead? 
R: I did when I first read the, uh, I thought oh blimey going all the 
way down to Bristol and that.  Moreover, then I asked Nurse J about it, 




Sub-themes that were explored under the umbrella of trust were the source of 
contact, confidence in approaching the person, and privacy. 
4.3.5.8.1 Source of contact 
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Patients that were eligible to participate in EQUAL were contacted by research 
nurses. Thirteen of the 14 participants in the agreed group had no strong feelings 
on who had contacted them and felt that this did not affect the outcome of their 
decision. 
Interestingly a great many in the group that did not agree to participate said they 
would have strongly considered participation had their current physician posed the 
question, with six of the ten interviewees or partners of interviewees who refused 
to participate in the EQUAL study expressing this. Interpersonal trust-in-physician 
was linked with the desire for participation. This suggests that the trust built over 
time in the physician-patient relationship has a role in the participants’ decision-
making process. The participants felt that they shared a relationship with their 
physician and they described them to be “good”, “nice” and said they had “every 
faith in them” and hence would have agreed to participate. 
“I: On the other hand say if the consultant you see in the kidney clinic, 
if he had said there is a study that’s going on, would you take part? 
What would your response be? 
O: I think we would have done anything because we have got every 
faith in him.”SPOUSE-OXF_DNA_16 
 
One spouse commented: 
“I think if Dr X … she gets on quite well with him, actually. If he had 
asked her on one of his visits and said, “Look, we are gonna do this 
research, you know – would you, do it?” I think that would have made 
a big difference.  I think that would have … she would have said, “Oh, 
yes, okay, it is fine. ” Because, you know, you build up a relationship 
with … sometimes … obviously, you do not see the same specialist all 
the time, but you do build up ... you know, even though you are only 
seeing him for five minutes, it is surprising how you do get this sort of 
thing going.  It is a confidence thing I suppose.” SPOUSE-
BRL_DNA_04 
 
It was important for a few others that the contact had originated from a trusted 
source which was to them the renal clinic. 
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“The renal unit, I see. I have found up there um, it is a different 
situation than the cardiology where I go, it is um, very friendly…… 
However, I have found the staff so very different than they are in 
cardiology. They are very helpful and very, they seem to care more 
about you yourself, you know?  Yes, and a good atmosphere, my 
partner always says that a good atmosphere in here isn’t it?  I said 
“Yeah”.” BRL_AGREE_12 
 
In one instance, one of the interviewees had both good and bad experiences with the 
medical fraternity. Both the participant and their spouse felt that who invited the 
individual to participate in research was key to whether they agreed to participate.  
O: If it were the doctor you see about your eyes you would have said 
no straightaway, he was absolutely obnoxious. 
I: So, it depends … are you saying it depends on the person? 
R: Definitely, it would be that because half of them medical doctors 
are obnoxious, like the one we saw about me eyes. “ I see Dr W; you 
could talk to him like a man to man type thing…. However, no problem 
at all with Dr W……it (agreement to research participation) comes 
down to your comfort zone with the doctor.” SAL_DNA_02 
 
4.3.5.8.2 Confidence in the approaching person 
This sub-theme captures the views of the agreed participants and the factor that 
had influenced them to participate in EQUAL. The declined group did not 
comment on the character and skills of the person who approached them.  
The consensus was that the inviting person should be able to appropriately answer 
any potential queries. 
“……It is no good trying to persuade someone to um take part in 
something if you cannot give them sort of honest answers to questions.  
Moreover, uh, therefore it is got to be a knowledgeable person to, be 
putting the study forward and in the same way, people who are 
sensible enough to be able to answer and um take part in the study. 
However, no, I think, a nurse, if she is qualified if she has the 
qualifications, there is no reason why a nurse or a doctor or whatever 
other um, comes in between those two could um put forward this 
study.” BRL_AGREE_09 
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Participant BRL_AGREE_11 was more than happy to be approached by a nurse and 
regardless of the person approaching he felt that a casual manner was what appealed 
to him. 
“I: What the person inviting you made a difference to whether you 
participated or not? 
Well, it might have done, if there was someone there in a white coat 
and a surgical hat on (laughs)… however, no it is done in a, in a 
casual manner and as far as I am concerned that was the way to do it. 
Basically, if you go in and see a doctor in a white coat and there are 
nurses in blue or whatever they have got now, it is purely formal. 
When it is informal, it puts you at ease.” BRL_AGREE_11 
 
4.4 Discussion 
4.4.1 Main Findings 
When interview data were analysed, all the patients were found to have 
expressed motivations and barriers for their participation. The different context of 
the interviews (agreed and decliners) might have had a bearing on the kind of 
topics that emerged from the participant's accounts. These fell into seven key 
themes: altruism and self-interest; convenience; help with the decision; medical 
research; personal and beliefs; study related, and trust. Additionally, a descriptive 
category of healthcare-related and patient activation emerged, which indicated 
differences between the agreed and declined group. What is of most importance is 
that the f indings of this study are the personal feelings of those older adults 
who agreed o r  d e c l i n e d  p a r t i c i p a t i o n ,  in clinical research and they give 
an indication of the circumstances which influence their decisions during 
recruitment and ongoing participation. In the qualitative data the key issues t h a t  
a r o s e  w e r e :   
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1. There was no significant difference in the themes by site (high, medium and 
low recruiting sites) and the recruitment rates were more likely related to 
resources and competing studies. 
2. The theme of convenience was overall demotivating to participation in 
EQUAL, with caring responsibilities and transportation difficulties being 
particularly discouraging to participation in the EQUAL eligible cohort.  
3. Patients who engaged with their healthcare and who were more activated were 
more likely to agree to participate in research.  
4. Altruistic morals had a strong influence which had driven them to take part in 
the EQUAL study. These altruistic morals were also strongly linked to 
participants’ perception of research. However, the relationship was 
complicated as all of these patients had also expressed altruistic morals which 
suggested that self-interest could be a prerequisite for altruism.  
5. Interpersonal trust-in-physician was strongly linked with the desire for 
participation. 
6. The agreed group overall had a very positive outlook towards life despite their 
illness and co-morbidities compared to the declined group which reflected in 
their enthusiasm to participate in research.  
7. A majority of participants in the agreed group and the declined group were not 
aware of the reason why they had been invited to join in the EQUAL study.  
4.4.2 Relationship to literature 
A considerable amount of time, effort and often resources are spent on recruitment 
into research with varying rates of success. It is imperative to gain an 
understanding of the reasons why individuals choose to participate or otherwise in 
research. Mapstone et al. attempted to identify reasons behind why many research 
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projects fail to recruit their targeted numbers. (333) Patients’ inclination to take 
part in research studies is probably to be prejudiced not only by the study design 
but also their perception to research. Numerous issues and several barriers to 
research participation have previously been widely studied by both quantitative 
and qualitative studies to date (260, 334, 349-352). Several articles have even 
specifically looked at the issues of motivation and deterrents to participation 
within a population of older adults (269, 353-356), but there is a distinct lack of 
studies that have attempted to investigate the experience of a range of older 
adults who had participated in the research. The unique aspect of this qualitative 
study is that it captures the motivation and barriers of older adults for 
participation in research. Another fascinating feature of this study is that it not 
only captures the experience of and reasons behind participation of the agreed 
group but also aimed to gain insight into the deterrents and barriers to 
participation in the declined group who were invited to participate in EQUAL. 
Patients who have declined to research are often a difficult group to gain access 
to but it essential to include their experiences if we are to improve recruitment 
and improve the validity of a study. 
The target population of the EQUAL study was different. They were not only 
older adults, but all had advanced chronic kidney disease. They also had other 
issues either resulting from their kidney disease or because of co-morbidities such 
as diabetes. Therefore, the themes and issues that have emerged from this 
qualitative study are novel and can translate to research involving older people 
and other chronic diseases. These issues must be considered in the planning of 
future research studies involving the elderly. 
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It is difficult to adequately assess how the participants of this study compare to the 
general population of research subjects (generalisability) with regards to age 
(elderly) and co-morbidity. Several authors note that older adults, in particular, are 
consistently underrepresented in clinical trials and studies. (278, 357) This gap is 
viewed as a significant disadvantage for the ageing population as the evidence of 
clinical research does not apply to them. (267) 
It should also be expected that most chronic conditions are likely to produce 
some of the complications mentioned above, especially in older adults. As a 
result of the issues that go with multi-morbidity and age, the risk-benefit ratio of 
clinical research participation is always considered both by researchers and 
participants. The risk-benefit matters drive the decision making, and where 
possible, patients should be permitted to take part in any research they are willing 
to. (358) 
Several assumptions are commonly made about older adults which prove 
detrimental to their participation in clinical research. (267, 359, 360) These 
assumptions may be seen as ageism. The literature reveals a perception 
among some clinicians that their older patients are vulnerable and unable to 
make informed decisions for themselves: such a ‘protective’ clinical paternalism 
can be a barrier to the inclusion of older individuals. An expectation of the 
UK Government is that older adults should be more “… proactive and participate 
in decisions about their care.”(361) 
Research by Levy et al. also found that older adults were more likely to participate 
in clinical research studies when convenient for them, for example, regarding 
location. (271) Although EQUAL offered home visits in most centres, the notion 
of research studies being associated with the hospital and the concern of getting to 
Chapter 4: Qualitative Chapter 
217 
 
the hospital was a barrier to EQUAL participation. The potential of home visits 
could have also been better communicated with the patients. This was rectified in 
the patient invitation letter by submitting a minor amendment. To overcome this 
barrier recruitment policy can be better shaped to recognise that older adult study 
participants are more likely to participate in medical research if the possibility of 
home visits is highlighted during the invitation. One of the unique elements 
elicited from the interviews was the aspect of caring responsibilities that were a 
barrier to participation. There is a minimal acknowledgement of this in the 
literature. (362) This barrier may also be addressed by offering home study visits 
in any research involving the elderly. 
Further, the availability of transportation was a critical issue, especially for those 
who had stopped driving or were widowed. It was a consistent topic of this study, 
and many of the participants reported that had there not been home visits then they 
would have been unable to take part. This is an important issue to consider when 
designing a study with older adults and budgeting for transport and home visits 
could aid recruitment. 
The chronic illness care model emphasises patient-oriented care, with patients and 
their families integrated as members of the care team. (363) Patient activation can 
be measured using the Patient Activation Measure (PAM) and is defined as the 
patients’ knowledge, skills, confidence and ability to take an active role in their 
health care. (364, 365) Patient activation has been shown to have an impact on the 
patient-assessed quality of chronic illness care. (366, 367) Improved patient 
activation has also been shown to improve patients self-management behaviours. 
(368) Therefore it is highly likely that patient activation has a role to play in 
patient engagement and participation in research. In this study, the agreed group 
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were overall more activated, being more forthcoming about health concerns not 
directly relating to the consultation, more aware of their medical condition 
(including the cause of their kidney failure) and would promptly consult their 
general practitioner in comparison with the declined group. 
This study has also shown that frailty, which could be a marker of co-morbidity, 
could have been a barrier to research participation. Patient frailty impacted on 
their mobility and this, in turn, made them more reliant on their family and 
friends. Ridda et al. in their study used the frailty index as a tool to measure 
frailty and to document barriers to recruitment. (268) In the above study, only 
39% of potentially eligible patients who were approached agreed to participate. 
In general, altruism (334, 369-373) and self-interest (369, 371-376) are frequently 
quoted to be vital in influencing inclination to participate in any research studies. 
Altruism is defined as “disinterested or selfless concern for the well-being of 
others”.(377) Altruism has been emphasised as an important and apt motivator for 
individuals to enrol in research, with an argument that clinical trials are more 
ethical when participants act out of altruism instead of self-interest (334, 369, 370, 
372, 373). The majority of the patients in the agreed group expressed altruistic 
morals which had driven them to participate in the EQUAL study, and this was a 
recurrent impetus expressed by the majority of the interviewees during the 
interview. Their altruistic belief seemed to be grounded on the belief that research 
studies would improve medical knowledge, improve treatments, ‘find a cure’ and 
ultimately ‘benefit others’. However, this was less forthcoming in the interviews 
in the group that did not agree to participate. An issue that was evident in this 
study was the personal sense of good that the participants felt they d e r i v ed  
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from being able to participate in a study which could improve healthcare for 
others in the future. This was in line with the findings in the literature. (360)  
The motivating themes for participation also included self-interest and personal 
gain. Some studies argue that self-interest is a stronger reason for participation 
than altruism. (378, 379) In this study on some occasions, it was difficult to 
disentangle altruism from self-interest and which of these was the overriding 
motivation for participation. The quotes suggested that the relationships were 
more complicated with self-interest often a prerequisite for altruism. Preserving a 
‘net personal gain’ and safeguarding their self-interest were found to be significant 
factors in promoting research participation. The self-interest in this study was 
governed by knowing more about their condition and being able to participate in 
finding a cure for the condition (kidney disease). If the participant invited to take 
part in research feels that they are participating in research that is worthwhile, it is 
more likely that they will have a positive experience. (360, 379). This was in line 
with the findings of Alexander et al. who noted that: “...Literature has provided 
strong evidence that research among vulnerable populations may not be harm‐
free but may also be of direct benefit to participants”.(360) Benevolence, and the 
ability to be significantly useful to society are their own rewards. Morrow-Howell, 
Hong & Tang investigated the personal benefits to volunteers. (380) They found 
that there was inconsistency as to whether specific groups of people benefit from 
volunteering more than others. They did, however, report some evidence which 
suggests that those individuals who are disadvantaged regarding personal and 
social resources, experience more positive outcomes. A variety of backgrounds 
and lifestyles were represented by the participants in this study, but the interviews 
did not explore in depth the difference in the benefits felt by any of the 
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participants. Future qualitative studies should investigate in-depth the effects of 
socioeconomic status on the benefits perceived by volunteering or participating. 
Another important issue noted in the study was that interpersonal trust in the 
physician could potentially have an important role in the participants’ decision-
making process. Also, it was also down to the confidence in the source, e.g., The 
Renal Unit and the qualities of the recruiter and sense of confidence in the person 
approaching them rather than the Nephrologist themselves. Adams et al. carried 
out a comparison of different recruitment methods to a clinical trial and found that 
the highest yield of participants came from direct presentations. They considered 
that this was due to the high level of trust exhibited by patients toward their 
physician and other caregivers. (381) Equally, a few studies have claimed that 
there is a prevalence of mistrust of health care in general and research projects in 
particular among older patients.(359, 381, 382) However, none of the authors 
expands upon this or speculates why this may be. None of the interviewees was 
introduced to EQUAL by their Nephrologist. It has been noted that health care 
providers, including doctors, play a critical role in recruitment because they often 
introduce the option of research to patients. (359) This can be an important 
strategy to improve recruitment in research, but there is always a fine balance 
between introducing research and the ethical issue of coercing patients to 
participate in research. Although there is a general belief that doctors are more 
successful at recruiting research participants than nurses, Donovan et al. found no 
significant difference in recruitment rates between doctors (urology consultants) 
and nurses for prostate cancer-related RCT. They also suggested that nurses were 
more cost-effective recruiters, despite spending longer on average with each 
patient. (383)  
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In this study, the participants voiced a preference for the initial contact to be in 
person in a clinic as opposed to it being in writing which could be related to the 
issue of trust. This is in line with findings reported by Tolmie. Et al. (354) 
Several authors have also indicated that, when invited to do so, older adults are 
generally not only agreeable but also have a positive approach to taking part in 
clinical trials and research (267, 384, 385). However, this study indicates that this 
willingness is often dependent upon the research process providing flexibility 
toward appointments and procedures. It is important to recognise that the fostering 
and maintenance of a relationship of trust are essential throughout the recruitment 
and retention of participants. 
Lovato et al. (1997) found that recruitment amongst the older population was not 
any more difficult than amongst individuals of any other age group, with 
participant refusal rates for trials in this segment of the population appearing like 
those in trials carried out primarily with other age groups. (260) This, however, 
goes against the findings of Gonzalez et al. who suggest that it proves to be: 
“...difficult, time-consuming and expensive”(273). While some retired 
individuals may have an abundance of time available, many healthy seniors 
either continue to work or have very active social lives with many time 
commitments as demonstrated by some participants in this study. If the 
investigators can coordinate their hospital appointments to research visit 
appointments, then the participants find it easier to participate. 
Finally, a unique finding of this research, not previously recognised in the 
literature, is that older adults may lack exact awareness of the reason why they 
have been invited to join a research study and what participation will entail. 
However, some studies have acknowledged this in other age groups as a product 
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of insufficient information given to the patients’ from the recruiters. (386) This is 
likely to be because of ageing but may also be a result of their co-morbidity 
burden including dementia. Therefore, some consideration and thought should be 
given regarding the ethics and process of invitation to research participation for 
elderly and multi-comorbid patients. A way to overcome this issue and in the 
process optimise recruitment and retention is a to train the recruiters to make sure 
they communicate the study effectively, face to face rather than via postal 
recruitment (since some participants experienced difficulty in being able to read 
recruitment materials due to visual or other impairments), that they involve carers 
and family, send reminders or newsletters and provide a contact helpline to allow 
patients to communicate with research nurses.(386) 
4.4.3 Strengths and Limitations 
This study sampled the views of several individuals over the age of 65 who had 
taken part or declined to take part, in EQUAL. Although not explicitly discussed 
in detail within the study, it included individuals from a variety of diverse 
current health statuses but did not explore the influences of socio-economic 
backgrounds and research participation. Although anecdotally in the interviews of those 
that did not agree to participate, interviewees were of low socio-economic status. It would 
have been useful to capture the perspectives of patients who dropped out of EQUAL 
as high patient drop out affects the study’s validity. Also, interviews of the research 
teams (research nurses) would have given insight into how centre priorities could 
potentially influence recruitment to a study. 
This study is unique as it may be the first to qualitatively study the perceptions of a  
group of patients who are not only elderly but also multi-morbid. The study 
explored a wide variety of issues and has yielded valuable insights on a breath of 
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topics. The study was not restricted to a specific region and explored barriers and 
facilitators across three of the EQUAL sites. A good understanding was achieved 
by a large group (N=34) of both the agreed and declined groups(16 in each group). 
One of the strengths of this study is the capturing of views expressed by those who 
had declined research participation. Typically, the voices of such individuals are 
not heard. Their accounts were compared and contrasted to those of patients who 
had agreed to participate. This study has therefore added significant value to the 
sparse literature which has explored the perspective of study decliners and reasons 
for non-participation. (387, 388). 
4.4.4 Recommendations 
Several recommendations for improving future practice and inclusion follow from 
the findings of this study:  
1. Recruiters should not adopt the same recruitment strategies for all 
demographic groups. 
2. As far as possible, investigators should be aware of the potential 
motivations and barriers to the recruitment and retention of the older 
adult. 
3. A face-to-face approach should strongly be considered as cold calls can 
put patients off and prevent them from engaging in further conversation. 
4. Patients’ doctors can play a critical role in recruitment and should 
introduce the option of research to patients even if they are not directly 
involved in recruitment. 
5. Inconvenience to the older adults should be minimal and offering home 
visits may be essential to alleviating this. For instance: 
- Transportation should be provided, or home visits should be arranged. 
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- Flexibility about appointment times and locations is likely to facilitate 
greater retention. 
- Given that a good proportion of older adults have caring responsibilities, 
home visits are therefore invaluable. 
6. Older adults are agreeable to research participation but will often seek 
permission from families. These groups should be targeted about raising 
their awareness of how research participation can benefit the older 
population and that their participation is appropriate and necessary. Also, 
they should be made aware of their own attitudes toward older adults 
being participants and how this can affect the recommendations they 
make to them. This can be achieved by families being present when older 
adults are approached for recruitment. 
This chapter has shown that older adults are generally willing and able to take part in 
clinical research. The insights of the study overall are to be used as a base on which to 
build future research and to guide the recruitment of older adults in future studies. 
There is also scope for improving the recruitment and participation process to ensure 
that all involved are fully aware of the issues that surround the older generation being 
a part of research and how this can affect the generalisability of the study results. 
Also, these insights can be used as a base on which to build future research protocols 
to allow more significant inclusion for those of an older generation who would wish 
to be involved and thus improve the generalisability of research.  
The next chapter seeks to understand the threats to generalisability that occur at the 
reporting phase of a study. The chapter describes a systematic review that looks at 
reporting of cohort studies before and after the introduction of the STROBE 
statement.
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CHAPTER 5. ASSESSING THE DESIGN AND QUALITY OF 
REPORTING OF CKD COHORT STUDIES ASSESSING 
MORTALITY IN THE ELDERLY BEFORE AND AFTER THE 
PUBLICATION OF STROBE: A SYSTEMATIC REVIEW. 
The previous chapter discussed the perspectives of older, frailer patients on 
participation/non-participation in an observational cohort study, the European Quality 
Study (EQUAL) and the impact that non-participation can have not only on a study’s 
internal validity but also its external validity (generalisability). This chapter is 
dedicated to the third study of the PhD which aims to review the impact of the 
STROBE statement upon reporting and study design of CKD cohort studies. 
Inadequate reporting is associated with potentially biased estimates of treatment 
effects and limits the assessment of a study’s strengths, weaknesses and 
generalisability. 
5.1. Introduction 
When assessing the value of a study two aspects need considering: the quality of 
methodological design and the reporting quality. 
5.1.1. Study design 
The scientific value and reliability of the conclusions drawn from a study 
are determined to a significant extent by the quality of the study design. 
(389) 
5.1.1.1. Importance of assessing study design 
Before including a study in systematic reviews and meta-analysis, it 
is essential to assess its methodological design. The quality 
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assessment can be utilised in many ways such as the inclusion of 
studies meta-analysis, guide a sensitivity analysis or meta-
regression, weighting studies, or highlighting areas of 
methodological quality poorly addressed by the included studies. 
(390) Low-quality studies can lead to a distortion of the summary 
effect estimate. 
5.1.1.2. Assessment of study design 
The quality of any study’s design can be assessed by considering various 
methodological aspects and a few tools have been developed for this 
purpose which includes quality scales, simple checklists, or checklists with 
a summary judgment for assessment of the risk of bias (391-394). Eighty-
six tools for assessing the quality of nonrandomized studies were identified 
by Sanderson et al. in their systematic review, (393) such as the Oxford 
quality scoring system (JADAD) (395), the Centre for Reviews and 
Dissemination-York (CRD) (396) and the Physiotherapy Evidence 
Database scale (PeDRO) (397) tools for assessment of bias in RCTs. 
Similarly, the CRD(396), the Scottish Intercollegiate Guidelines Network 
(SIGN) (398), the Critical Appraisal Skills Programme (CASP) (399) and 
the Newcastle-Ottawa Scale (NOS) (400, 401) have been developed to 
assess bias in observational studies.  
5.1.2. Study reporting 
Good reporting is the final and integral part of the research study and 
should not be regarded as something new and extra. 
5.1.2.1. Study reporting: What is it?  
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Good reporting not only informs future research but also contributes to 
systematic reviews and clinical practice guidelines which in turn inform 
health policies and clinical practice. 
Poor study reporting can be categorised as follows: (389)  
a. Non-reporting of a study, due to failure to publish completed research 
even if presented at a conference; 
b. Incomplete reporting, which occurs when there is missing of crucial 
information such as the omission of vital aspects of study’s methods 
(participant selection, interventions, randomisation in trials), incomplete 
results (data cannot be included in the meta-analysis) or inadequate 
reporting of harms;  
c. Selective reporting, which occurs when there is biased reporting of data 
within a published article with emphasis on alternate or sub-group 
analysis rather than a presentation of main outcomes of the research;  
d. Misleading reporting, which is a result of presenting the study in a more 
positive way, or with a post hoc change of focus, resulting in a 
misrepresentation of study findings. For example, in a review of breast 
cancer trials by Vera-Badillo et al. the authors comment that “…spin was 
frequently used to influence, positively, the interpretation of negative 
trials, by emphasising the apparent benefit of a secondary endpoint. The 
authors found bias in reporting efficacy and toxicity in 32.9% and 67.1% 
of trials, respectively, with spin and bias used to suggest efficacy in 59% 
of the trials that had no significant difference in their primary 
endpoint.”(402) 
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Inadequate reporting of research is common with several published 
reviews showing that crucial elements of trial methods and results are 
commonly missing from journal articles. Poor reporting of trial methods 
can hamper bias assessment. (403) Poor reporting of interventions can 
also impede the replication of the study. (404) Poor reporting of data 
could weaken the determination of effect size. (405, 406) The problems 
related to poor reporting are common in publically and commercially-
sponsored research. (407-409) These deficiencies in reporting have 
severe implications for clinical practice, future research, development of 
systematic reviews and clinical practice guidelines, policy-making and 
ultimately for patients. 
5.1.2.2. Importance of study reporting 
Accurate and rigorous reporting of research is of utmost importance as 
published research (peer-review publication) is often the only lasting 
record of a research study. (410) Mainland in his textbook comments that 
“incompleteness of evidence is not merely a failure to satisfy a few 
highly critical readers. (411) It infrequently makes the data that are 
presented of little or no value.”(412) While some readers might be 
satisfied with skimming an article or a summary, others will need to 
critically appraise it in detail to include in a systematic 
review/metanalysis or to be included in the drafting of clinical practice 
guidelines. Clinicians, researchers, systematic reviewers and 
policymakers need a clear understanding of precisely what was done and 
what was found. Good reporting should be transparent and accurate, 
should not mislead, should allow replication and be sufficient for 
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inclusion in a systematic review or metanalysis. (413) Inadequate 
reporting leads to potentially biased estimates of treatment effects and 
limits the assessment of a study’s strengths, weaknesses and 
generalisability. (414)  
5.1.2.3. Study reporting and generalisability 
Korn and Ehringhaus et al. in their article make a statement referring to 
the importance of reporting and implications this has upon the 
interpretation of a study’s generalisability: “clinical research involving 
human participants can only be justified ethically when such experiments 
are done to produce generalisable knowledge.”(415) Studies should be 
reported in a way that allows the reader to evaluate the generalisability of 
the findings to other populations. If the information is not present in the 
publication the reader of the article is left to decipher how much of the 
results apply to a particular patient being treated with the disease in 
question in a different context. Generalisability in an article can be 
assessed using seven key determinants that provide a more systematic 
evaluation of this concept : (i) population definition, (ii) definition of 
outcome, (iii) recruitment of subjects, (iv) inclusion and exclusion 
criteria, (v) data collection, (vi) subject retention, and (vii) length of 
follow-up.(416) 
5.1.2.4. Assessment of study reporting 
Authors and journals have a responsibility to ensure that research is 
adequately reported. There are several tools that assess the quality of 
reporting of clinical studies. Reporting guidelines lay down a set of items 
needed for a clear and transparent reporting of what was done and what 
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was found in a research study, thinking about specific issues that could 
introduce bias into the research. (417) The guidelines are structured 
advice, often presented as a checklist. The reporting guidelines are based 
on evidence and are drafted with the consensus of relevant stakeholders 
such as statisticians, epidemiologists, methodologists, content experts, 
journal editors, and consumer representatives (multidisciplinary group). 
The Consolidated Standards of Reporting Trials (CONSORT) Statement 
was first introduced in 1996 and revised five years later in 2001(418). 
Many medical journals encouraged this scheme, which has helped to 
improve the quality of reports of randomised trials. Similar initiatives to 
improve the reporting of other types of research arose after the 
introduction of CONSORT. (419). The STrengthening the Reporting of 
OBservational Studies in Epidemiology (STROBE) initiative developed 
recommendations on what should be incorporated in a precise and 
thorough report of an observational study. The STROBE statement and 
checklist were published in October 2007(420, 421). The other reporting 
guidelines for the main study types include:  
a. Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) for transparent reporting of systematic 
reviews (422, 423)  
b. CAse REport guidelines (CARE) to improve the completeness 
and transparency of published case reports (424)  
c. The Standards for Reporting Qualitative Research (SRQR) to 
improve the transparency of all aspects of qualitative research 
(425) 
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d. STandards for the Reporting of Diagnostic Accuracy Studies 
(STARD) to improve the quality of reporting of diagnostic 
accuracy studies(426, 427) 
e. STrengthening the REporting of Genetic Association studies 
(STREGA) which builds on the STROBE statement providing 
additions to 12 of the 22 items on the STROBE checklist to 
improve reporting of results of genetic studies(428) 
f. Standards for QUality Improvement Reporting Excellence 
(SQUIRE) for reporting of quality improvement work(429, 430)  
g. Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) for reporting guidance on studies of economic 
evaluation(431) amongst others(419). 
It was envisioned that if these reporting guidelines were adopted by 
authors and journals, issues such as confounding, bias, and 
generalisability could become more obvious. Reporting guidelines could 
also potentially reduce the over-zealous reporting of the research 
findings, and potentially have an impact on improving the methodology 
of studies in the long term. (432) Also over time, it was hoped that 
reporting guidelines would have an impact on improving the 
methodology of studies by increasing awareness of these issues amongst 
researchers designing new studies (433, 434). 
5.1.3. Impact of guidelines on study design and reporting quality 
A review by Samaan Z et al. evaluated adherence to several reporting 
guidelines in different fields of research. (435) Several studies have 
assessed the impact of the CONSORT statement on the quality of 
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reporting of RCTs (436-439). A systematic review carried out by Pint et 
al. showed that journal adoption of CONSORT was associated with 
improved reporting of RCTs (436). A Cochrane review published in 
2012 suggested that despite correlative improvements in reporting when 
CONSORT was endorsed by journals, the completeness of reporting of 
RCTs remained substandard as journals were not sufficiently explicit to 
the potential authors regarding their advocacy of the CONSORT 
statement (439). Moher et al studied the impact of CONSORT on the 
quality of study design of RCTs reported in four leading medical 
journals: The British Medical Journal (BMJ), The Journal of the 
American Medical Association (JAMA), The Lancet (journals that 
adopted CONSORT) and New England Journal of Medicine (NEJM) 
(journal that did not adopt CONSORT and was therefore used as a 
comparator). There was an improvement in reporting, and in the trial 
design assessed by JADAD scale in all four journals, however, this 
increase was only statistically significant in the adopter journals (437). 
There have been only a couple of studies assessing the impact of the 
2007 STROBE statement on the quality of reporting of observational 
studies. (440, 441) A study by Bastuji-Garin et al. looked at the impact of 
STROBE on observational studies published in the four dermatology 
journals with the highest impact factors. The authors commented that 
reporting was insufficient in a substantial amount of articles published 
from 2004 to 2010, with the lowest reporting rates for “sample size 
estimation”, “description of statistical methods” and of “efforts to limit 
potential sources of bias”, “discussion of external validity”, and 
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“discussion of limitations”. The study concluded that the publication of 
the STROBE statement had failed to significantly influence the quality of 
observational study reporting and felt this was probably due to the 
selected dermatology journals not endorsing STROBE. The authors 
hypothesised that this was probably in keeping with most other medical 
journals and overall low penetration of STROBE in the period 
analysed(441). 
The impact of the STROBE statement on the quality of reporting and the 
methodological quality has not been examined in the renal literature. 
Further, as only two of the 48 nephrology journals (Arab Journal of 
Nephrology and Transplantation and American Journal of Kidney 
Diseases) have endorsed STROBE, it cannot be assumed that the 
introduction of STROBE would have improved reporting of renal 
studies. 
5.1.4. Objectives 
Based on the above background and the primary aim of the Doctorate of 
Philosophy (PhD) the objectives of this review were:  
1. To determine whether the publication of the STROBE statement 
is associated with an improvement in the reporting quality of 
cohort studies assessing mortality in elderly patients with 
Chronic Kidney Disease (CKD) 
2. To determine whether the publication of the STROBE statement 
is associated with an improvement in the methodological quality 
(decrease in risk of bias) of cohort studies assessing mortality in 
elderly patients with CKD. 
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5.2. Materials and Methods 
5.2.1 Data selection 
(a) A systematic literature search was performed in Medline and Embase 
using the OvidSP interface to identify all papers describing pre-dialysis 
CKD cohort studies in the elderly (> 65 years) where mortality was 
reported as an outcome. The search query is presented in Appendix 5.1. 
Papers published between 1
st
 January 2002 and 31
st
 December 2013 were 
included, as the KDOQI Clinical Practice Guidelines for Chronic Kidney 
Disease: Evaluation, Classification, and Stratification were published in 
2002 (442). Only articles published in English were considered for the 
review. The initial search strategy yielded more than 10,000 hits. Hence 
the number of studies were reduced by restricting the search to European 
and North American studies. Each article was double sifted at the title, 
abstract and full-text stage using predefined study inclusion and 
exclusion criteria by Dr Rao (100%) and a third each by Dr Bruek, Dr 
Methven and Dr Caskey. Any disagreements about inclusion were 
resolved by discussion. 
The systematic review aimed to cover reporting and design of 
observational studies before and after the publication of the STROBE 
statement which was published in October 2007. Reporting and 
methodological quality were assessed during two time periods: before 
STROBE between 1/1/2002-31/12/2007 and after STROBE 1/10/2008-
31/12/2013, allowing a one-year run-in period after STROBE publication 
(October 2007). By excluding publications in the immediate twelve 
months post-STROBE, a period of one year was allowed for submission, 
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revision and publication of research adhering to the new guidelines. The 
analysis was also carried out by dividing the after STROBE period into 
immediate post-STROBE (1/10/2008-31/12/2010) and late post-
STROBE (1/1/11-31/12/13). 
5.2.2 Data extraction 
The reporting of the selected studies was assessed using the STROBE 
checklist itself, and the methodological quality assessed using three tools 
(below). Thirteen of the 22 STROBE checklist items were assessed with 
two to six questions per item generating 55 questions. The STROBE 
checklist is presented in Appendix 5.2. These could be answered as 
“yes,” “partly,” “no,” “unclear,” or “not applicable”. A similar 
methodology was used to that reported in the publication by Langan et al. 
(443). 
To assess methodological quality, the articles were scored on the 
Newcastle Ottawa Scale (NOS). At the time this study was designed 
NOS was recommended by Cochrane for evaluating the risk of bias in 
observational studies for inclusion in systematic reviews (Appendix 5.3) 
(400, 401). The articles were also scored using the Scottish 
Intercollegiate Guidelines Network (SIGN) checklist for cohort 
studies(398) (Appendix 5.4), and Critical Appraisal Skills Programme 
(CASP) cohort studies checklist(399) (Appendix 5.5) to estimate the 
concurrent validity of NOS tool. These three checklists were chosen 
because they were simple checklists without an additional summary 
judgement (444). 
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The eligible papers that were identified by the sifting process were each 
scored using the STROBE, NOS, SIGN and CASP checklists by two 
reviewers (Dr Rao (100%) and a third each by Dr Bruek, Dr Methven 
and Dr Caskey). Where there was disagreement between reviewers, the 
consensus was reached by discussion. 
5.2.3 Outcome measure 
The quality of study reporting was calculated by specific STROBE items 
and at a manuscript level. A STROBE question score (SQS) was 
calculated; the number of publications in a period that adequately 
reported a question divided by the number of publications in which this 
question was applicable, expressed as a percentage (item analysis). A 
Manuscript STROBE score (MSS) was calculated for every manuscript; 
the number of questions (maximum of 55 questions) adequately reported 
in the publication divided by the number of applicable questions, 
expressed as a percentage (manuscript analysis).  
Similarly, to assess the quality of study design the manuscript NOS score 
(MNOS), manuscript SIGN score (MSiS) and manuscript CASP score 
(MCAS) were calculated; the number of questions adequately addressed 
(in each appraisal tool) divided by the number of applicable items, 
expressed as a percentage in order to facilitate comparison. 
5.2.4 Data analysis 
Comparison between pre- and post-period SQS was performed by 
calculating the risk (proportion) difference between the two groups using 
the Wald test and respective 95% confidence intervals, with Benjamini 
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and Hochberg adjusted p values (False Discovery Rate) to control for 
multiple testing(445).  
MSS, MNOS, MSiS and MCAS were reported as a median with 
respective interquartile range (IQR). Pre- and post-period median MSS, 
MNOS, MSiS and MCAS were compared using the Mann-Whitney 
(MW) test. Despite excluding articles published for one year after the 
introduction of STROBE, this could potentially have been insufficient for 
uptake and penetration of the latest information. Therefore a spline linear 
regression model was used to determine the impact of STROBE over 
time(446).  
Sub-group analyses of MSS were carried out restricting articles to those 
published in nephrology journals, STROBE endorsing and non-endorsing 
journals and by journal impact factor in the year that the article was 
published. Sensitivity analyses were carried out by excluding the 
outlying MSS if any data points were less than 1.5 interquartile ranges 
(IQRs) below the first quartile or above the third quartile (< Q1 - 
1.5×IQR or > Q3 + 1.5×IQR). 
Simple and weighted kappa statistics were used to compare agreement 
between reviewers for the NOS, SIGN and CASP checklists.  
These were assessed at three levels: raters agreement on applicability, 
clarity (cannot say) and yes/no. 
All tests were two-tailed, and p values, < 0.05 were considered 
statistically significant. Data were analysed using STATA v13.1 (College 
Station, TX, USA) and SAS v9.3 (SAS Institute, Cary, NC, USA) 
software. 




The study was reported per the PRISMA reporting guidelines. (447) 
5.3 Results 
5.3.1 Reporting Quality 
Figure 5.1 shows the flow diagram of exclusions. Of the 3621 articles 
initially identified by the Medline and Embase search, 3584 (98.9%) 
were excluded after the sifting process (Figure 5.1). Only 37 articles met 
the pre-defined selection criteria for the scoring stage of the review 
during the inclusion period. Of these 37 articles, 11 were in the pre-
STROBE era (1/1/2002-31/12/2007) & 26 in the post-STROBE period 
(1/10/2008-31/12/2013). Twenty-two of these articles were published in 
nephrology and 15 in other medical journals. The list of articles 
considered at the scoring stage of the study is provided in Appendix 5.6. 




Figure 5.1: Prisma flow diagram 
Table 5.1 summarises the STROBE, NOS, SIGN and CASP scores for 
each of the articles in the pre and post-STROBE period. In most cases, 
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reporting quality (STROBE) and methodological quality (NOS, SIGN 
and CASP) correlated well. However, in some articles, methodological 
quality scored highly with a low score for reporting and vice versa. 
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Table 5.1: Summary of pre and post-STROBE period Manuscript STROBE score (MSS), Manuscript NOS score (MNOS), 
Manuscript SIGN score (MSiS) & Manuscript CASP score (MCAS) by the article. The citations for the manuscripts are listed in 
Appendix 5.1 
Publication date Journal 
Study Reporting Study Design 
MSS MNOS MSiS MCAS 
Pre-STROBE 
Dec-02 Journal of American College of Cardiology 76.5 55.6 22.2 33.3 
Jun-03 American Journal of Kidney Diseases 77.8 88.9 91.7 100.0 
Oct-04 Journal of the American Society of Nephrology 66.7 66.7 50.0 33.3 
Apr-05 
The Journal of the American Medical 
Association 
88.7 88.9 100.0 100.0 
Sep-05 Journal of the American Society of Nephrology 64.7 88.9 80.0 83.3 
Dec-05 Journal of the American Society of Nephrology 84.6 66.7 61.5 83.3 
Nov-06 British Medical Journal 82.0 100.0 100.0 91.7 
Jul-07 Renal Failure 49.1 100.0 88.9 100.0 
Jul-07 Journal of the American Society of Nephrology 80.4 100.0 100.0 100.0 
Nov-07 Nephrology Dialysis Transplantation 51.1 100.0 80.0 91.7 
Dec-07 Archives of Internal Medicine 77.8 88.9 83.3 91.7 
Post-STROBE 
Nov-08 Nephrology Dialysis Transplantation 83.0 88.9 83.3 100.0 
Dec-08 Nephrology Dialysis Transplantation 84.9 77.8 90.0 83.3 
Feb-09 Journal of the American Society of Nephrology 72.9 100.0 83.3 91.7 
Apr-09 American Journal of Kidney Diseases 90.0 100.0 69.2 100.0 
Jul-09 American Journal of Kidney Diseases 83.7 100.0 100.0 91.7 
Jul-09 
Clinical Journal of the American Society of 
Nephrology 
75.0 37.5 25.0 33.3 
Dec-09 Journal of American Geriatric Society 78.4 100.0 87.5 100.0 
Jul-10 Nephrology Dialysis Transplantation 77.6 100.0 90.9 91.7 
Oct-10 Journal of Nephrology 39.6 100.0 100.0 100.0 
Sep-10 Journal of General Internal Medicine 83.0 77.8 54.5 41.7 
Nov-10 Rejuvenation Research 73.6 88.9 80.0 91.7 
Sep-11 Clinical Journal of the American Society of 92.2 66.7 90.9 75.0 




Jan-12 Nefrologia 50.0 77.8 90.9 91.7 
Feb-12 Age and Ageing 83.0 100.0 91.7 100.0 
Apr-12 Nephrology Dialysis Transplantation 87.8 88.9 91.7 100.0 
Apr-12 The American Journal of Medicine 79.6 100.0 83.3 83.3 
May-12 Journal of American Geriatric Society 83.0 88.9 91.7 100.0 
May-12 Nephrology Dialysis Transplantation 88.0 100.0 66.7 75.0 
Jun-12 
The Journal of the American Medical 
Association 
84.9 88.9 66.7 66.7 
Jun-12 
Clinical Journal of the American Society of 
Nephrology 
83.0 88.9 76.9 83.3 
Jul-12 Journal of American Geriatric Society 79.6 88.9 100.0 91.7 
Dec-12 Family Practice 84.6 77.8 63.6 83.3 
Feb-13 American Journal of medicine 83.0 88.9 75.0 100.0 
Apr-13 BMC Nephrology 84.6 100.0 70.0 100.0 
May-13 BMC Nephrology 83.0 100.0 88.9 83.3 
Sep-13 
Clinical Journal of the American Society of 
Nephrology 
90.2 100.0 80.0 66.7 
 
Chapter 5: Systematic Review 
243 
 
Details regarding the reporting of the 55 STROBE items in the 37 included cohort 
studies are shown in Table 5.2. Some of the STROBE question scores showed a 
ceiling effect as they were already at a maximum level in the pre-STROBE period 
and could therefore only remain static or decline. Others saw improvements over the 
period such as “choice of quantitative groups” (30% vs 71%, p=0.02), “addressing 
of losses to follow up” (0% vs 36%, p < 0.001), “description of and carrying out 
sensitivity analysis” (18% vs 58%, p = 0.01 & 18% vs 65%, p = 0.002) and “usage 
of flow diagram” (0% vs 19%, p = 0.01). However, after adjusting for multiple 
testing, the change in only two items’ scores remained unlikely to be due to chance; 
“addressing of losses to follow up” (p =0.02) and “carrying out sensitivity analysis” 
(p = 0.04). The majority of STROBE questions showed little improvement between 
the two periods. Some critical questions, such as hypothesis specification and those 
important to the interpretation of study validity such as sample size estimation, 
addressing missing data, addressing loss to follow up, the reason for non-
participation and usage of flow diagram continue to be under-reported with less than 
50% reporting these items in both periods
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Table 5.2: Median STROBE QUESTION SCORE (SQS), Difference (95% CI) with a p-value of the 55 data items (22 items were further sub-divided to 55 












Difference LCI UCI p-value FDR FDR* 
Title and Abstract 
1A Is the design described adequately in the title or abstract? 0.73 0.69 -0.04 -0.35 0.28 0.83 0.91 0.93 
1B 
Does the abstract provide an informative summary of what was done 
and found? 
1.00 1.00 0.00 - - - - - 
Introduction 
2 Is the scientific background and rationale for the investigation reported? 1.00 1.00 0.00 - - - - - 
3A Are any pre-specified hypotheses reported? 0.18 0.23 0.05 -0.23 0.33 0.73 0.91 0.93 
3B Are the objectives reported? 0.73 0.96 0.23 -0.04 0.51 0.09 0.62 0.64 
Methods 
4 
Are the key elements (ie, retrospective/prospective, cohort/cross-
sectional) of the study design presented early in the paper? 
1.00 0.92 -0.08 -0.18 0.03 0.14 0.62 . 
5A Are the settings reported? 0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74 
5B Are the locations reported? 1.00 0.88 -0.12 -0.24 0.01 0.07 0.52 . 
5C Are relevant dates including periods of recruitment reported? 1.00 0.96 -0.04 -0.11 0.04 0.31 0.62 . 
5D Are relevant dates including periods of exposure reported? 1.00 0.93 -0.07 -0.21 0.06 0.30 0.62 . 
5E Are relevant dates including periods of follow-up reported? 0.91 0.96 0.05 -0.13 0.24 0.58 0.81 0.87 
5F Are relevant dates including periods of data collection reported? 0.73 0.92 0.20 -0.09 0.48 0.17 0.62 0.74 
6A Are the eligibility criteria for participants described? 1.00 0.92 -0.08 -0.18 0.03 0.14 0.62 . 
6B Are the sources of participants described? 1.00 0.92 -0.08 -0.18 0.03 0.14 0.62 . 
6C Are the methods of selection described? 1.00 0.96 -0.04 -0.11 0.04 0.31 0.62 . 
6D Are the methods of follow-up described? 0.91 0.96 0.05 -0.13 0.24 0.579 0.81 0.87 
6E 
If it is a matched study, are the matching criteria and the numbers of 
exposed and unexposed described? 
0.00 1.00 1.00 - - - - - 
7A Are all outcomes described if applicable? 0.91 0.96 0.05 -0.13 0.24 0.58 0.81 0.87 
7B Are all exposures described if applicable? 1.00 1.00 0.00 - - - - - 
7C Are all predictors described if applicable? 0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74 
7D Are potential confounders described? 0.91 0.92 0.01 -0.18 0.21 0.89 0.93 0.94 
7E Are all effect modifiers described? 0.73 0.80 0.07 -0.23 0.38 0.64 0.86 0.91 
7F Are diagnostic criteria described if applicable? 0.80 0.92 0.12 -0.15 0.39 0.40 0.73 0.84 
8A 
Are the sources of data and details of methods of measurement given for 
each variable of interest? 
0.91 0.85 -0.06 -0.28 0.16 0.57 0.81 0.87 
8B 
If there is more than 1 group, are the measurement methods 
comparable? 
0.75 1.00 0.25 -0.17 0.67 0.25 0.62 0.74 
9 Was there any effort to address potential sources of bias? 0.91 0.92 0.01 -0.18 0.21 0.89 0.93 0.94 




Did they describe how the study size was determined? 
 
0.00 0.04 0.04 -0.04 0.13 0.31 0.62 0.74 
11A 
Did they describe how quantitative variables were handled in the 
analysis? 
0.80 0.80 0.00 -0.29 0.29 1 1 1 
11B 
Did they describe which groupings were chosen for quantitative 
variables? 
0.90 0.83 -0.07 -0.31 0.17 0.58 0.81 0.87 
11C Did they describe why quantitative groups were chosen? 0.30 0.71 0.41 0.07 0.75 0.02 0.17 0.14 
12A 
Did they describe all statistical methods including those to deal with 
confounding? 
0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74 
12B Did they describe methods to examine subgroups and interactions? 0.73 0.72 -0.01 -0.32 0.31 0.96 0.98 0.99 
12C Did they explain how missing data were addressed? 0.27 0.38 0.11 -0.21 0.43 0.50 0.81 0.87 
12D Did they explain if applicable how losses to follow-up were addressed? 0.00 0.36 0.36 0.16 0.56 <0.001 0.02 0.02 
12E Did they describe any sensitivity analysis? 0.18 0.58 0.40 0.10 0.69 0.01 0.14 0.12 
Results 
13A 
Did they report the numbers of individuals at each stage of the study 
numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, and completed follow-up and were 
analysed? 
0.64 0.81 0.17 -0.15 0.49 0.30 0.62 0.74 
13B Did they give reasons for nonparticipation at each stage? 
a
 0.30 0.48 0.18 -0.18 0.53 0.33 0.64 0.75 
13C Did they use a flow diagram if appropriate? 0.00 0.19 0.19 0.04 0.34 0.01 0.15 0.13 
14A 
Did they give the characteristics of study participants (e.g., 
demographic, clinical, and social) and information on exposures and 
potential confounders? 
1.00 1.00 0.00 - - - - - 
14B 
Did they indicate the number of participants with missing data for each 
variable of interest? 
0.27 0.15 -0.12 -0.42 0.18 0.43 0.74 0.85 
14C Did they summarize follow-up time (average and total amount)? 0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74 
15A Did they report numbers of outcome measures over time? 1.00 1.00 0.00 - - - - - 
15B Did they report summary measures over time? 0.82 0.92 0.10 -0.15 0.35 0.41 0.73 0.84 
16A 
Did they give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence interval)? 
0.82 0.92 0.03 -0.24 0.29 0.84 0.91 0.93 
16B 
Did they detail which confounders were adjusted for and why they were 
included? 
0.90 0.92 0.02 -0.19 0.24 0.83 0.91 0.93 
16C 
Did they report category boundaries when continuous variables were 
categorized? 
0.90 0.88 -0.03 -0.25 0.20 0.83 0.91 0.93 
16D 
Did they, if relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful period? 
0.33 0.26 -0.07 -0.43 0.28 0.69 0.90 0.93 
17A 
Did they report on other analyses done, eg, analysis of subgroups or 
interactions? 
0.64 0.85 0.21 -0.11 0.53 0.19 0.62 0.74 
17B Did they do a sensitivity analysis? 0.18 0.65 0.47 0.18 0.76 0.002 0.04 0.03 
Discussion 
18 Did they summarize key results with reference to study objectives? 0.82 1.00 0.18 -0.05 0.41 0.12 0.62 0.70 




Did they discuss the limitations of the study taking into account 
potential sources of bias or imprecision (including discussion of the 
magnitude of any potential sources of bias)? 
0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74 
20 
Did they give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from similar 
studies, and other relevant evidence? 
1.00 1.00 0.00 - - - - - 
21 
Did they discuss the generalisability (external validity) of the study 
results? 
0.73 0.76 0.04 -0.27 0.35 0.80 0.91 0.93 
Other Information 
22A 
Did they give the source of the funding in the present study and, if 
applicable, for the original study on which the present article is based? 
0.73 0.77 0.03 -0.28 0.34 0.84 0.91 0.93 
22B 
Did they give the role of the funders in the present study and, if 
applicable, for the original study on which the present article is based? 
0.36 0.46 0.09 -0.25 0.44 0.60 0.81 0.87 
* False Discovery Rate (FDR) calculated excluding questions which had 100% completeness in the pre-STROBE phase. 
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Pre- and post-period analyses revealed an increase in MSS (median score 
77.8 (IQR, 64.7-82.0) vs 83 (IQR, 78.4-84.9), p= 0.04) (see table 5.3). 
Any pre-STROBE period articles with MSS scores less than 47.4 and 
post-STROBE period less than 69 were considered to be outliers. 
Excluding outliers, the improvement in the MSS between the two periods 
showed a stronger statistical relationship (p=0.01).  The results were 
essentially unchanged when restricted to nephrology journals or stratified 
by STROBE endorsing or non-endorsing journals, though there was less 
statistical power to test for differences. Journals with impact factor < 5 
saw a greater change over the two periods when compared to journals with 
impact factor ≥ 5, but given the overlap in the confidence intervals this 
may have occurred by chance.
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 N median MSS (IQR) N  median MSS (IQR) p value 
All Journals 11 77.8 (64.7-82.0) 26 83 (78.4-84.9) 0.04 
 
All Journals (excluding outliers) * 11 77.8 (64.7-82.0) 24 83 (79.6-84.9) 0.01 
 
Nephrology Journals 6 72.3 (64.7-80.4) 16 83.4 (76.3-87.9) 0.09 
 
STROBE endorsing Journals (3) 2 79.9 (77.8-82) 3 90 (83.7-90.9) 0.08 
Non-STROBE endorsing Journals (13) 9 76.5 (64.7-80.4) 23 83 (77.6-84.6) 0.10 
 
Impact FACTOR < 5 3 51.1 (49.1-77.8) 16 83 (78-84.6) 0.06 
Impact FACTOR ≥ 5  8 79.1 (71.6-83.3) 10 83.4 (79.6-90.0) 0.13 
* Excluding articles that were less than 1.5 interquartile ranges (IQRs) below the first quartile (< Q1 - 1.5×IQR). Pre-STROBE=47.4 
& Post-STROBE=69
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Time series analysis of MSS showed that there was a significant 
improvement in the quality of reporting in the latter three years (1/1/11 to 
31/12/13) when compared to the first three years (1/10/2008 to 
31/12/2010) after the introduction of the STROBE statement (Table 5.4). 
Longitudinal analysis of the MSS using a spline linear regression model 
(Figure 5.2), having excluded outliers, suggesting a turning point in 2008 
with a slight negative trend in the pre-STROBE period (coefficient - 0.06, 
SE 0.11) and a positive slope in the post-STROBE period (coefficient 0.21 
SE 0.05) but this may have occurred by chance (Slope change coefficient 
0.27, SE 0.16; p value=0.10).
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Table 5.4: Quality of the reporting of observational studies as assessed using the Manuscript STROBE score (MSS) over time.
  Pre-STROBE 
publication  
(period 1) 








1/1/11 to 31/12/13 
p value 
period 
1 vs 2 
p value 
period 
1 vs 3 
N 11 10 14   
Median MSS  77.8 80.7 83.8 0.23 0.003 
IQR 64.7-82.0 75-83.7 83-87.8   




Figure 5.2: Time series of Manuscript STROBE scores (MSS) from spline linear 
regression models. 
5.3.2 Methodological quality (study design) 
There was no evidence of any change in the methodological quality of 
studies in the pre and post-STROBE period using the Newcastle Ottawa 
Scale (NOS) (median MNOS 88.9% [IQR, 66.7-100] vs 88.9% [IQR, 
88.9-100], p= 0.51), Scottish Intercollegiate Guidelines Network (SIGN) 
(median MSiS 83.3% [IQR, 61.5-100] vs 83.3% [IQR, 70-90.9], p= 0.93) 
and Critical Appraisal Skills Programme (CASP) (median MCAS 91.7% 
[IQR, 83.3-100] vs 91.7% [IQR, 83.3-100], p= 0.93) (Figure 5.3). 




Figure 5.3: Box plot summarising the methodological quality of the studies in the Pre 
and Post-STROBE period as assessed using the NOS, CASP and SIGN 
5.3.3 Inter-rater agreement 
The inter-rater agreement for each of the tools was overall inadequate, 
with the NOS tool having a poor agreement between the three pairs of 
raters (Table 5.5). The CASP tool fared slightly better compared to the 
SIGN tool in raters assessment of clarity.
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Table 5.5: Summary of simple and weighted Kappa coefficient, measuring agreement 
between reviewers for the NOS, SIGN and CASP tool. 
 Kappa Agreement P value 
NOS (weighted) 
Reviewer 1 vs Reviewer 2 0.18 Poor 0.12 
Reviewer 1 vs Reviewer 3 0.28 Fair 0.004 
Reviewer 1 vs Reviewer 4 0.12 Poor 0.02 
SIGN (unweighted) 
Does not apply vs Everything else grouped 
Reviewer 1 vs Reviewer 2 -0.02 poor 0.87 
Reviewer 1 vs Reviewer 3 0.05 poor 0.51 
Reviewer 1 vs Reviewer 4 0.19 poor <0.001 
 
Cannot say vs No/Yes grouped  
Reviewer 1 vs Reviewer 2 -0.04 poor 0.62 
Reviewer 1 vs Reviewer 3 0.47 moderate <0.001 
Reviewer 1 vs Reviewer 4 -0.04 poor 0.49 
 
No vs Yes  
Reviewer 1 vs Reviewer 2 0.31 Fair 0.004 
Reviewer 1 vs Reviewer 3 0.51 Moderate <0.001 
Reviewer 1 vs Reviewer 4 0.24 Fair <0.001 
CASP (unweighted) 
Cannot tell vs No/Yes grouped  
Reviewer 1 vs Reviewer 2 0.90 Very good 0.30 
Reviewer 1 vs Reviewer 3 0.72 good <0.001 
Reviewer 1 vs Reviewer 4 0.05 poor 0.05 
 
Yes vs No  
Reviewer 1 vs Reviewer 2 0.69 good <0.001 
Reviewer 1 vs Reviewer 3 -0.06 poor 0.64 
Reviewer 1 vs Reviewer 4 -0.07 poor 0.40 




This systematic review assessed the impact of the publication of the STROBE 
statement on the quality of study design and reporting of methodology. It 
showed that, after the publication of STROBE, a sizable proportion of the 
STROBE items and sub-criteria continue to be underreported in CKD cohort 
studies of mortality in elderly patients. Reporting rates were lowest for 
hypothesis specification, usage of flow diagrams and addressing missing data. 
There was evidence of improvement in the reporting quality of CKD cohort 
studies particularly in the latter three years of the post-STROBE period, 
which was also seen when looking at the temporal patterns but this may have 
occurred by chance. There was no evidence that the quality of study design as 
assessed by three different tools NOS, SIGN and CASP had improved. 
However, these quality assessment tools have poor to moderate inter-rater 
reliability and might not be suitable for use without consensus agreement 
between raters. 
5.4.1 The disparity between articles in the two periods 
In this review, there were a disproportionate number of articles (2.5 
times) in the post-STROBE period compared to the pre-STROBE period. 
The reason for this disparity could be due to the potential impact of the 
publication of the CKD guidelines which were published in 2002. (442) 
This effect has been previously described in the literature. An editorial by 
Coresh et al. states that “The number of articles in the SCOPUS database 
retrieved by searching on CKD (June 10, 2012) had increased from 188 
in 2000 to 356 in 2002 and 4,035 in 2011”(53) 
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5.4.2 Reporting quality 
Inadequate reporting not only hinders meticulous assessment by others of 
the strengths and weaknesses in study design, conduct, and analysis, it 
affects the judgement of whether and how results can be included in 
systematic reviews and also impacts on the reader assessment of the 
studies generalisability (448). The results of this review are consistent 
with other studies assessing deficiencies in reporting of individual 
STROBE items such sample size, use of flow diagram and reporting of 
missing data (440, 441, 443, 449-452).  
As previously mentioned several studies, including a Cochrane review, 
have demonstrated improvements in reporting quality of randomised 
control trials (RCTs) after the introduction of the Consolidated Standards 
of Reporting Trials (CONSORT) statement with a significant 
improvement in journals endorsing this guideline statement(436-439, 
453). An RCT has also shown that using reporting guidelines in the peer 
review process improves the quality of manuscripts (454). Our study 
showed weak evidence of improvement in the quality of reporting of 
CKD cohort studies over time following the introduction of the STROBE 
statement. The improvements, unfortunately, fell short of the intended 
expectations when compared to the impact the CONSORT statement had 
achieved upon the reporting quality of RCTs. These results were similar 
to the only other study looking at the quality of reporting of observational 
cohort studies, published in the dermatology literature. Those authors 
attributed the lack of improvement to the short follow up period after 
STROBE introduction (2008–10)(441). However, in our study, the small 
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improvement could be attributable to the fact that the reporting of 
nephrology literature in the pre-STROBE period was already of a higher 
standard (median MSS 77.8 IQR 64.7-82.0) in comparison to 
dermatology literature (median score 58 IQR 46-73).  
Journal endorsement of reporting guidelines has also been shown to 
improve the reporting quality of manuscripts submitted to journals (454). 
However, given that only two medical journals (British Medical Journal 
& Ageing) and one renal journal (American Journal of Kidney Diseases) 
included in this review had endorsed the STROBE statement, any 
evidence of improvement in reporting quality of cohort studies in 
nephrology literature is probably owed to the penetration of the STROBE 
statement over time rather than to its endorsement by journals (455). The 
lack of improvement of reporting standards seen in the STROBE 
endorsing journals is not an indictment of these journals but may be 
attributable to the small sample size to accurately test for differences 
between the groups.  An important observation that was made during the 
process of this review was that despite studies having similar crude 
scores, reflected by their similar MSS, some studies had failed to 
adequately report essential criteria and had significant omissions. This is 
because a similar weight is attributed to all items on the checklists. 
5.4.3 Methodological quality 
For most of the articles included in this study reporting and 
methodological quality were well correlated. However, the assessment of 
the methodological quality of a study is dependent mainly on adequate 
reporting of the research. Therefore, drawing any inferences about a 
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study’s design quality is made harder if the reporting quality is 
inadequate. One of the primary goals of reporting guidelines was to 
improve reporting clarity and not necessarily improve the quality of 
research, but in due course achieve this as an indirect effect. Due to the 
interchangeable usage of the terminology ‘reporting quality’ and 
‘methodological quality’, the STROBE statement has often been used 
inappropriately for the assessment of methodological quality of 
observational research (434). There are some assessment tools that have 
been developed to assess quality and risk of bias in observational studies 
with only half of the identified tools having described their development 
or validity and reliability (444). The review by Sanderson et al. revealed 
the lack of an ideal tool for assessing the quality of observational 
epidemiological studies (444). The bias assessment tools used in this 
study (NOS, SIGN and CASP) were subjective, differed by content, 
format and validity. The bias assessment tools identified deficiencies in 
the articles relating to consideration of participants lost to follow up 
(attrition bias), exposure level or prognostic factor measured only once 
(detection bias), and inadequate methods of outcome assessment 
(detection bias). However, given that the assessment of methodological 
quality is largely reliant on the reporting of study design, one might, 
therefore, fail to detect differences in design quality if reporting is 
inadequate. Also given the latency period of designing a new study, 
undertaking it and then publishing it, might have been simply too soon 
for the STROBE statement to have influenced the methodological quality 
of studies. The NOS tool was previously recommended by Cochrane for 
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evaluating the risk of bias, but published literature has demonstrated poor 
inter-rater reliability between individual reviewers (456, 457). The results 
of our study are consistent with these findings as all the three tools (NOS, 
SIGN and CASP) showed poor agreement between individual reviewers. 
The usability of a tool depends on its clarity. Moreover, the tools contain 
items whose scoring is subjective and dependent on reviewers’ 
perceptions and domain knowledge. Cochrane now recommends the 
ACROBAT-NRSI bias assessment tool for non-randomized studies 
which has been developed by members of the Cochrane Bias Methods 
Group and the Cochrane Non-Randomised Studies Methods Group (458, 
459). However, at the time of drafting this manuscript, this tool remains 
to be tested for consistency between individual reviewers. This tool has 
since been replaced by the Risk Of Bias In Non-randomised Studies - of 
Interventions (ROBINS I) tool. (460) 
A strategy to improve inter-rater agreement would be to provide training 
to reviewers before the implementation of the tools. Due to the poor 
reliability of the tools demonstrated here, it should be strongly 
considered that each study should be assessed by at least two reviewers 
before inclusion in a systematic review/meta-analysis.  
5.4.4 Strengths and limitations 
One of the strengths of this review is that it assessed the impact of 
STROBE upon both the quality of reporting and study design. The study 
also has good internal validity as the selection, and evaluation processes 
were independently performed by two reviewers. However, as the 
articles were included from one field of medicine (CKD), we must be 
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cautious in generalising our findings to other areas. The other limitation 
of the study was that it only covered articles from Europe and North 
America. There was also an imbalance in the number of studies assessed 
in the two periods probably due to the KDIGO CKD guidelines which 
were published in 2002.  This imbalance could have potentially 
introduced a lack of power to detect a difference in quality. It was also 
impossible to blind the reviewers to the publication date during the 
sifting stage of the review, and the journal name during the review of 
quality which could have biased the reviewers’ assessment of the quality 
of the study. Finally, while this review examined a five-year period post-
STROBE, it is possible that it failed to find any benefit for 
methodological quality due to the extended latency period between 
designing a new study, obtaining funding, undertaking data collection, 
analysis and publication. 
5.4.5 Conclusion 
This study highlights continuing deficiencies in the reporting of 
observational studies in the nephrology literature. However, the 
publication of the STROBE statement may have positively influenced the 
quality of some aspects of observational study reporting. There was no 
evidence, however, that methodological quality improved over this time-
period. With continued efforts from researchers and with a particular 
focus on the domains identified as deficient by the STROBE statement 
and bias reporting tools, this presents an opportunity to improve the 
validity of observational research in nephrology. With increased 
awareness by authors and editors regarding compliance of manuscripts to 
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the STROBE statement and journal endorsement of the STROBE 
statement, we hope that not only reporting but also the design of future 
studies will be improved.
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CHAPTER 6 SUMMARY AND 
CONCLUSIONS 
CKD is recognised as a growing and an important public health issue, which 
affects up to 14% of the population of the developed world. (155-157) CKD is 
prevalent in the elderly and is associated with increased morbidity and mortality. 
(158, 159, 383) Both observational studies and RCTs play a valuable role in 
nephrology and have informed clinical practice. As with clinical trials, the most 
significant challenge to observational research is external validity. External 
validity is often used interchangeably with the term "generalisability" (106). 
Threats to generalisability can occur at the design stage due to selective inclusion 
criteria, at the recruitment stage due to non-participation of specific groups, and 
finally at the reporting stage due to poor reporting. 
The works presented in this PhD thesis attempts to understand more fully the 
various factors that could affect a study’s generalisability. The study examined 
was the EQUAL Study, an international prospective observational cohort study to 
determine when dialysis should be initiated in elderly patients. (129). The PhD 
was a mixed method study of convergent parallel/ triangulation design with the 
results of the individual studies being merged/triangulated at the phase of 
interpretation (Figure 6.1) to answer the overarching question of the thesis “ What 
are the factors that affect the generalisability of cohort studies?”. 




Figure 6.1: Factors affecting the generalisability of EQUAL 
6.1. Quantitative arm 
How to understand the applicability of observational data to the whole patient 
population by linking to existing GP databases (Chapter 4)? 
A general challenge of all research and particularly that of a cohort study is 
external validity (generalisability). (107) For the results of any study to be useful, 
their relevance beyond the studied population needs to be understood, i.e. their 
generalisability. (107) In the North American Atherosclerosis Risk in 
Communities (ARIC) study, generalisability was examined by nesting study 
patients in communities covered by broad surveillance. (97, 98) In the UK, four 
key GP databases hold longitudinal patient data which have shown to be 
generalisable to the UK regarding demographics and crude prevalences of 
significant conditions (180, 183, 461). Although various methods have been used 
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in evaluating the generalisability of RCTs, no published studies have used GP 
databases for understanding the generalisability of either RCTs or that of 
observational research. (462, 463) 
This study showed that patients in EQUAL were more likely to be younger, male 
and from an urban setting compared to the primary and secondary care cohort 
patients. The EQUAL patients were also less likely to have cardiovascular, 
cerebrovascular, peripheral vascular and rheumatic diseases, with no prevalence 
of dementia. The EQUAL patients were more likely to start RRT, and the 
probability that they were alive at one year compared to the primary and 
secondary care patients was greater. The overall better health of EQUAL patients 
meant that they were less liable to be admitted to hospital for illnesses. 
Future Directions 
The results of this study suggest that some things might be helpful to improve the 
generalisability of observational data. 
 Future studies (RCTs and observational research) could make a comparison 
between the study (experimental) and the eligible populations at the same 
time as the study is conducted.  
 If this is not achievable, GP databases and chronic disease registries should 
be used to understand how the results of the studies (RCTs and 
observational studies) would be generalisable to the real-world population.  
 Statistical techniques such as probabilistic sensitivity analysis (Episens 
model, Orsini et al.) may help to quantify the effect of bias. (257) 
Researchers can use this technique to report results that incorporate their 
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uncertainties regarding systematic errors and hence avoid overstating their 
certainty about the effect under study. (257, 258) 
 
6.2. Qualitative Arm 
What are the issues that underpin patient recruitment to the European QUALity 
Study on treatment in advanced chronic kidney disease - EQUAL (Chapter 3)? 
Many research projects fail to recruit their targeted numbers, and it is, therefore, 
essential to gain an understanding of the reasons why individuals choose to 
participate or otherwise. (333) To date, there are no published studies that have 
attempted to study the perceptions regarding research participation of elderly 
multi-morbid patients using qualitative methods, as in this study. This study is also 
unique in capturing views expressed by those who had declined to participate 
in research (the declined group). 
The study showed that patients who agreed to participate in research often report 
being activated in their own healthcare and this seemed to relate to their decision to 
take part in research. Altruistic morals had a strong influence on participation in 
the EQUAL study. Interestingly, however, the relationship was complicated as the 
majority of the participants had also expressed self-interest which suggested that 
this could be a prerequisite for altruism. The issue of caring responsibility and 
transportation were the main reasons causing inconvenience and negatively 
influenced participation. Interpersonal trust between the patient and their physician 
was a substantial factor influencing participation. 
Future Directions 
Chapter 6: Summary & Conclusions 
265 
 
The results of this study suggest a number of things might be helpful to improve 
the recruitment of older adults. 
 Recruiters could consider adopting different recruitment strategies for 
various demographic groups. (464)  
 An opt-out recruitment method may be considered as a strategy to optimise 
recruitment in research. (465, 466)  
 A face-to-face approach maybe strongly considered as this approach can 
engage in further conversation with the potential participant. 
 It may be beneficial for families to be present when older adults are 
approached for recruitment. However, not all (older adults, or other) 
patients would want their families present and unless it is thought that they 
are not competent to make a decision. Could this be imposed? 
 Patients physicians should probably play a critical role in at least 
introducing the option of research to patients even if they are not directly 
involved in recruitment. 
 Inconvenience to the older adults should be minimal with either 
transportation provided if the study requires a visit to the hospital, or home 
visits arranged.  
 Finally, flexibility about the appointment times and locations is likely to 
facilitate participation and also promote retention. 
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6.3. Systematic Review 
Has the publication of the STROBE statement had an impact on the quality of 
reporting and the methodological quality of cohort studies in nephrology (Chapter 
5)? 
Good reporting is crucial as it not only informs future research but also 
contributes to systematic reviews and clinical practice guidelines. This, in turn, 
informs health policies and clinical practice. (410, 467, 468) Good reporting also 
assists the reader in making judgements about the generalisability of the findings 
to other populations. STROBE guidelines were developed to improve the quality 
of reporting of observational studies (420, 421). The impact of the STROBE 
statement on the quality of reporting and the methodological quality has not been 
examined in the renal literature. Further, this is the first time a study has assessed 
the impact of the introduction of a reporting guideline on both the design of 
studies and the quality of the subsequent reporting.  
This review showed that that, after the publication of STROBE, a sizable 
proportion of the STROBE items and sub-criteria continue to be underreported in 
CKD cohort studies of mortality in elderly patients. There was, however, evidence 
of improvement in the overall reporting quality of CKD cohort studies particularly 
in the latter three years of the post-STROBE period. There was no evidence that 
the quality of the study design had improved in the time frame studied. 
Future Directions 
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The results of this study suggest that some things might be helpful to improve the 
reporting of cohort studies. 
 Increased awareness by authors and editors regarding the compliance of 
manuscripts to the STROBE statement could potentially improve journal 
reporting.  
 Journal endorsement of the STROBE statement could have an impact not 
only on reporting but also the design of future studies. (454)  
 
6.4. Reflections on the Mixed Method Approach Adopted 
The mixed methods approach of this PhD thesis has aided a breadth and depth of 
understanding of some of the issues with corroboration of the results from the 
quantitative and qualitative arms of the study. (469-472) Using a combination of 
methods allowed me to consider several rather than just one face of the problem 
giving a richer and a truer account. Reliance on one method can result in bias. For 
example, 
a. Measurement bias: For example response bias, in which participants sometimes 
tend to tell you what you want to hear. With a mixed method triangulated 
approach one can combine self-reported and observational research methods to 
help balance out the problem. 
b. Sampling bias: Sampling bias, e.g., omission bias occurs when the researcher 
covers only some parts because it is more convenient (inclusion bias). In this case, 
the qualitative study was conducted in three of the ten EQUAL recruitment sites, 
but the sample was representative to corroborate some of the results of the 
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quantitative study. Therefore, mixed methods (triangulation) combines the 
different strengths of these methods to ensure one gets sufficient coverage. 
Some of the issues are illustrated below with representative quotes from the 
qualitative study. In both the quantitative and the qualitative studies there was 
evidence that older people were more likely to decline participation. The 
quantitative arm of this study showed that patients in EQUAL were three and ten 
years younger than patients in the secondary care cohort and primary care cohort 
respectively. There were decreasing odds of participation; for every 5-year age 
band increase, the likelihood of participation reduced significantly. The qualitative 
arm provided insight into some of the reasons behind non-participation of the 
elderly (≥ 75 years) with issues of convenience such as caring responsibilities, 
reliance on friends and family and transportation being predominant. 
“I: When you were approached to take part in the EQUAL study 
you did mention that there was too much on at that time, would you 
mind elaborating? 
R: Well as I said my husband does not endure very good health, he 
is a diabetic, he is under the urinal clinic, he has had heart surgery, he 
is having problems even with his sugar levels at the moment, and I 
have to do a lot for him.  I have to help him dress, I help him to wash, 
and it is all happening now.  Up until this year, he was quite 
independent, so these sorts of things were all going through my mind.” 
BRL_DNA_09 
 
“I: Please can we start with your background, and then going on to 
your kidney condition. 
R: Mm.  Well as I say I, I cannot go very far because of him, you know, 
I have got make sure he is ok….He fell down in the greenhouse….And 
we had to call the ambulance….., we do not go out very much now, we 
used to, …. he cannot walk very far.  He could not; he cannot walk 
from there to there without getting out of breath. 
R: My daughter, she has just gone back yesterday, uh, she comes down 
from Sheffield to help, but she cannot afford to come down here all the 
time because her husband works in Holland and she is got to be at 
home with her children” BRL_DNA_14 
 
“R: …..I cannot really go out if it is peeing with rain, and I am a bit 
limited, I cannot drive any longer, I have been banned from driving. 
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I: Is that to do with your eyesight? 
R: I did lose this, my right eye, I have completely lost that, had a 
haemorrhage and it is got better, but it is not good enough for driving 
…..So, it does limit you to what you can do, you know, you have to rely 
on people, and you have to rely on transport to get you to the hospital 
etc.” OXF_DNA_05 
 
The quantitative arm has shown that higher Charlson Co-morbidity Index (CCI) 
was associated with lower odds of participation in EQUAL, with patients with 
CCI ≥4 30% less likely to participate in EQUAL (comparing apparently eligible 
patients in secondary care with those recruited to the EQUAL study). The 
qualitative interviews provided some further explanations for non-participation, 
with frailty and functional status, which is closely linked to co-morbidity, being 
raised as a barrier to research participation.  
“R: I’ve got to the stage now where even doing vacuuming I can only 
vacuum for so long, and then I have to have a sit down and have a 
breath – breather I should say, and ugh certain jobs in the house are 
now becoming a little bit too difficult to try and do, but obviously, age 
is – has crept up on me and ugh I try and do what I can when I can.  I 
feel now especially in the afternoon I do need to take a rest it is about 
an hour sleep, and then I feel I can carry on a little bit more, but 
having said that – that also times when I have got a job to keep 
awake” BRL_DNA_09 
Related to this, the interviews suggested a link between non-participation and self-
reported mobility, something which often accompanies deteriorating health. 
Finally, the declined group also talked about an increased burden from hospital 
appointments affecting the decision to participate in the study.  
R: It is because, this, this is not to do with my kidneys, this is 
purely to do with the fact that I cannot balance…..Moreover, I do feel 
very vulnerable. Moreover, that is frightening….Moreover, the fewer 
times I have to out of that front door the better it is for me.……I know 
that it won’t help my case, but research has got to take place to help 
people in the future, I’m well aware of that, but I’m not just an 
ordinary kidney patient, I’ve got another problem as well you see, and 
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I thought I couldn’t set myself up for all this. Because of my balance, I 
am frightened I will fall.  If I fall and break an arm, I am in real 
serious trouble” BRL_DNA_13 
The quantitative arm showed that patients in the primary and secondary care 
cohort had more than twice the rate of hospital admissions compared to patients in 
EQUAL. Although this link was not overtly established in the qualitative 
interviews, the declined group suggested that they had a higher burden of hospital 
appointments which could be a proxy for increased hospitalisation.  
“R: Well what it was, with all the clinics. I mean this is sort of like 
injections, foot clinic, diabetic clinic, renal clinic and the eye clinic, 
everybody seems to want blood….. I cannot remember, I was panicking 
(laughter) it is all sort of more visits and more blood……It was “help, 
please, no more” …... was my reaction.” OXF_DNA_17 
Therefore, the two arms account for the information obtained, and the qualitative 
findings provided some insights into the patterns that emerge from the quantitative 
data, and hence mixed methods are particularly valuable. 
6.5. Summary 
In summary, this thesis has described the various factors presenting threats to the 
generalisability of cohort studies occurring at design, recruitment and reporting 
stages of cohort studies using the example of a cohort study of advanced CKD in 
the elderly -EQUAL. It has done this through the use of a mixed-methods 
approach and in doing so has demonstrated the importance of multiple/mixed 
methods as an approach to understanding complex topics (generalisability of 
cohort studies), understanding issues in depth and improving reliability and 
validity of findings. Finally, this thesis provides recommendations and issues to be 
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taken into consideration for enhancing generalisability (external validity) of 
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Renal Unit address 
 









Dear <Title & surname>, 
 
Re: The European Quality (EQUAL) Study on treatment in advanced chronic 
kidney disease 
 
I am writing to ask if you would consider taking part in this research study. It aims to 
establish the treatments that give patients aged 65 years and older with low levels of 
kidney function the best prognosis and quality of life. The findings will hopefully provide 
helpful, patient-centred information to patients in the future with advanced kidney 
disease to help them make decisions about treatment. 
 
Your kidney care will continue as normal, we just want to collect information about the 
care you receive and how it affects your symptoms and quality of life. To do this, with 
your consent, a research nurse will contact you to arrange a convenient time and place 
for your visits. [It may be possible to arrange a home visit if this would suit you.]* They 
will ask you questions about your health and undertake a short physical examination. 
They will then ask you to answer some questions about your quality of life, symptoms 
and satisfaction with treatment. A blood test will be taken. With your consent, 
information will be gathered from your clinical records by the nurse. The whole visit 
should take 30-45 minutes. More details can be found on the enclosed pamphlet. 
 
If you are happy for one of the research nurses to contact you with more information 
about the study then you don’t need to do anything – someone will get in touch in the 
next couple of days. If you would prefer not to be contacted, just let me know by calling 
the number at the top of this letter. 
 





<Title & name of local healthcare team member> 
<Job title> 
 
Enc: EQUAL: An introduction for patients 
 


















EQUAL UK Lead Investigator: 








Dr Fergus Caskey 
Helen McNally 
 





  Tel: 0117 323 4300 
Fax: 0117 323 8677 
 
Patient Information Sheet 
 
The EQUAL Study 





We would like to invite you to take part in a research study.  Before you decide it 
is important for you to understand why the research is being done and what it 
would involve for you.  Please take time to read the following information carefully 
and discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part.  
 
Thank you for reading this. 
 
What is the purpose of the study?  
The study aims to establish the treatments that give patients aged 65 years and older 
with low levels of kidney function the best prognosis and quality of life. The findings 
will hopefully provide helpful, patient-centred information to patients in the future with 
advanced kidney disease to help them make decisions about treatment. 
 
Why have I been approached?  
You have been chosen because you are aged 65 years or older and your kidney 
function has reached a level (about 20% of normal) below which some patients begin 
to have symptoms related to their kidney function. 
 
Do I have to take part in this study?  
No, it is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form. 
If you decide to take part you are still free to withdraw at any time and without giving 





What will happen to me if I take part?  
If you agree to take part in this study your treatment plan and care will not alter.  
 
A research nurse will contact you to arrange a convenient time and place for your 
initial visit. At this visit, they will ask you questions about your health and undertake a 
short physical examination. They will then ask you to answer some questions about 
your quality of life, symptoms and satisfaction with treatment. A blood test will be 
arranged. With your consent, information will be gathered from your clinical records 
by the nurse. The whole visit should take 30-45 minutes. 
 
Follow up visits will be arranged with you at a time and place that suits approximately 
every six months. These do not involve additional blood and urine collections. If your 
kidney function decreases to 10% or you and your consultant decide you should start 
dialysis, follow up visits will start taking place every 3 months. A second set of blood 
tests will be requested around this time. 
 
Up to three blood samples (one at the beginning of the study and up to two later in 
the study) will be stored anonymously outside the UK for the current study and 
possibly future research. 
 
What are the possible disadvantages and risks of taking part?  
The only disadvantage that may arise from taking part in the study would arise from 
the additional time spent with the research nurse or from being asked questions 
about your quality of life and decision making. 
 
Will any genetic tests be done? 
A blood sample will be taken at your first study visit for DNA analysis. This will be 
used to better understand the link between genetic factors and risk of kidney disease. 
This DNA analysis will not be used to tell us whether kidney disease might affect 
other members of your family. If you would prefer for this not to happen you may 
indicate this on the consent form. 
 
What are the possible benefits of taking part?  
It is unlikely that the results of this study will directly benefit your care. The 
information we get from this study may, however, help us to treat future patients with 
kidney failure better. 
 
What happens when the research study stops? 
At the end of the research you care remains the same. We would like to have the 
opportunity to contact you or your GP in the future to see how you are and what your 
general health is like. We may also want to contact you or your GP for your opinion 
about your treatment and how satisfied you have been with your care. 
 
Will my taking part in this study be kept confidential?  
All information collected about you during the course of the research will be kept 
confidential. A unique study identifier will be generated to identify you so that your 
name and address will never be entered onto the main study database. A “key” 
linking your study identifier to you will be kept securely in the local centre to allow 
monitoring of the research and in the national coordinating centre in Bristol to enable 
linkage with national registries such as the UK Renal Registry. This key will be 
destroyed 10 years after the end of the study. 
 
What will happen to the results of the research study?  
The results of this study will be published in national and international journals. You 




of the published results from the ERA-EDTA website (www.era-edta-reg.org) or 
writing to: 
 
Dr Fergus Caskey 
Department of Renal Medicine 





Who is organising and funding the research?  
The study has been organised by a group of researchers in five European countries 
(Germany, Italy, The Netherlands, Sweden and The UK), lead by Dr Kitty Jager in 
Amsterdam. The research is funded by a grant by the European Renal Association – 
European Dialysis and Transplant Association. The doctors conducting the research 
are not being paid for including and looking after the patients in the study.  
 
Who has reviewed the study?  
In the UK, the study has been reviewed by the National Research Ethics Service 
(NRES) Committee South West – Central Bristol 
 
Contacts for Further Information  
If you do require additional information, please contact: 
Dr Fergus Caskey 




Tel: 0117 323 2312 
 
Complaints 
For independent advice you can discuss the study with your consultant nephrologist 
or contact the North Bristol Advice and Complaints Team: 
 
Advice and Complaints Team, 
Frenchay Hospital, 
Beckspool Road, 
Bristol BS16 1JE 
Tel  0117 340 3741 or 3076 
http://www.nbt.nhs.uk/patients-carers/advice-complaints 
 
Thank you for reading this. We hope you agree 
to take part in this study 
 
You will be given a copy of the information sheet and a signed consent 






Appendix 3.1: Codes related to Renal Replacement Therapy in The Health 
Improvement Network-THIN (read codes) and Hospital Episode Statistics 
(HES) 
Medcode Description 
ZV42000 [v]kidney transplanted 
Z94.0 kidney transplant status 
T86.1 kidney transplant failure and rejection 
N16.5 renal tubulo-interstitial disorders in transplant rejection 
TB00100 kidney transplant with complication; without blame 
TB00111 renal transplant with complication; without blame 
SP08300 kidney transplant failure and rejection 
SP08J00 chronic rejection of renal transplant 
SP08N00 unexplained episode of renal transplant dysfunction 
SP08R00 renal transplant rejection 
SP08T00 urological complication of renal transplant 
SP08W00 vascular complication of renal transplant 
7B00211 allotransplantation of kidney from cadaver 
7B00212 cadaveric renal transplant 
7B00300 allotransplantation of kidney from cadaver heart-beating 
7B00400 allotransplantation kidney from cadaver heart non-beating 
7B00600 xenograft renal transplant 
7B00y00 other specified transplantation of kidney 
7B00z00 transplantation of kidney nos 
7B01500 transplant nephrectomy 
7B01511 excision of rejected transplanted kidney 
7B06300 exploration of renal transplant 
7B0F.00 interventions associated with transplantation of kidney 
7B0F100 pre-transplantation of kidney work-up; recipient 
7B0F300 post-transplantation of kidney examination; recipient 
7B0Fy00 os interventions associated with transplantation of kidney 
7B0Fz00 interventions associated with transplantation of kidney nos 
SP08C00 Accelerated rejection of renal transplant 
SP08E00 Acute rejection of renal transplant - grade I 
SP08F00 Acute rejection of renal transplant - grade II 
SP08G00 Acute rejection of renal transplant - grade III 
SP08H00 Acute rejection of renal transplant 
SP08J11 Chronic transplant nephropathy 
SP08K00 Chronic rejection of renal transplant - grade 1 
SP08L00 Chronic rejection of renal transplant - grade II 
SP08M00 Chronic rejection of renal transplant - grade III 
SP08P00 Stenosis of vein of transplanted kidney 
SP08Q00 Aneurysm of artery of transplanted kidney 
SP08S00 Aneurysm of vein of transplanted kidney 
SP08V00 Very mild acute rejection of renal transplant 
SP08X00 Rupture of artery of transplanted kidney 
SP08Y00 Rupture of vein of transplanted kidney 




Z99.2 dependence on renal dialysis 
ZV45100 [V]Renal dialysis status 
14V2.00 H/O: renal dialysis 
14V2.11 H/O: kidney dialysis 
4I29.00 Peritoneal dialysis sample 
4N...00 Dialysis fluid examination 
4N0..00 Dialysis fluid urea level 
4N1..00 Dialysis fluid creatinine level 
4N2..00 Dialysis fluid glucose level 
4N3..00 Peritoneal dialysis fluid cell count 
4N4..00 Dialysis fluid potassium level 
4N5..00 Dialysis fluid sodium level 
7L1A.11 Dialysis for renal failure 
7L1A000 Renal dialysis 
7L1A011 Thomas intravascular shunt for dialysis 
7L1A100 Peritoneal dialysis 
7L1A200 Haemodialysis NEC 
7L1A400 Automated peritoneal dialysis 
7L1A500 Continuous ambulatory peritoneal dialysis 
7L1A600 Peritoneal dialysis NEC 
7L1B.11 Placement ambulatory dialysis apparatus - compens renal fail 
7L1B000 Insertion of ambulatory peritoneal dialysis catheter 
7L1B100 Removal of ambulatory peritoneal dialysis catheter 
7L1B200 Flushing of peritoneal dialysis catheter 
7L1C000 Insertion of temporary peritoneal dialysis catheter 
7L1f000 Extracorporeal albumin haemodialysis 
SP01500 Mechanical complication of dialysis catheter 
SP05613 [X] Peritoneal dialysis associated peritonitis 
SP06B00 Continuous ambulatory peritoneal dialysis associated perit 
SP0E.00 Disorders associated with peritoneal dialysis 
SP0E000 Bloodstained peritoneal dialysis effluent 
SP0E100 Thrombus in peritoneal dialysis catheter 
SP0F.00 Haemodialysis first use syndrome 
SP0G.00 Anaphylactoid reaction due to haemodialysis 
SP3y900 Acute hypercalcaemia of dialysis 
TA02.00 Accid cut,puncture,perf,h'ge - kidney dialysis/oth perfusion 
TA02000 Accid cut,puncture,perf,h'ge - kidney dialysis 
TA02011 Accidental cut/puncture/perf/haem'ge during renal dialysis 
TA12000 Foreign object left in body during kidney dialysis 
TA12011 Foreign object left in body during renal dialysis 
TA22000 Failure of sterile precautions during kidney dialysis 
TA22011 Failure of sterile precautions during renal dialysis 
TA42000 Mechanical failure of apparatus during kidney dialysis 
TA42011 Mechanical failure of apparatus during renal dialysis 
TB11.00 Kidney dialysis with complication, without blame 
TB11.11 Renal dialysis with complication, without blame 
U641.00 [X]Kidny dialysis caus abn reac pt/lat comp no misad at time 




Z131500 Warming patient with warm haemodialysis 
Z131600 Warming patient with warm peritoneal dialysis 
Z132800 Cooling patient using cool peritoneal dialysis 
Z1A..00 Dialysis training 
Z1A1.00 Peritoneal dialysis training 
Z1A1.11 PD - Peritoneal dialysis training 
Z1A2.00 Haemodialysis training 
Z1A2.11 HD - Haemodialysis training 
Z919.00 Care of haemodialysis equipment 
Z919100 Priming haemodialysis lines 
Z919200 Washing back through haemodialysis lines 
Z919300 Reversing haemodialysis lines 
Z919400 Recirculation of the dialysis machine 
Z91A.00 Peritoneal dialysis bag procedure 
Z91A100 Putting additive into peritoneal dialysis bag 
ZV56.00 [V]Aftercare involving intermittent dialysis 
ZV56000 [V]Aftercare involving extracorporeal dialysis 
ZV56011 [V]Aftercare involving renal dialysis NOS 
ZV56100 [V]Preparatory care for dialysis 
ZV56y00 [V]Other specified aftercare involving intermittent dialysis 
ZV56y11 [V]Aftercare involving peritoneal dialysis 
ZV56z00 [V]Unspecified aftercare involving intermittent dialysis 
ZVu3G00 [X]Other dialysis 
SP3y800 Dysequilibrium syndrome 
 
OPCS code Description 
M011 Autotransplantation of kidney 
M012 Allotransplantation of kidney from live donor 
M013 Allotransplantation of kidney from cadaver NEC 
M014 Allotransplantation of kidney from cadaver heart beating 
M015 Allotransplantation of kidney from cadaver heart non-beating 
M018 Other specified transplantation of kidney 
M019 Unspecified transplantation of kidney 
M026 Excision of rejected transplanted kidney 
X401 Renal dialysis 
X402 Peritoneal dialysis NEC 
X403 Haemodialysis NEC 
X404 Haemofiltration 
X405 Automated peritoneal dialysis 
X406 Continuous ambulatory peritoneal dialysis 
X407 Haemoperfusion 
X408 Other specified compensation for renal failure 
X409 Unspecified compensation for renal failure 
 
ICD10 Description 
T861 Kidney transplant failure and rejection 
Z940 Kidney transplant status 




Z491 Extracorporeal dialysis 
Z492 Other dialysis 
Z992 Dependence on renal dialysis 
Y602 During kidney dialysis or other perfusion 
Y612 During kidney dialysis or other perfusion 
Y622 During kidney dialysis or other perfusion 




Appendix 3.2: Secondary care referral codes to Nephrology within THIN 
nhsspec speciality subspec 
ABG General Surgery Nephrology 
AEI General Medical Nephrology 
AHK Orthopaedic Nephrology 
AKM Rheumatology Nephrology 
ANO Ear Nose & Throat Nephrology 
AQQ Gynaecology Nephrology 
ATS Obstetrics Nephrology 
AWU Paediatrics Nephrology 
AZW Ophthalmology Nephrology 
BCY Psychiatry Nephrology 
BGA Geriatrics Nephrology 
BJC Dermatology Nephrology 
BME Neurology Nephrology 
BPG Genito-Urinary Nephrology 
BSI X - Ray Nephrology 
BVK Pathology Nephrology 
BYM Other Nephrology 
CBO Non-referral report Nephrology 
CEQ   Nephrology 
 
Medcode Description 
8H4L.00 Referred to nephrologist 
8HVa.00 Private referral to nephrologist 
9NNf500 Under care of nephrologist 
ZL18O00 Under care of nephrologist 
ZL5AN00 Referral to nephrologist 
ZL9AO00 Seen by nephrologist 
ZLD3O00 Discharge by nephrologist 
9b9H.00 Nephrology 
9N1m.00 Seen in nephrology clinic 
ZLE6M00 Discharge from nephrology service 
9N1m.11 Seen in renal clinic 
9Ni1.00 Did not attend renal clinic 




Appendix 3.3: Additional health data (ahd) codes relating to Laboratory test 
results  
Laboratory variables ahd code 
eGFR (µmol/l) 1001400326 
Serum creatinine 1001400019 
Albumin creatinine ratio (mg/mmol) 1001400319 
Hb (g/dl) 1001400027 
Calcium (corrected) (mmol/l) 1001400012 
Phosphate (mmol/l) 1001400061 
Parathyroid hormone (pmol/l) 1001400272 
Albumin (g/L) 1001400002 




Appendix 3.4: Table of BNF codes relating to the class of medications 
BNF code Drug class 
Anti-hypertensive 
02040000 Beta-adrenoceptor blocking drugs 
02050000 Hypertension and heart failure 
02050100 Vasodilator antihypertensive drugs 
02050200 Centrally-acting antihypertensive drugs 
02050300 Adrenergic neurone blocking drugs 
02050400 Alpha-adrenoceptor blocking drugs 
02050500 Drugs affecting the renin-angiotensin system 
02050501 Angiotensin-converting enzyme inhibitors 
02050502 Angiotensin-II receptor antagonists 
02050503 Renin inhibitors 
02060200 Calcium channel blockers 
Antiplatelet/Anticoagulant 
02080100 Parenteral anticoagulants 
02080200 Oral anticoagulants 
02090000 Antiplatelet drugs 
Lipid-regulating drugs 
02120000 Lipid-regulating drugs 
Iron 
09010101 Oral iron 
09010102 Parenteral iron 
Erythropoietin stimulating agents 
09010300 Drugs used in hypoplastic, haemolytic & renal anaemia 
Phosphate binders 




Appendix 3.5: Codes related to patient consultation locations 
Locate code Description 
A Clinic (often by nurse) 
B Night Visit by Deputising Service conducted by a locum GP - often an 
emergency. Request for visit made either between 8pm and 7am, at weekends 
or holidays 
C Follow-up/routine visit 
D Night Visit by Local Rota, conducted by colleague or locum GP - often an 
emergency. Request for visit made either between 8pm and 7am, at weekends 
or holidays 
E Mail from Patient 
F Night Visit by Practice Doctor - often an emergency. Request for visit made at 
weekends or holidays either between 8pm and 7am, 
G Out of Hours visit by Practice Doctor, often an emergency. Request for visit 
made either between 7-9am or 5-8pm 
H Out of Hours visit by Non-Practice Doctor, examination by a doctor other than 
the patients GP, often an emergency. Request for visit made either between 7-
9am or 5-8 pm 
I Surgery Consultation 
J Telephone Call from Patient 
K Acute Visit by GP to patients home, usually during normal working hours 
L Discharge Details 
M Letter from Outpatients 
N Repeat Issue 
O Other 
P Results Recording 
Q Mail to patient 
R Emergency Consultation 
S Administration 
T Casualty attendance 
U Telephone call to patient 
V Third party consultation 
W Hospital Admission 
X Home visit 
Y Day case report (following surgical procedure in hospital without an overnight 
stay) 
Z Walk in centre (minor illness & injury treatment ª not part of GP surgery) 
a Minor injury service (service offered by GP surgery or hospital unit) 
b Community clinic 
c Night visit 
d Co-op surgery consultation (collaborative out-of hours service by local GPÊs) 
e Health authority entry 
f Co-op telephone advice (collaborative out-of hours service by local GPÊs) 
g Telephone consultation 




i Hotel visit 
j Nursing home visit 
k Residential home visit 
l Twilight visit 
m Co-op home visit (collaborative out of hours service by local GPÊs) 
n GOS18 report (referral from optician) 
o NHS direct report 
p Community nursing note 
q Community nursing report 
r Health visitor note 
s Health visitor report 
t Social services report 
u Triage 
v Non-consultation medication data 
w GP to GP communication transaction 
x Non-consultation data 




Appendix 4.1: Topic Guide: agreed (Version submitted to the ethics 
committee) 
Background 
Perhaps if we could start off with why you have been attending the renal clinic? 
Prompts: a. how long? b. what is wrong c. treatment 
 
Patient approach 
1. How were you first approached regarding the EQUAL study? 
Prompts: 1. where/whom 2. Good/ not so good  
2. What influenced your decision to take part/ not take part? 
3. Do you have any views on how we should approach people to take part?  What 
would have worked for you? 
            Prompts: 1. person/phone/ in clinic/written 
 
Information  
1. I'm keen to know your thoughts on the information you were given about the 
equal study when you were approached to take part? 
Prompts: 1. Pamphlet/ PIS 2. Did they read it? 3. 
Sufficient/elaborate/poor/missing   4. Written/verbal/face to face 5. Did it 
affect your decision? How? 
2. Having read the information was it clear to you what was going to happen in 
the study? 
Prompts: 1. Uncertainties about the study  
3. Did you have the opportunity ask questions and did the answers bring about 
more clarity?  




1. How did you come to your decision about whether or not to take part? 
(Reasons for taking part/not taking part). Which was/ were the most important 
reasons? Anything in particular that ‘put you off’? 
Prompts:  1. Any key information that helped type/source/content 2. Decision 
Easy/difficult; how long did you take deciding?  3. Factors-family etc   4. 
Aspects of the study 5. Previous experiences 6. Doctor/unit 
2. What was your nurse/doctor’s reaction about your decision? 
3. Would any incentives have influenced your decision to participate in this 
study? 
               Prompts: 1. Transport 2. Home visit   
 
Consent 
1. Did you understand the process of consent? 
Prompts: 1. enough information to consent 2. Different elements of the form 3. 
Patient rights 
 
Additional demands on the patient: extra procedures and time pressures 
1. Were there any commitments and pressures that were contributory to your not 
participating in this study? Prompts: 1. travel distance, travel costs and 




2. Was there anything about the study that you thought was too demanding? 
Prompts: 1. Frequency of visits 2. Length of the study 3. blood test 
 
Medical research 
1. I would be keen to know your views on medical research?  
Prompts: 1. Importance 2. How would it help patients in the future(better 
treatments for other in the future)?  
2.  Have you had previous experiences of being part of a medical study? If so can 
you please share these with me? 
3. If you were to be approached regarding another study what factors about it 
would influence whether or not you agreed to take part? 
4. Would your decision be different if your doctors approached you to participate 




Appendix 4.2: Topic Guide: declined (Version submitted to the ethics 
committee) 
Background 
Perhaps if we could start off with why you have been attending the renal clinic? 
Prompts: a. how long? b. what is wrong c. treatment 
 
Patient approach 
1. How were you first approached regarding the EQUAL study? 
Prompts: 1. where/whom 2. Good/ not so good  
2. What influenced your decision? 
3. Do you have any views on how we should approach people to take part?  What 
would have worked for you? 
Prompts: 1. person/phone/ in clinic/written 
 
Information  
1. I'm keen to know your thoughts on the information you were given about the 
equal study when you were approached to take part?  
Prompts: 1. Pamphlet/ PIS 2. Did they read it? 3. 
Sufficient/elaborate/poor/missing 4. Written/verbal/face to face 5. Did it affect 
your decision? How? 
2. Having read the information was it clear to you what was going to happen in 
the study? 
Prompts: 1. Uncertainties about the study 
3. Did you have the opportunity ask questions and did the answers bring about 
more clarity?  
 
Decision making 
1. How did you come to your decision? (Reasons for taking part/not taking part) 
Prompts:  1. Any key information that helped type/source/content 2. Decision 
Easy/difficult 3. Factors-family etc   4. Aspects of the study 5. Previous 
experiences 6. Doctor/unit 
2. What was your nurse/doctor’s reaction about your decision? 
3. Would any incentives have influenced your decision to participate in this 
study? 
Prompts: 1. Transport 2. Home visit   
 
Additional demands on the patient: extra procedures and time pressures 
1. Were there any commitments and pressures that were contributory to your not 
participating in this study? Prompts: 1. travel distance, travel costs and 
financial constraints 2. Family duties 3. Medical problems 
2. Was there anything about the study that you thought were demanding? 
Prompts: 1. Frequency 2. Length of the study 3. Blood test 
 
Medical research 
1. I would be keen to know your views on medical research? 
Prompts: 1. Importance 2. How would it help patients in the future(better 
treatments for other in the future)?  
2.  Have you had previous experiences of being part of a medical study? If so can 




3. If you were to be approached regarding another study what factors about it 
would influence your participation/ non-participation? 
4. Would your decision be different if your doctors approached you to participate 




Appendix 4.3: Topic Guide: agreed (Final Version) 
Background 
Perhaps if we could start off with why you have been attending the renal clinic? 
Prompts: a. how long? b. what is wrong c. treatment d. other medical problems e. 
physical barriers (vision, deafness, memory) f. caring responsibilities 
 
Patient Activation 
1. Are you aware of your health problems and what causes them? 
2. If you are not feeling well, what do you do? Do you know when you need to 
see the doctor and when you can take care of your own health problems? 
3. When you see the doctor, if something is bothering you regarding your health 
do you tell, the doctor of this even if he/she do not ask? 
4. Do you know what each of your tablets do? 
5. Do you know what treatments are available for your health problems? eg 
kidney failure 
6. Do you take over the counter remedies for your health if required?   
7. Do you know of life style measures for your health problems? Diet? Exercise? 




4. How were you first approached regarding the EQUAL study? 
Prompts: 1. where/whom 2. Good/ not so good  
5. What influenced your decision to take part/ not take part? 
Explore around Altruism and perceived personal benefit gained. 
6. Do you have any views on how we should approach people to take part?  What 
would have worked for you? 
              Prompts: 1. person/phone/ in clinic/written 
 
Information  
5. I'm keen to know your thoughts on the information you were given about the 
equal study when you were approached to take part? 
Prompts: 1.Aims and objectives of the study 2. Pamphlet/ PIS 3. Did they 
read it? 4. Any terminology that stood out (CKD, kidney disease and 
percentage).5. Sufficient/elaborate/poor/missing  6. Written/verbal/face to 
face  7. Did it affect your decision? How? 
6. Having read the information was it clear to you what was going to happen in 
the study? 
Prompts: 1. Uncertainties about the study  
7. Did you have the opportunity ask questions and did the answers bring about 
more clarity?  




4. How did you come to your decision about whether or not to take part? 
(Reasons for taking part/not taking part). Which was/ were the most important 




Prompts:  1. Any key information that helped type/source/content 2. Decision 
Easy/difficult; how long did you take deciding?  3. Factors-family etc   4. 
Aspects of the study  5. Previous experiences 6. Doctor/unit 
5. What was your nurse/doctor’s reaction about your decision? 
6. Would any incentives have influenced your decision to participate in this 
study? 
               Prompts: 1. Transport 2. Home visit   
 
Consent 
2. Did you understand the process of consent? 
Prompts: 1. enough information to consent 2. Different elements of the form  
3. Patient rights 
 
Additional demands on the patient: extra procedures and time pressures 
3. Were there any commitments and pressures that were contributory to your not 
participating in this study? Prompts: 1. travel distance, travel costs and 
financial constraints 2. Family duties 3. Medical problems 
4. Was there anything about the study that you thought was too demanding? 




5. I would be keen to know your views on medical research?  
Prompts: 1. Importance 2. How would it help patients in the future (better 
treatments for other in the future)?  
6.  Have you had previous experiences of being part of a medical study? If so can 
you please share these with me? 
7. If you were to be approached regarding another study what factors about it 
would influence whether or not you agreed to take part? 
Would your decision be different if your doctors approached you to participate in a 




Appendix 4.4: Topic Guide: declined (Final version) 
Background 
Perhaps if we could start off with why you have been attending the renal clinic? 
Prompts: a. how long? b. what is wrong c. treatment d. other medical problems e. 
physical barriers (vision, deafness, memory) f. caring responsibilities 
 
Patient Activation 
9. Are you aware of your health problems and what causes them? 
10. If you are not feeling well, what do you do? Do you know when you need to 
see the doctor and when you can take care of your own health problems? 
11. When you see the doctor, if something is bothering you regarding your health 
do you tell, the doctor of this even if he/she do not ask? 
12. Do you know what each of your tablets do? 
13. Do you know what treatments are available for your health problems? eg 
kidney failure 
14. Do you take over the counter remedies for your health if required?   
15. Do you know of life style measures for your health problems? Diet? Exercise? 




7. How were you first approached regarding the EQUAL study? 
Prompts: 1. where/whom 2. Good/ not so good  
8. What influenced your decision? 
Explore around Altruism  
9. Do you have any views on how we should approach people to take part?  What 
would have worked for you? 
Prompts: 1. person/phone/ in clinic/written 
 
Information  
9. I'm keen to know your thoughts on the information you were given about the 
equal study when you were approached to take part?  
10. Prompts: 1.Aims and objectives of the study 2. Pamphlet/ PIS 3. Did they 
read it? 4. Any terminology that stood out (CKD, kidney disease and 
percentage).5. Sufficient/elaborate/poor/missing  6. Written/verbal/face to face  
7. Did it affect your decision? How? 
11. Having read the information was it clear to you what was going to happen in 
the study? 
Prompts: 1. Uncertainties about the study 
12. Did you have the opportunity ask questions and did the answers bring about 
more clarity?  
 
Decision making 
7. How did you come to your decision? (Reasons for taking part/not taking part) 
Prompts:  1. Any key information that helped type/source/content 2. Decision 
Easy/difficult  3. Factors-family etc   4. Aspects of the study  5. Previous 
experiences 6. Doctor/unit 




9. Would any incentives have influenced your decision to participate in this 
study? 
Prompts: 1. Transport 2. Home visit   
 
Additional demands on the patient: extra procedures and time pressures 
5. Were there any commitments and pressures that were contributory to your not 
participating in this study? Prompts: 1. travel distance, travel costs and 
financial constraints 2. Family duties 3. Medical problems 
6. Was there anything about the study that you thought were demanding? 
Prompts: 1. Frequency 2. Length of the study 3. Blood test 
 
Medical research 
8. I would be keen to know your views on medical research? 
Prompts: 1. Importance 2. How would it help patients in the future(better 
treatments for other in the future)?  
9.  Have you had previous experiences of being part of a medical study? If so can 
you please share these with me? 
10. If you were to be approached regarding another study what factors about it 
would influence your participation/ non-participation? 
11. Would your decision be different if your doctors approached you to participate 




Appendix 5.1: Search strategy for systematic review 
Chronic Kidney Disease (CKD): 
exp renal insufficiency, chronic/ 










impaired kidney function*.ti,ab. 
impaired renal function*.ti,ab. 
decreased kidney function*.ti,ab. 




























old age .ti,ab. 





community dwelling .ti,ab. 
nursing home .ti,ab. 
home for the aged .ti,ab. 




mortality/ or *"cause of death"/ or *fatal outcome/ or *hospital mortality/ or 
*mortality, premature/ or *survival rate/ 
exp Renal Insufficiency, Chronic/mo [Mortality] 
Europe:  




2. UK.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
3. United Kingdom.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
4. England.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
5. English.mp. 












18. (Moldova or Moldavian* or Moldovan).mp. 
19. Montenegr*.mp. 












29. (Finland or Finns or Finn or Finnish).mp. 
30. (France or French).mp. 
31. German*.mp. 
32. (Great Britain or Great British).mp. 
33. (Northern Ireland or Northern Irish).mp. 
34. (Greece or Greek).mp. 
35. Iceland*.mp. 
36. (Ireland or Irish).mp. 
37. (Italy or Italian*).mp. 
38. Luxembourg*.mp. 
39. (Netherlands or Dutch).mp. 
40. (Portugal or Portuguese).mp. 
41. (Denmark or Danish).mp. 
42. (Norway or Norwegian*).mp. 
43. (Sweden or Swedish).mp. 
44. (Spain or Spanish).mp. 




49. (Turkey or Turkish).mp. 




54. (Cyprus or Cypriot*).mp. 
55. Czech*.mp. 





58. (Monaco or Monacian* or Monegasque*).mp. 
59. (San Marino or Sammarinese*).mp. 
60. (Vatican or Vanticanian*).mp. 
 
America:  
1. exp North America/ 
2. Canada.mp. 
3. (US or USA).mp. 
4. United States.mp. 
5. America*.mp. 
6. (Alabama or Alaska or Arizona or Arkansas or California or Colorado or 
Connecticut or Delaware or Florida or Georgia or Hawaii or Idaho or Illinois or 
Indiana or Iowa or Kansas or Kentucky or Louisiana or Maine or Maryland or 
Massachusetts or Michigan or Minnesota or Mississippi or Missouri or Montana or 
Nebraska or Nevada or New Hampshire or New Jersey or New Mexico or New York 
or North Carolina or North Dakota or Ohio or Oklahoma or Oregon or Pennsylvania 
or Rhode Island or South Carolina or South Dakota or Tennessee or Texas or Utah or 






PY(Publication Year):  
Time period 1/1/2002 to 31/12/2013 
 
PT (Publication Type):  
Deselect conference papers and other publication types which will not use STROBE 
guidance for reporting (e. letter to the editor) 
(autobiography or biography or case reports or clinical conference or clinical trial, all 
or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical 
trial, phase iv or clinical trial or congresses or consensus development conference or 
consensus development conference, nih or controlled clinical trial or dictionary or 




cases or legislation or letter or news or newspaper article or patient education handout 
or portraits or randomized controlled trial or video-audio media or webcasts) 
 
Selection of human studies: 










STROBE Description Rules/Explanatory notes 
Answer choices 
yes partly no unclear not 
applicable 
Title and Abstract 
1a Is the design described adequately in the title or 
abstract? 
If the study design was not specifically stated, this should be recorded as not 
being complete.  
     
1b Does the abstract provide an informative summary of 
what was done and found? 
The abstract provides key information that enables readers to understand a 
study and decide whether to read the article and should only present 
information that is provided in the article. 
     
Introduction 
2 Is the scientific background and rationale for the 
investigation reported? 
The paper should give an overview of what is known on a topic and what 
gaps in current knowledge are addressed by the study. 
     
3a Are any pre-specified hypotheses reported?  Objectives are the detailed aims of the study. Well-crafted objectives specify 
populations, exposures and outcomes, and parameters that will be estimated. 
     
3b Are the objectives reported?      
Methods 
4 Are the key elements (i.e., retrospective/prospective, 
cohort/cross-sectional) of the study design presented 
early in the paper? 
For example, authors should indicate that the study was a cohort study, 
which followed people over a particular time period and describes the group 
of persons that comprised the cohort and their exposure status. Authors 
should refrain from simply calling a study ‘prospective’ or ‘retrospective’ 
because these terms are ill-defined 
     
5a Are the settings reported? Studies that did not report the setting or locations but referred readers to a 
previous publication should be considered as inconsistent with complete 
reporting. Readers need information on setting and locations to assess the 
context and generalisability of a study’s results. 
     
5b Are the locations reported?      
5c Are relevant dates including periods of recruitment 
reported? 
Authors should state dates rather than only describing the length of time 
periods. If the dates of recruitment were recorded anywhere in the article 
(not necessarily in the “Methods” section), the corresponding item should be 
rated as complete.  
     
5d Are relevant dates including periods of exposure 
reported? 
     
5e Are relevant dates including periods of follow-up 
reported? 
     
5f Are relevant dates including periods of data 
collection reported? 
     
6a Are the eligibility criteria for participants described? Detailed descriptions of the study participants help readers understand the 
applicability of the results. Clinical, demographic and other characteristics of 
     




6c Are the methods of selection described? eligible participants should be described. Eligibility criteria may be 
presented as inclusion and exclusion criteria. 
     
6d Are the methods of follow-up described?  Knowing details about follow-up procedures, including whether procedures 
minimised nonresponse and loss to follow-up and whether the procedures 
were similar for all participants, informs judgments about the validity of 
results. 
     
6e If it is a matched study, are the matching criteria and 
the numbers of exposed and unexposed described?  
Because matching can be done in various ways, with one or more controls 
per case, the rationale for the choice of matching variables and the details of 
the method used should be described. To allow readers to judge whether the 
matched design was appropriately taken into account in the analysis, we 
recommend that authors describe in detail what statistical methods were used 
to analyse the data. 
     
7a Are all outcomes described if applicable? Disease outcomes require an adequately detailed description of the 
diagnostic criteria. 
     
7b Are all exposures described if applicable?       
7c Are all predictors described if applicable?      
7d Are potential confounders described? If the confounders were recorded anywhere in the article (not necessarily in 
the “Methods” section), the corresponding item should be rated as complete. 
     
7e Are all effect modifiers described? Authors should declare all ‘candidate variables’ considered for statistical 
analysis, rather than selectively reporting only those included in the final 
models 
     
7f Are diagnostic criteria described if applicable?      
8a Are the sources of data and details of methods of 
measurement given for each variable of interest? 
The way in which exposures, confounders and outcomes were measured 
affects the reliability and validity of a study. Measurement error and 
misclassification of exposures 
alternatively, outcomes can make it more difficult to detect cause-effect 
relationships or may produce spurious relationships. 
     
8b If there is more than 1 group, are the measurement 
methods comparable? 
     
9 Was there any effort to address potential sources of 
bias? 
Authors should have made attempts to address sources of bias if they 
incorporated any tools to do this, e.g., using standardised definitions or 
validated scoring systems should be rated as complete. Addressing sources 
of bias should never be considered “not applicable” in an observational 
study. 
     
10 Did they describe how the study size was 
determined? 
 
The importance of sample size determination in observational studies 
depends on the context. Investigators should report pertinent formal sample 
size calculations if they were done. 
     
11a Did they describe how quantitative variables were 
handled in the analysis? 
Authors should explain why and how they grouped quantitative data, 
including the number of categories, the cut-points, and category mean or 
median values. Whenever data are reported in tabular form, the counts of 
cases, controls, persons at risk, person-time at risk, etc. should be given for 
     
11b Did they describe which groupings were chosen for 
quantitative variables? 




11c Did they describe why quantitative groups were 
chosen? 
each category. Tables should not consist solely of effect-measure estimates 
or results of model fitting. 
     
12a Did they describe all statistical methods including 
those to deal with confounding? 
In relation to statistical methods, unless authors state which confounders 
were adjusted for and why, should not be rated as complete. Authors should 
clarify reasons for particular analyses. 
     
12b Did they describe methods to examine subgroups and 
interactions? 
Readers need to know which subgroup analyses were planned in advance, 
and which arose while analysing the data. 
     
12c Did they explain how missing data was addressed? Authors should report the number of missing values for each variable of 
interest (exposures, outcomes, confounders) and for each step in the 
analysis. Authors should give reasons for missing values if possible, and 
indicate how many individuals were excluded because of missing data when 
describing the flow of participants through the study. 
     
12d Did they explain if applicable how losses to follow-
up were addressed? 
Authors to report how many patients were lost to follow-up and what 
censoring strategies they used. 
     
12e Did they describe any sensitivity analysis?  Sensitivity analyses are useful to investigate whether or not the main results 
are consistent with those obtained with alternative analysis strategies or 
assumptions 
     
Results 
13a Did they report the numbers of individuals at each 
stage of the study numbers potentially eligible, 
examined for eligibility, confirmed eligible, included 
in the study, and completed follow-up and were 
analysed? 
Those included in a study often differ in relevant ways from the target 
population to which results are applied. This may result in estimates of 
prevalence or incidence that do not reflect the experience of the target 
population. 
     




Explaining the reasons why people no longer participated in a study or why 
they were excluded from statistical analyses helps readers judge whether the 
study population was representative of the target population and whether 
bias was possibly introduced. 
     
13c Did they use a flow diagram if appropriate?      
14a Did they give the characteristics of study participants 
(e.g., demographic, clinical, and social) and 
information on exposures and potential confounders? 
Readers need descriptions of study participants and their exposures to judge 
the generalisability of the findings. Information about potential confounders, 
including whether and how they were measured, influences judgments about 
study validity. Authors should give the mean and Standard deviation, or 
when the data have an asymmetrical distribution, as is often the case, the 
median and percentile range (e.g., 25th and 75th percentiles). 
     
14b Did they indicate the number of participants with 
missing data for each variable of interest? 
As missing data may bias or affect the generalisability of results, authors 
should tell readers amounts of missing data for exposures, potential 
confounders, and other important characteristics of patients. Should also 
include the extent of loss to follow-up. 
     
14c Did they summarise follow-up time (average and 
total amount)? 
Readers need to know the duration and extent of follow-up for the available 
outcome data. 
     




time? Consider reporting the event rate per person-year of follow-up. If the risk of 
an event changes over follow-up time, present the numbers and rates of 
events in appropriate intervals of follow-up or as a Kaplan-Meier life table 
or plot. 
15b Did they report summary measures over time?      
16a Did they give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(e.g., 95% confidence interval)? 
Readers can compare unadjusted measures of association with those adjusted 
for potential confounders and judge by how much, and in what direction, 
they changed. 
     
16b Did they detail which confounders were adjusted for 
and why they were included? 
Authors should explain all potential confounders considered and the criteria 
for excluding or including variables in statistical models. Decisions about 
excluding or including variables should be guided by knowledge, or explicit 
assumptions, on causal relations. 
     
16c Did they report category boundaries when continuous 
variables were categorized? 
Authors should report the category boundaries, and report the range of the 
data and the mean or median values within categories. 
     
16d Did they, if relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful 
period? 
it was only appropriate to translate relative risk into absolute risk if there 
was convincing evidence of a causal association. 
     
17a Did they report on other analyses done, e.g., analysis 
of subgroups or interactions? 
Authors should report which analyses were planned, and which were not. 
This will allow readers to judge the implications of multiplicity, taking into 
account the study’s position on the continuum from discovery to verification 
or refutation. 
     
17b Did they do a sensitivity analysis?  Sensitivity analyses are helpful to investigate the influence of choices made 
in the statistical analysis, or to investigate the robustness of the findings to 
missing data or possible biases. 
Discussion 
18 Did they summarise key results concerning study 
objectives? 
The short summary reminds readers of the main findings and may help them 
assess whether the subsequent interpretation and implications offered by the 
authors are supported by the findings. 
     
19 Did they discuss the limitations of the study taking 
into account potential sources of bias or imprecision 
(including discussion of the magnitude of any 
potential sources of bias)? 
Authors should identify the sources of bias and confounding that could have 
affected results, but also to discuss the relative importance of different 
biases, including the likely direction and magnitude of any potential bias. 
Authors may compare the study being presented with other studies in the 
literature regarding validity, generalisability and precision. In this approach, 
each study can be viewed as a contribution to the literature, not as a stand-
alone basis for inference and action. 
     
20 Did they give a cautious overall interpretation of 
results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, 
and other relevant evidence? 
Authors should consider potential sources of bias, including loss to follow-
up and non-participation. Due consideration should be given to confounding, 
the results of relevant sensitivity analyses, and to the issue of multiplicity 
and subgroup analyses. Authors should also consider residual confounding 
due to unmeasured variables or imprecise measurement of confounders. 
Authors should put their results in context with similar studies and explain 




how the new study affects the existing body of evidence, by referring to a 
systematic review. 
21 Did they discuss the generalisability (external 
validity) of the study results? 
Can results be applied to an individual, groups or populations that differ 
from those enrolled in the study with regard to age, sex, ethnicity, the 
severity of disease, and co-morbid conditions? Are the nature and level of 
exposures comparable, and the definitions of outcomes relevant to another 
setting or population? Are results from health services research in one 
country applicable to health systems in other countries? 
     
Other Information 
22a Did they give the source of the funding in the present 
study and, if applicable, for the original study on 
which the present article is based? 
      
22b Did they give the role of the funders in the present 
study and, if applicable, for the original study on 
which the present article is based? 
Unless the role of the funders was specifically stated, this should not be 
recorded as complete. 
     
a
 For studies based on disease registries or databases, a number of the checklist items are not applicable, e.g., the dates of recruitment, numbers eligible at each stage of the study, reasons for 
nonparticipation, or flow diagrams 




Appendix 5.3: Newcastle-Ottawa Quality Assessment Scale for cohort 
studies 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and 
Outcome categories. A maximum of two stars can be given for Comparability 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community 
b) somewhat representative of the average ______________ in the community 
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort 
b) drawn from a different source 
c) no description of the derivation of the non exposed cohort 
3) Ascertainment of exposure 
a) secure record (eg surgical records) 
b) structured interview 
c) written self report 
d) no description 




1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor) 
b) study controls for any additional factor (This criteria could be modified to indicate specific 
control for a second important factor.) 
Outcome 
1) Assessment of outcome 
a) independent blind assessment 
b) record linkage 
c) self report 
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest) 
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for 
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an 
adequate %) follow up, or description provided of those lost) 





Appendix 5.4: Scottish Intercollegiate Guidelines Network (SIGN) checklist for cohort studies  
 
S I G N 
Methodology Checklist 3: Cohort studies 
Study identification (Include author, title, year of publication, journal title, pages) 
Guideline topic:   Key Question No: Reviewer: 
Before completing this checklist, consider: 
1. Is the paper really a cohort study? If in doubt, check the study design algorithm available from SIGN and make 
sure you have the correct checklist. 
2. Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison 
Outcome). IF NO REJECT (give reason below). IF YES complete the checklist.. 
Reason for rejection: 1. Paper not relevant to key question □   2. Other reason □  (please specify): 
Please note that a retrospective study (ie a database or chart study) cannot be rated higher than +. 
Section 1: Internal validity 
In a well conducted cohort study: Does this study do it? 
1.1 The study addresses an appropriate and clearly focused question. Yes  □ 
Can’t say □ 
No □ 
 
SELECTION OF SUBJECTS 
1.2 The two groups being studied are selected from source populations that are 
comparable in all respects other than the factor under investigation. 
Yes  □ 




1.3 The study indicates how many of the people asked to take part did so, in each of 
the groups being studied. 
 





1.4 The likelihood that some eligible subjects might have the outcome at the time of 
enrolment is assessed and taken into account in the analysis. 
Yes  □ 







1.5 What percentage of individuals or clusters recruited into each arm of the study 
dropped out before the study was completed. 
 
1.6 Comparison is made between full participants and those lost to follow up, by 
exposure status. 
Yes  □ 





1.7 The outcomes are clearly defined. Yes  □ 
Can’t say □ 
No □ 
 
1.8 The assessment of outcome is made blind to exposure status. If the study is 
retrospective this may not be applicable. 
Yes  □ 




1.9 Where blinding was not possible, there is some recognition that knowledge of 
exposure status could have influenced the assessment of outcome. 
Yes  □ 
Can’t say □ 
No □ 
□ 
1.10 The method of assessment of exposure is reliable. Yes  □ 
Can’t say □ 
No □ 
 
1.11 Evidence from other sources is used to demonstrate that the method of outcome 
assessment is valid and reliable. 
Yes  □ 




1.12 Exposure level or prognostic factor is assessed more than once. Yes  □ 





1.13 The main potential confounders are identified and taken into account in the design 
and analysis. 
Yes  □ 








SECTION 2:  OVERALL ASSESSMENT OF THE STUDY 
2.1 How well was the study done to minimise the risk of bias or confounding? 
 
High quality (++) □ 
Acceptable (+) □ 
Unacceptable – reject 0  
2.2 Taking into account clinical considerations, your evaluation of the methodology 
used, and the statistical power of the study, do you think there is clear evidence of 






2.3 Are the results of this study directly applicable to the patient group targeted in this 
guideline? 
Yes □ No □ 
2.4 Notes. Summarise the authors conclusions. Add any comments on your own assessment of the study, and the 




Appendix 5.5: Critical Appraisal Skills Programme (CASP) cohort checklist 











Three broad issues need to be considered when appraising a cohort study. 
     Are the results of the study valid? What are the  results? 
Will the results help locally? 
The 12 questions on the following pages are designed to help you think about 
these issues systematically. 
 
• The first two questions are screening questions and can be answered 
quickly. If the answer to those two is "yes", it is worth proceeding with 
the remaining questions. 
 
• There is a fair degree of overlap between several of the questions. 
 
• You are asked to record a "yes", "no" or "can't tell" to most of the questions. 
 
• A number of italicised hints are given after each question. These are 
designed to remind you why the question is important. There will not 




©CASP This work is licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 
Unported License. To view a copy of this license, visit 
http://creativecommons.org/licenses/by-nc-sa/3.0/ 
©Critical Appraisal Skills Programme (CASP) Cohort Study checklist_14.10.10 
Appendices 
 
A Are the results of the study valid? 
Screening Questions 
 
    1 Did the study address a clearly focused issue? 
HINT:  A question can be focused in terms of? 
 the population studied 
 the risk factors studied 
 the outcomes considered 
 is it clear whether the study tried to detect a 







 2 Did the authors use an appropriate method to 
answer their question? 
HINT: Consider 
 is a cohort study a good way of answering the 
question under the circumstances? 












3 Was the cohort recruited in an acceptable 
way? 
 
HINT: We are looking for selection 




 Was the cohort representative of 
a defined population? 
 Was there something special about the 
cohort? 
 Was everybody included  
 who should have been included? 





  4 Was the exposure accurately measured to 
minimize bias? 
 
HINT: We are looking for measurement or 
classification bias: 
 
 Did they use subjective or objective 
measurements? 
 Do the measures truly reflect what you want them 
to (have they been validated)? 
 Were  all  the  subjects  classified  into  exposure 




5. Was the outcome accurately measured to 
minimize bias? 
HINT: We are looking for measurement or classification 
bias: 
 
 Did they use subjective or objective 
measurements? 
 Do the measures truly reflect what you want them 
to (have they been validated)? 
 Has a reliable system been established for 
detecting all the cases (for measuring disease 
occurrence)? 
 Were  the  measurement  methods  similar  in  the 
different groups? 
 Were the subjects and/or the outcome assessor 



































A. Have the authors identified all important 
confounding factors? 
List the ones you think might be important, that 
the author missed. 
 
 
B. Have they taken account of the confounding 





 Look for restriction in design, and techniques eg 
modelling, stratified-, regression-, or sensitivity 
























   
A. Was the follow up of subjects complete enough? 
 




 The good or bad effects should have had long 
enough to reveal themselves 
 The persons that are lost to follow-up may have 
different outcomes than those available for 
assessment 
 In an open or dynamic cohort, was there 
anything special about the outcome of the people 


















B What are the results? 




 What are the bottom line results? 
 Have they reported the rate or the proportion 
between the exposed/unexposed, the ratio/the 
rate difference? 
 How strong is the association between exposure 
and outcome (RR,)? 
 What is the absolute risk reduction (ARR)? 
 
9. How precise are the results? 
HINT: 
 Size of the confidence intervals 
 
10. Do you believe the results? 
HINT: 
 Big effect is hard to ignore! 
 Can it be due to bias, chance or confounding? 
 Are the design and methods of this study 
sufficiently flawed to make the results 
unreliable? 
 Consider Bradford Hills criteria (eg time 










C Will the results help me locally? 
  11. Can the results be applied to the local population? 
 
HINT: Consider whether 
 
 The subjects covered in the study could be 
sufficiently different from your population to 
cause concern 
 Your local setting is likely to differ much 
from that of the study 


















One observational study rarely provides sufficiently robust evidence to 
recommend changes to clinical practice or within health policy decision making. 
However, for certain questions observational studies provide the only evidence. 
Recommendations from observational studies are always stronger when 
supported by other evidence.
Appendices 
 
Appendix 5.6: List of articles included for the systematic review by date of 
publication 
1. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of 
cardiovascular outcomes and mortality in elderly individuals. Journal of the American 
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